Trogocytosis-mediated therapy using CD38 antibodies

CD38 antibody variants with specific Fc region mutations induce CD38 reduction via trogocytosis, addressing the limitations of existing antibodies by enhancing immune response and targeting refractory tumors.

JP2024160275AInactive Publication Date: 2024-11-13GENMAB AS
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024125676
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-05-16
Filing Date
2024-08-01
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current CD38 antibodies lack the ability to effectively induce complement-dependent cytotoxicity, antibody-dependent cytotoxicity, and antibody-dependent cellular phagocytosis while also inhibiting CD38 enzyme activity, necessitating the development of CD38 antibodies with enhanced potency for therapeutic use.

Method used

Development of CD38 antibody variants with specific mutations in the Fc region, including E430, E345, and S440 residues, to induce CD38 reduction via trogocytosis on CD38-expressing immune cells, promoting an immune response and reducing immunosuppressive activity.

Benefits of technology

The CD38 antibody variants effectively reduce CD38 expression on immunosuppressive cells, enhancing immune responses and targeting tumor cells, including those refractory to previous treatments, by inducing trogocytosis and modulating immune cell function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160275000018
    Figure 2024160275000018
  • Figure 2024160275000019
    Figure 2024160275000019
  • Figure 2024160275000020
    Figure 2024160275000020
Patent Text Reader

Abstract

To provide antibody variants for therapeutic use involving trogocytosis-mediated reduction of CD38 on CD38-expressing immunosuppressive cells.SOLUTION: The invention provides CD38 antibody variants comprising one or more mutations in the Fc region, e.g., a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, where the amino acid residues are numbered according to the EU index.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to antibody variants that bind to CD38, particularly their use in the treatment of cancer and other diseases and disorders. [Background technology]

[0002] 2. Background of the Invention CD38 is a type II transmembrane glycoprotein that is normally found on hematopoietic cells and is present at low levels in solid tissues. Expression of CD38 on hematopoietic cells depends on the differentiation and activation state of the cells. Lineage-committed hematopoietic cells express the protein, which is lost by mature cells and is expressed again on activated lymphocytes. CD38 is also expressed on B cells, with plasma cells expressing particularly high levels of CD38. Approximately 80% of resting NK cells and monocytes express CD38 at low levels, as do various other blood cell types, including lymph node germinal center lymphoblasts, intrafollicular cells, dendritic cells, red blood cells, and platelets (Lee and Aarhus 1993; Zocchi, Franco et al. 1993; Malavasi, Funaro et al. 1994; Ramaschi, Torti et al. 1996). With respect to solid tissues, CD38 is expressed by intraepithelial cells and lamina propria lymphocytes in the intestine, by Purkinje cells and neurofibrillary tangles in the brain, epithelial cells in the prostate, beta cells in the pancreas, osteoclasts in bone, retinal cells in the eye, and the sarcolemma of smooth and striated muscles.

[0003] CD38 is expressed in a number of hematological malignancies. Expression has been observed in malignant cells, particularly in multiple myeloma (MM) (Lin, Owens et al. 2004) and chronic lymphocytic leukemia (CLL) (Damle 1999), and also in Waldenström's macroglobulinemia (Konoplev, Medeiros et al. 2005), primary systemic amyloidosis (Perfetti, Bellotti et al. 1994), mantle cell lymphoma (Parry-Jones, Matutes et al. 2007), acute lymphoblastic leukemia (Keyhani, Huh et al. 2000), acute myeloid leukemia (Marinov, Koubek et al. 1993; Keyhani, Huh et al. 2000), NK cell leukemia (Suzuki, Suzumiya et al. 2004), NK / T cell lymphoma (Wang, Wang et al. 2015), and plasma cell leukemia (van de Donk, Lokhorst et al. 2012).

[0004] Other diseases in which CD38 expression may be involved include, for example, bronchial epithelial carcinoma of the lung, breast cancer (arising from malignant proliferation of the epithelial lining of the breast ducts and lobules), pancreatic tumors (insulinomas) arising from beta cells, tumors arising from the intestinal epithelium (e.g., adenocarcinoma and squamous cell carcinoma), carcinoma of the prostate, seminoma of the testis, ovarian cancer, and neuroblastoma. Other disclosures also suggest a role for CD38 in autoimmunity such as Graves' disease, thyroiditis (Antonelli, Fallahi et al. 2001), type 1 and type 2 diabetes (Mallone and Perin 2006), and inflammation of airway smooth muscle cells in asthma (Deshpande, White et al. 2005). Furthermore, CD38 expression is also associated with HIV infection (Kestens, Vanham et al. 1992; Ho, Hultin et al. 1993).

[0005] CD38 is a multifunctional protein. Functions attributed to CD38 include both receptor-mediated and (ecto)enzymatic activity in adhesion and signaling events. As an ectoenzyme, CD38 mediates the binding of NAD + It uses Ca as a substrate for the formation of cyclic ADP-ribose (cADPR) and ADPR, but also for the formation of nicotinamide and nicotinic acid-adenine dinucleotide phosphate (NAADP). cADPR is transported from the endoplasmic reticulum to the Ca 2+ It has been shown to function as a second messenger in cellular mobilization.

[0006] Several anti-CD38 antibodies have been described in the literature, e.g., WO 2006 / 099875 A1, WO2008037257 A2, WO 2011 / 154453 A1, WO 2007 / 042309 A1, WO 2008 / 047242 A1, WO2012 / 092612 A1; Cotner, Hemler et al. 1981; Ausiello, Urbani et al. 2000; Lande, Urbani et al. 2002; de Weers, Tai et al. 2011; Deckert, Wetzel et al. 2014; Raab, Goldschmidt et al. 2015; Eissler, Filosto et al. 2018; Roepcke, Plock et al. 2018; and Schooten et al. 2019. It will be described in 2018.

[0007] CD38 antibodies may affect CD38-expressing tumor cells by one or more of the following mechanisms of action: complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), programmed cell death, trogocytosis, clearance of immune suppressor cells, and modulation of enzyme activity (van de Donk, Janmaat et al. 2016; Krejcik, Casneuf et al. 2016; Krejcik, Frerichs et al. 2017; Chatterjee, Daenthanasanmak et al. 2018; van de Donk 2018). However, in 2014, it was proposed that CD38 antibodies capable of inducing effective CDC, ADCC, and ADCP as well as effectively inhibiting CD38 enzyme activity have never been described before (Lammerts van Bueren, Jakobs et al. 2014).

[0008] Optimization of effector functions can improve the efficacy of therapeutic antibodies for treating cancer or other diseases, for example, to improve the ability of the antibody to elicit an immune response against antigen-expressing cells. Such efforts are described, for example, in: WO 2013 / 004842 A2; WO 2014 / 108198 A1; WO 2018 / 031258 A1; Dall'Acqua, Cook et al. 2006; Moore, Chen et al. 2010; Desjarlais and Lazar 2011; Kaneko and Niwa 2011; Song, Myojo et al. 2014; Brezski and Georgiou 2016; Sondermann and Szymkowski 2016; Zhang, Armstrong et al. 2017; Wang, Mathieu et al. 2018.

[0009] However, despite these and other efforts in the art, a need exists for CD38 antibodies with controlled potency for therapeutic use. Summary of the Invention

[0010] The present invention relates to the therapeutic use of CD38 antibody variants, in particular antibody variants capable of modulating trogocytosis-mediated reduction of CD38 on CD38-expressing immune cells.

[0011] Thus, in one aspect, the invention relates to an antibody variant for use in treating cancer in a subject, wherein the antibody variant comprises: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells.

[0012] In one aspect, the invention relates to an antibody variant for use in enhancing an immune response in a subject, wherein the antibody variant comprises: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells.

[0013] In one aspect, the invention relates to an antibody variant for use in treating cancer in a subject, wherein the antibody variant comprises: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and It induces the loss of CD38 via trogocytosis on CD38-expressing tumor cells.

[0014] In one aspect, the invention relates to a method of treating cancer in a subject comprising administering to the subject an antibody variant, wherein the antibody variant: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells.

[0015] In one aspect, the invention relates to a method of promoting an immune response in a subject comprising administering to the subject an antibody variant, wherein the antibody variant: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells.

[0016] In one aspect, the invention relates to a method of treating cancer in a subject comprising administering to the subject an antibody variant, wherein the antibody variant: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells.

[0017] In some embodiments of the aspects described herein, the one or more amino acid residue mutations are selected from the group consisting of E430G, E345K, E430S, E430F, E430T, E345Q, E345R, E345Y, S440Y and S440W, such as E430G.

[0018] In some embodiments of the aspects described herein, the CD38-expressing immune cells are CD38-expressing immunosuppressive cells.

[0019] [The present invention 1001] 1. An antibody variant for use in treating cancer in a subject, comprising: an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells, The antibody variant. [The present invention 1002] The antibody variant for use in the present invention 1001, wherein reduction of CD38 on said CD38 expressing immune cells via trogocytosis enhances the immune response. [The present invention 1003] The antibody variant for any of the uses of the present invention, wherein the CD38-expressing immune cells are CD38-expressing immunosuppressive cells. [The present invention 1004] The antibody variant for use of the present invention 1003, wherein depletion of CD38 via trogocytosis on said CD38 expressing immunosuppressive cells reduces their immunosuppressive activity. [The present invention 1005] The antibody variant for use according to the invention 1003 or 1004, wherein the CD38 expressing immunosuppressive cells comprise regulatory T cells (Treg), regulatory B cells (Breg), myeloid-derived suppressor cells (MDSC), immunosuppressive NK cells, immunosuppressive NKT cells, immunosuppressive antigen presenting cells (APC), immunosuppressive macrophages, or any combination of two or more thereof. [The present invention 1006] The antibody variant for use in any one of claims 1003 to 1005, wherein the CD38-expressing immunosuppressive cells include CD38-expressing Treg. [The present invention 1007] The antibody variant for use according to any of the preceding claims, wherein said trogocytosis is caused by effector cells expressing Fc gamma receptors (FcγR). [The present invention 1008] The antibody variant for use according to the present invention 1007, wherein the effector cells expressing said Fcγ receptors comprise macrophages, monocytes, or a combination thereof. [The present invention 1009] The antibody variant for use according to any of the preceding claims, wherein reduction of CD38 on said CD38-expressing immune cells via trogocytosis promotes an immune response, including an effector T cell (Teff) response. [The present invention 1010] The Teff response is + CD4 + T cells, CD3 + CD8 + Antibody variants for use in the present invention 1009, mediated by T cells, or both. [The present invention 1011] The antibody variant for any of the aforementioned uses of the present invention, wherein reduction of CD38 via trogocytosis on said CD38-expressing immune cells promotes an immune response against tumor cells in a subject. [The present invention 1012] The antibody variant for use in any of the preceding inventions, wherein tumour cells of said cancer lack detectable CD38 expression. [The present invention 1013] The antibody variant for use according to any of claims 1001 to 1011, wherein tumor cells of said cancer express CD38. [The present invention 1014] The antibody variant for use in any of the preceding claims, wherein the subject has a blood cancer. [The present invention 1015] The antibody variant for use in accordance with the present invention 1013, wherein said hematological cancer is selected from the group consisting of multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (adult) (AML), mantle cell lymphoma, follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL). [The present invention 1016] The antibody variant for use according to the present invention 1014, wherein said cancer is CLL. [The present invention 1017] The antibody variant for use in accordance with the present invention 1014, wherein said cancer is mantle cell lymphoma. [The present invention 1018] The antibody variant for use in accordance with the present invention 1014, wherein said cancer is DLBCL. [The present invention 1019] The antibody variant for use in accordance with the present invention 1014, wherein said cancer is FL. [The present invention 1020] The antibody variant for use in accordance with the present invention 1014, wherein said cancer is MM. [The present invention 1021] The antibody variant for use in accordance with the present invention 1014, wherein said cancer is acute myeloid leukemia (adult) (AML). [The present invention 1022] The antibody variant for use according to any of claims 1001 to 1013, wherein the cancer comprises a solid tumor. [The present invention 1023] The antibody variant for use in accordance with the present invention 1022, wherein said solid tumor is selected from the group consisting of lung cancer, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, melanoma, colorectal cancer, prostate cancer, castration-resistant prostate cancer, stomach cancer, ovarian cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, squamous cell carcinoma of the head and neck, cancer of the esophagus or gastrointestinal tract, breast cancer, fallopian tube cancer, brain tumor, urethral cancer, genitourinary cancer, endometrial cancer, cervical cancer, lung adenocarcinoma, renal cell carcinoma (RCC) (e.g., renal clear cell carcinoma or renal papillary cell carcinoma), mesothelioma, nasopharyngeal carcinoma (NPC), cancer of the esophagus or gastrointestinal tract, or a metastatic lesion of any of them. [The present invention 1024] The antibody variant for use according to any of claims 1001 to 1023, wherein said cancer is refractory to previous treatments comprising a CD38 antibody. [The present invention 1025] The antibody variant for use according to any of claims 1001 to 1023, wherein said cancer relapses after a previous treatment comprising a CD38 antibody. [The present invention 1026] The antibody variant for use according to the invention 1024 or 1025, wherein said CD38 antibody is daratumumab. [The present invention 1027] The antibody variant for use according to any of the preceding claims, further comprising determining the presence of CD38-expressing immune cells in a biological sample taken from the subject prior to use. [The present invention 1028] The antibody variant for use according to any of the preceding claims, further comprising determining the presence of CD38-expressing Tregs in a biological sample taken from the subject prior to use. [The present invention 1029] The antibody variant for use according to the invention 1027 or 1028, wherein said biological sample is selected from a blood sample, a bone marrow sample and a tumor biopsy. [The present invention 1030] Optionally, the following steps: (a) plating approximately 500,000 freshly isolated PBMCs per well in cell culture medium overnight at 37°C; (b) adding approximately 100,000 per well of CD38 antibody-opsonized Tregs labeled with a common fluorescent intracellular amine dye overnight at 37° C.; and (c) measuring CD38 expression on Tregs by flow cytometry, where a decrease in CD38 on CD38 antibody-opsonized Tregs compared to controls indicates trogocytosis. When measured in an assay including An antibody variant for any of the aforementioned uses of the invention which reduces the number of CD38 molecules on Tregs in the presence of peripheral blood lymphocytes (PBMCs). [The present invention 1031] The antibody variant for use in the present invention 1030, wherein said control is an isotype control antibody. [The present invention 1032] 1030. An antibody variant for use in the present invention, which in said assay results in a reduction of CD38 expression on Tregs compared to a reference antibody having an identical amino acid sequence except for mutations of one or more amino acid residues corresponding to E430, E345 and S440 in the human IgG1 heavy chain, said amino acid residues being numbered according to the EU index. [The present invention 1033] The antibody variant for use according to any of the preceding claims, wherein the one or more amino acid residue mutations are selected from the group consisting of E430G, E345K, E430S, E430F, E430T, E345Q, E345R, E345Y, S440Y and S440W. [The present invention 1034] The antibody variant for any of the above uses of the invention, wherein the one or more amino acid residue mutations are selected from the group corresponding to E430G, E345K, E430S and E345Q. [The present invention 1035] The antibody variant for use according to any of the preceding claims, wherein the one or more amino acid residue mutations comprise E430G. [The present invention 1036] The antibody variant for use according to any of the preceding claims, wherein the mutation of one or more amino acid residues consists of E430G. [The present invention 1037] An antibody variant for use according to any of the preceding claims, wherein the variant Fc region comprises one or more further mutations, which do not reduce both complement dependent cytotoxicity (CDC) and antibody dependent cellular cytotoxicity (ADCC) induced by an antibody variant that does not comprise said one or more further mutations. [The present invention 1038] The antibody variant for use according to the invention 1037, wherein said one or more further mutations are 12 or fewer mutations, such as 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 mutation, such as a substitution, insertion or deletion, of amino acid residues. [The present invention 1039] The antibody variant for use in any of the preceding inventions, wherein said variant Fc region is of human IgG1, IgG2, IgG3 or IgG4 isotype, or mixed isotypes thereof, except for the recited mutations. [The present invention 1040] The antibody variant for use in any of the preceding inventions, wherein said variant Fc region is a human IgG1 Fc region, except for the recited mutations. [The present invention 1041] The antibody variant for use in any of the preceding inventions, wherein said variant Fc region is of the human IgG1m(f), IgG1m(a), IgG1m(x), IgG1m(z) allotype, or mixed allotypes thereof, except for the recited mutations. [The present invention 1042] An antibody variant for use according to any of the preceding claims which is a bivalent antibody. [The present invention 1043] An antibody variant for use according to any of the preceding claims which is a full length antibody. [The present invention 1044] The antibody variant for use in any of the preceding inventions which, except for the recited mutations, is a human antibody. [The present invention 1045] An antibody variant for use according to any of the preceding claims which is a bivalent antibody. [The present invention 1046] An antibody variant for use according to any of the preceding inventions which is a monoclonal antibody. [The present invention 1047] The antibody variant for use in any of the preceding inventions which, except for the recited mutations, is an IgG1 antibody. [The present invention 1048] The antibody variant for use in any of the preceding inventions which, except for the recited mutations, is a human monoclonal full length bivalent IgG1m(f),κ antibody. [The present invention 1049] (a) does not bind to a variant of human CD38 in which Asp at position 202 is replaced by Gly, (ii) binds to a variant of human CD38 in which Gln at position 272 is replaced by Arg, (iii) binds to a variant of human CD38 in which Ser at position 274 is replaced by Phe, and (iv) binds to a variant of human CD38 in which Thr at position 237 is replaced by Ala; (b) does not bind to a variant of human CD38 in which Ser at position 274 is substituted with Phe to the same extent as it binds to human CD38 and does not bind to a variant of human CD38 in which Gln at position 272 is substituted with Arg to the same extent as it binds to human CD38; or (c) binds to a variant of human CD38 in which Ser at position 274 is substituted with Phe to the same extent as it binds to human CD38, binds to a variant of human CD38 in which Gln at position 272 is substituted with Arg to the same extent as it binds to human CD38, and binds to a variant of human CD38 in which Thr at position 237 is substituted with Ala to the same extent as it binds to human CD38. An antibody variant for use according to any of the preceding claims. [The present invention 1050] An antibody variant for use according to any of the preceding claims, which specifically binds to the domains SKRNIQFSCKNIYR (SEQ ID NO:86) and EKVQTLEAWVIHGG (SEQ ID NO:87) and optionally further has binding characteristic (b) or (c) of the invention 1049. [The present invention 1051] (a) has an inhibitory effect on CD38 cyclase activity, optionally having the binding characteristics of an antibody of the invention (a) or (b) of 1049; (b) does not have an inhibitory effect on CD38 cyclase activity, and optionally has the binding characteristics of the antibody of (c) of the invention 1049; (c) induce complement-dependent cytotoxicity (CDC) of cells expressing human CD38; (d) induce antibody-dependent cellular cytotoxicity (ADCC) of cells expressing human CD38; (e) induce antibody-dependent cellular phagocytosis (ADCP); (f) does not induce apoptosis in the absence of an Fc cross-linking antibody; or (g) having any combination of characteristics of one of (a) and (b) and one or more of (c) through (f); An antibody variant for use according to any of the preceding claims. [The present invention 1052] An antibody variant for use in any of the preceding claims, which has an inhibitory effect on the cyclase activity of human CD38. [The present invention 1053] The cyclase activity is (a) seeding 200,000 Daudi or Wien133 cells in 100 μL of 20 mM Tris-HCL per well in a multi-well plate; or seeding 0.6 μg / mL His-tagged soluble CD38 (SEQ ID NO:84) in 100 μL of 20 mM Tris-HCL per well; (b) adding 1 μg / mL of CD38 antibody and 80 μM of NGD to each well; (c) measuring the fluorescence until a plateau is reached (e.g., 5, 10, or 30 minutes); and (d) determining the percent inhibition by comparison with a control, such as wells incubated with an isotype control antibody. The antibody variant for use in the present invention 1051 or 1052, which is determined by a method comprising: [The present invention 1054] The CDC: (a) plating 100,000 CD38-expressing cells per well in 40 μL of culture medium supplemented with 0.2% BSA in a multi-well plate; (b) pre-incubating the cells with 40 μL of serially diluted CD38 antibodies (0.0002–10 μg / mL) for 20 min; (c) incubating each well with 20% pooled normal human serum at 37° C. for 45 minutes; (d) adding a viability dye and measuring the percentage of cell lysis with a flow cytometer; (e) determining maximum lysis using nonlinear regression An antibody variant for use in any of claims 1051 to 1053, as determined by an assay comprising: [The present invention 1055] The antigen-binding region comprises: (a) a VH CDR1 having the sequence set forth in SEQ ID NO:37, a VH CDR2 having the sequence set forth in SEQ ID NO:38, a VH CDR3 having the sequence set forth in SEQ ID NO:39, a VL CDR1 having the sequence set forth in SEQ ID NO:41, a VL CDR2 having the sequence AAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:42; (b) a VH CDR1 having the sequence set forth in SEQ ID NO:9, a VH CDR2 having the sequence set forth in SEQ ID NO:10, a VH CDR3 having the sequence set forth in SEQ ID NO:11, a VL CDR1 having the sequence set forth in SEQ ID NO:13, a VL CDR2 having the sequence DAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:14; (c) a VH CDR1 having the sequence set forth in SEQ ID NO:2, a VH CDR2 having the sequence set forth in SEQ ID NO:3, a VH CDR3 having the sequence set forth in SEQ ID NO:4, a VL CDR1 having the sequence set forth in SEQ ID NO:6, a VL CDR2 having the sequence AAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:7; (d) a VH CDR1 having the sequence set forth in SEQ ID NO:16, a VH CDR2 having the sequence set forth in SEQ ID NO:17, a VH CDR3 having the sequence set forth in SEQ ID NO:18, a VL CDR1 having the sequence set forth in SEQ ID NO:20, a VL CDR2 having the sequence set forth in SEQ ID NO:DAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:21; (e) a VH CDR1 having the sequence set forth in SEQ ID NO:23, a VH CDR2 having the sequence set forth in SEQ ID NO:24, a VH CDR3 having the sequence set forth in SEQ ID NO:25, a VL CDR1 having the sequence set forth in SEQ ID NO:27, a VL CDR2 having the sequence AAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:28; (f) a VH CDR1 having the sequence set forth in SEQ ID NO:30, a VH CDR2 having the sequence set forth in SEQ ID NO:31, a VH CDR3 having the sequence set forth in SEQ ID NO:32, a VL CDR1 having the sequence set forth in SEQ ID NO:34, a VL CDR2 having the sequence AAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:35; (g) a VH CDR1 having the sequence set forth in SEQ ID NO:44, a VH CDR2 having the sequence set forth in SEQ ID NO:45, a VH CDR3 having the sequence set forth in SEQ ID NO:46, a VL CDR1 having the sequence set forth in SEQ ID NO:48, a VL CDR2 having the sequence AAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:49; (h) a VH CDR1 having the sequence set forth in SEQ ID NO:51, a VH CDR2 having the sequence set forth in SEQ ID NO:52, a VH CDR3 having the sequence set forth in SEQ ID NO:53, a VL CDR1 having the sequence set forth in SEQ ID NO:55, a VL CDR2 having the sequence AAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:56; or (i) a VH CDR1 having the sequence set forth in SEQ ID NO:88, a VH CDR2 having the sequence set forth in SEQ ID NO:89, a VH CDR3 having the sequence set forth in SEQ ID NO:90, a VL CDR1 having the sequence set forth in SEQ ID NO:91, a VL CDR2 having the sequence AAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:92 An antibody variant for use in any of the present inventions 1001 to 1054, comprising a variable heavy chain (VH) region and a variable light chain (VL) region comprising a complementarity determining region (CDR) selected from the group consisting of: [The present invention 1056] (i) a VH region comprising the VH CDRs and VL CDRs of (a) and an amino acid sequence having at least 80% identity, such as 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:36, optionally differing from SEQ ID NO:36 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (ii) a VH region comprising the VH CDRs and VL CDRs of (b) and an amino acid sequence having at least 80% identity, such as 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:8, optionally differing from SEQ ID NO:8 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (iii) a VH region comprising the VH CDRs and VL CDRs of (c) and an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:1, optionally differing from SEQ ID NO:1 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (iv) a VH region comprising the VH CDRs and VL CDRs of (d) and an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:15, optionally differing from SEQ ID NO:15 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (v) a VH region comprising the VH CDRs and VL CDRs of (e) and an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:22, optionally differing from SEQ ID NO:22 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (vi) a VH region comprising the VH CDRs and VL CDRs of (f) and an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:29, optionally differing from SEQ ID NO:29 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (vii) a VH region comprising the VH CDRs and VL CDRs of (g) and an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:43, optionally differing from SEQ ID NO:43 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; or (viii) a VH region comprising the VH CDRs and VL CDRs of (h) and an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:50, optionally differing from SEQ ID NO:50 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions. The antibody variant for use in the present invention 1055, comprising [The present invention 1057] (i) a VH region, and a VL region comprising an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:40, optionally differing from SEQ ID NO:40 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (ii) a VH region of, and a VL region comprising an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:12, optionally differing from SEQ ID NO:12 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (iii) a VH region of, and a VL region comprising an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:5, optionally differing from SEQ ID NO:5 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (iv) a VH region of, and a VL region comprising an amino acid sequence having at least 80% identity to SEQ ID NO:19, e.g., 90%, 95%, 97%, 98% or 99% identity, optionally differing from SEQ ID NO:19 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (v) a VH region of, and a VL region comprising an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:26, optionally differing from SEQ ID NO:26 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (vi) a VH region of, and a VL region comprising an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:33, optionally differing from SEQ ID NO:33 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (vii) a VH region and a VL region comprising an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:47, optionally differing from SEQ ID NO:47 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; or (viii) a VH region, and a VL region comprising an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:54, optionally differing from SEQ ID NO:54 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions. The antibody variant for use in the present invention 1055 or 1056, comprising [The present invention 1058] (a) a VH region comprising SEQ ID NO:36 and a VL region comprising SEQ ID NO:40; (b) a VH region comprising SEQ ID NO:8 and a VL region comprising SEQ ID NO:12; (c) a VH region comprising SEQ ID NO:1 and a VL region comprising SEQ ID NO:5; (d) a VH region comprising SEQ ID NO:15 and a VL region comprising SEQ ID NO:19; (e) a VH region comprising SEQ ID NO:22 and a VL region comprising SEQ ID NO:26; (f) a VH region comprising SEQ ID NO:29 and a VL region comprising SEQ ID NO:33; (g) a VH region comprising SEQ ID NO:43 and a VL region comprising SEQ ID NO:47; or (h) a VH region comprising SEQ ID NO:50 and a VL region comprising SEQ ID NO:54 An antibody variant for use according to any of the preceding claims. [The present invention 1059] An antibody variant for use in the present invention 1058, comprising a VH region comprising SEQ ID NO:36 and a VL region comprising SEQ ID NO:40. [The present invention 1060] An antibody variant for use in the present invention 1058 comprising a VH region comprising SEQ ID NO:8 and a VL region comprising SEQ ID NO:12. [The present invention 1061] 1. A nucleic acid or combination of nucleic acids for use in treating cancer in a subject, comprising: The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing immune cells; Said nucleic acid or combination of nucleic acids. [The present invention 1062] A nucleic acid or combination of nucleic acids for use according to the invention 1061, comprising any one or more of the further features of the inventions 1002 to 1060. [The present invention 1063] 1. A delivery vehicle comprising a nucleic acid or a combination of nucleic acids for use in treating cancer in a subject, comprising: The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing immune cells; The delivery vehicle. [The present invention 1064] A delivery vehicle of the present invention 1063 comprising any one or more of the additional features of the present inventions 1002 to 1060. [The present invention 1065] The delivery vehicle of the present invention 1063 or 1064 which is a particle. [The present invention 1066] The delivery vehicle of the present invention 1065, wherein said particle is a lipid nanoparticle (LNP). [The present invention 1067] The delivery vehicle of the present invention 1066, wherein said LNP comprises a lipid, an ionizable amino lipid, a PEG lipid, cholesterol, or any combination thereof. [The present invention 1068] 1. An antibody variant for use in enhancing an immune response in a subject, comprising: an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells, The antibody variant. [The present invention 1069] 1. An antibody variant for use in treating cancer in a subject, comprising: an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing tumor cells, The antibody variant. [The present invention 1070] An antibody variant for use according to the invention 1068 or 1069, comprising any one or more of the further features of the invention 1002 to 1060. [The present invention 1071] 1. A method of treating cancer in a subject comprising administering to the subject an antibody variant, The antibody variant comprises: an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells, The method. [The present invention 1072] 1. A method of enhancing an immune response in a subject comprising administering to the subject an antibody variant, The antibody variant comprises: an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells, The method. [The present invention 1073] 1. A method of treating cancer in a subject comprising administering to the subject an antibody variant, The antibody variant comprises: an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing tumor cells, The method. [The present invention 1074] The method of any of claims 1071 to 1073, wherein said antibody variant is administered in a therapeutically effective amount and / or for a time sufficient to treat said disease. [The present invention 1075] A method according to any one of claims 1071 to 1074, further comprising the features of any one of claims 1002 to 1060. [The present invention 1076] 1. A nucleic acid or combination of nucleic acids for use in enhancing an immune response in a subject, comprising: The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing immune cells; Said nucleic acid or combination of nucleic acids. [The present invention 1077] 1. A nucleic acid or combination of nucleic acids for use in treating cancer in a subject, comprising: The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing tumor cells; Said nucleic acid or combination of nucleic acids. [The present invention 1078] A nucleic acid or combination of nucleic acids for use according to the invention 1076 or 1077, comprising any one or more of the further features of the invention 1002 to 1060. [The present invention 1079] 1. A delivery vehicle comprising a nucleic acid or a combination of nucleic acids for use in promoting an immune response in a subject, comprising: The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing immune cells; The delivery vehicle. [The present invention 1080] 1. A delivery vehicle comprising a nucleic acid or a combination of nucleic acids for use in treating cancer in a subject, comprising: The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing tumor cells; The delivery vehicle. [The present invention 1081] A delivery vehicle of the present invention 1079 or 1080 comprising any one or more of the additional features of the present invention 1002 to 1060. [The present invention 1082] A delivery vehicle according to any one of claims 1079 to 1081, which is a particle. [The present invention 1083] The delivery vehicle of the present invention 1082, wherein the particle is a lipid nanoparticle (LNP). [The present invention 1084] The delivery vehicle of the present invention 1083, wherein said LNP comprises a lipid, an ionizable amino lipid, a PEG lipid, cholesterol, or any combination thereof. [The present invention 1085] 1. A method of treating cancer in a subject comprising administering to the subject a nucleic acid or a combination of nucleic acids, The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing immune cells; The method. [The present invention 1086] 1. A method of enhancing an immune response in a subject, comprising administering to the subject a nucleic acid or a combination of nucleic acids, The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing immune cells; The method. [The present invention 1087] 1. A method of treating cancer in a subject comprising administering to the subject a nucleic acid or a combination of nucleic acids, The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing tumor cells; The method. [The present invention 1088] The method of any one of claims 1085 to 1087, further comprising any one or more features of claims 1002 to 1060. [The present invention 1089] 1. A method of treating cancer in a subject comprising administering to the subject a delivery vehicle comprising a nucleic acid or a combination of nucleic acids, The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing immune cells; The method. [The present invention 1090] 1. A method of enhancing an immune response in a subject, comprising administering to the subject a delivery vehicle comprising a nucleic acid or a combination of nucleic acids, The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing immune cells; The method. [The present invention 1091] 1. A method of treating cancer in a subject comprising administering to the subject a delivery vehicle comprising a nucleic acid or a combination of nucleic acids, The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing tumor cells; The method. [The present invention 1092] The method of any one of claims 1089 to 1091, further comprising any one or more features of claims 1002 to 1060. [The present invention 1093] The method of any one of claims 1089 to 1092, wherein the delivery vehicle is a particle. [The present invention 1094] The method of claim 1093, wherein the particle is a lipid nanoparticle (LNP). [The present invention 1095] The method of claim 1094, wherein said LNP comprises a lipid, an ionizable amino lipid, a PEG lipid, cholesterol, or any combination thereof. These and other aspects and embodiments of the present invention are described in greater detail below. [Brief description of the drawings]

[0020] [Figure 1] 1 shows an amino acid sequence alignment using Clustal 2.1 software for human IgG1m(a), IgG1m(f), IgG2, IgG3 and IgG4 Fc segments corresponding to residues P247 to K447 of the human IgG1 heavy chain, where amino acid residues are numbered according to the EU index as described in Kabat. The amino acid sequences shown correspond to residues 130-330 of the heavy chain constant region of the allotypic variants of human IgG1 designated IgG1m(za) (SEQ ID NO:64; UniProt Accession No. P01857), IgG1m(f) (SEQ ID NO:65), IgG1m(z) (SEQ ID NO:66), IgG1m(a) (SEQ ID NO:67) and IgG1m(x) (SEQ ID NO:68); residues 126-326 of the IgG2 heavy chain constant region (SEQ ID NO:79; UniProt Accession No. P01859); residues 177-377 of the IgG3 heavy chain constant region (SEQ ID NO:80; UniProt Accession No. P01860); and residues 127-327 of the IgG4 heavy chain constant region (SEQ ID NO:81; UniProt Accession No. P01861). [Diagram 2] Binding of CD38 antibody variants IgG1-A-E430G, IgG1-B-E430G and IgG1-C-E430G to CD38-expressing NALM16 cells is shown in comparison with CD38 antibodies IgG1-A, IgG1-B, IgG1-C, and an isotype control antibody. For details, see Example 2. [Diagram 3] Binding of CD38 antibody variants IgG1-A-E430G, IgG1-B-E430G and IgG1-C-E430G to CD38 expressed on cynomolgus monkey PBMCs (A) or to Daudi cells expressing high copy numbers of human CD38 (B) is shown compared to an isotype control antibody. For details, see Example 2. [Figure 4] Percent lysis induced by CD38 antibody variants IgG1-A-E430G, IgG1-B-E430G and IgG1-C-E430G in comparison to CD38 antibodies IgG1-A, IgG1-B and IgG1-C in CDC assays of Ramos (A), Daudi (B), Wien-133 (C), NALM-16 (D), REH (E), RS4;11 (F), U266 (G) and RC-K8 (H) tumor cell lines. For details, see Example 3. [Diagram 5] Figure 1 shows the effect of CD38 antibody variants IgG1-A-E430G, IgG1-B-E430G and IgG1-C-E430G on the number of viable NK cells (A), T cells (B) and B cells (C) in a CDC assay performed on whole blood, compared to CD38 antibodies IgG1-A, IgG1-B and IgG1-C. For details, see Example 3. [Figure 6] Figure 1 shows the percentage lysis of Daudi cells induced by CD38 antibody variants IgG1-A-E430G, IgG1-B-E430G and IgG1-C-E430G in a chromium release ADCC assay compared to CD38 antibodies IgG1-A, IgG1-B, IgG1-C and an isotype control antibody. For details, see Example 4. [Figure 7] Dose-dependent FcγRIIIa cross-linking of CD38 antibody variants IgG1-A-E430G, IgG1-B-E430G and IgG1-C-E430G in ADCC reporter assays compared to CD38 antibodies IgG1-A, IgG1-B, IgG1-C and isotype control antibodies. For details, see Example 4. [Figure 8] The effect of CD38 antibody variants IgG1-A-E430G, IgG1-B-E430G and IgG1-C-E430G on the percentage of PKH-29pos, CD14pos and CD19neg macrophages in ADCP assay is shown in comparison with CD38 antibodies IgG1-A, IgG1-B, IgG1-C and isotype control antibody. For details, see Example 5. [Figure 9] Percent lysis of Ramos (A), Daudi (B,C), Wien-133 (D,E) and NALM-16 (F,G) tumor cell lines induced by CD38 antibody variants IgG1-A-E430G, IgG1-B-E430G and IgG1-C-E430G in apoptosis assays performed with (C,E,G) or without (A,B,D,F) Fc cross-linking antibodies is shown compared to CD38 antibodies IgG1-A, IgG1-B, IgG1-C and isotype control antibodies. For details, see Example 6. [Figure 10] The enzyme activity of CD38 is shown. [Figure 11] The effect of CD38 antibody variants IgG1-A-E430G, IgG1-B-E430G and IgG1-C-E430G on the cyclase activity of HisCD38 (A), Daudi cells (B) and Wien-133 cells (C), reflected as % NDG conversion over time, is shown in comparison with CD38 antibodies IgG1-A, IgG1-B, IgG1-C and an isotype control antibody. [Figure 12] Figure 1 shows the effect of CD38 antibody variants IgG1-A-E430G, IgG1-B-E430G and IgG1-C-E430G on CD38 expression on Daudi cells after 45 min co-culture with macrophages, compared to CD38 antibodies IgG1-A, IgG1-B, IgG1-C and an isotype control antibody. Macrophages were from donor A (A,B) or donor B (B,D) and antibody-opsonized cells were tested for CD38 expression (A,B) or human IgG staining (C,D). [Figure 13]The effect of CD38 antibody variants IgG1-B-E430G and IgG1-C-E430G on CD38 expression on T regulatory cells with or without PBMCs is shown compared to IgG1-B. [Figure 14] 1 shows an alignment of the amino acid sequences of VH (A) and VL (B) of antibodies C and EH described herein. The CDR regions are underlined. [Figure 15-1] Percent lysis of various B cell tumor cell lines induced by CD38 antibody variants IgG1-A-E430G (closed triangles), IgG1-B-E430G (closed circles) and IgG1-C-E430G (closed squares) in a CDC assay is shown compared to CD38 antibody IgG1-B (open circles) and an isotype control antibody (open diamonds). For details, see Example 3. [Figure 15-2] This is a continuation of Figure 15-1. [Figure 15-3] This is a continuation of Figure 15-2. [Figure 15-4] This is a continuation of Figure 15-3. [Figure 16] A summary of some of the EC50 values ​​presented in Table 4 is shown. The EC50 values ​​of CDC induced by antibodies IgG1-B, IgG1-B-E430G and IgG1-C-E430G in 20 different B cell tumor cell lines are shown. Each square, triangle or circle represents a different B cell tumor cell line. IgG1-B-E430G was not tested in AML cell lines, so the EC50 values ​​obtained in AML cell lines are not included. [Figure 17-1] The percentage lysis of various AML tumor cell lines induced by CD38 antibody variant IgG1-C-E430G (closed circles) in a CDC assay is shown in comparison to CD38 antibody IgG1-B (open circles) and an isotype control antibody (closed squares). For details, see Example 3. [Figure 17-2] This is a continuation of Figure 17-1. [Figure 18]The percentage of T regulatory cell lysis induced by CD38 antibody variants IgG1-B-E430G (closed circles) and IgG1-C-E430G (closed squares) in a CDC assay is shown compared to CD38 antibody IgG1-B (open circles). For details, see Example 3. [Figure 19] Figure 1 shows the percent lysis of Daudi, Wien-133, Granta 519, and MEC-2 cells induced by CD38 antibody variants IgG1-B-E430G, IgG1-C-E430G in a chromium release ADCC assay compared to CD38 antibodies IgG-B, IgG1-C, and IgG1-b12-E430G. For details, see Example 4. [Figure 20] Dose-dependent FcγRIIIa cross-linking of CD38 antibody variants IgG1-A-E430G, IgG1-B-E430G and IgG1-C-E430G in an ADCC reporter assay using T regulatory cells is shown in comparison with CD38 antibodies IgG1-A, IgG1-B, IgG1-C and an isotype control antibody. For details, see Example 4. [Figure 21] Figure 2 shows tumor size (mm3) in mice treated with either CD38 antibody variant IgG1-C-E430G or PBS (negative control). For details, see Example 9. [Figure 22] Assay setup for measuring trogocytosis: 1) Daudi cells were labeled with PKH-26 (membrane stain) and cell trace violet (cytosol stain) and opsonized with CD38 antibody. 2) Labeled Daudi cells and macrophages were co-cultured at 37° C. for 2 hours to allow macrophages to attach. 3) Cell membrane transfer from Daudi cells to macrophages or trogocytosis. 4) Dissociation of macrophage-Daudi interactions and degradation of Daudi cell membrane within macrophages. For details, see Example 8. [Figure 23]Complement-mediated cytotoxicity by IgG1-C-E430G or Darzalex® in bone marrow mononuclear cells from three patients with newly diagnosed MM (A, B, and D) and one patient with relapsed / refractory MM (C). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0021] Detailed Description of the Invention In describing aspects of the present invention, specific terminology is used for the sake of clarity, however, the invention is not intended to be limited to the specific terminology so selected, and it is understood that each specific term includes all technical equivalents that operate in a similar manner to accomplish a similar purpose.

[0022] definition The term "CD38" as used herein generally refers to human CD38 having the sequence set forth in SEQ ID NO:83 (UniProtKB - P28907 (CD38_HUMAN)), but may also refer to variants, isoforms and orthologs thereof, unless the context indicates otherwise. Variants of human CD38 having S274, Q272R, T237A or D202G mutations are described in WO 2006 / 099875 A1 and WO 2011 / 154453 A1.

[0023] The term "immunoglobulin" refers to a class of structurally related glycoproteins consisting of two pairs of polypeptide chains, one pair of low molecular weight light (L) chains and one pair of heavy (H) chains, all four of which may be interconnected by disulfide bonds. The structure of immunoglobulins has been well characterized; see, for example, Fundamental Immunology, Chapter 7 (Paul, W., ed., 2nd ed. Raven Press, NY (1989)). Briefly, each heavy chain typically consists of a heavy chain variable (VH) region and a heavy chain constant (CH) region. The CH region usually consists of three domains, CH1, CH2 and CH3. The heavy chains are generally interconnected via disulfide bonds at the so-called "hinge region". Each light chain typically consists of a light chain variable (VL) region and a light chain constant region, the latter usually consisting of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability (i.e., hypervariable regions that may be hypervariable in sequence and / or in the form of structurally defined loops), also called complementarity determining regions (CDRs), sandwiched between more conserved regions called framework regions (FRs). Each VH and VL region is typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (see also Chothia and Lesk J. Mol. Biol. 196, 901 917 (1987)).

[0024] Unless otherwise stated or contradicted by context, CDR sequences herein are identified according to the IMGT rules using DomainGapAlign (Lefranc MP., Nucleic Acids Research 1999;27:209-212 and Ehrenmann F., Kaas Q. and Lefranc M.-P. Nucleic Acids Res., 38, D301-307 (2010); see also internet http address www.imgt.org / ).

[0025] Unless otherwise indicated or contradicted by the context, references to amino acid positions of the CH or Fc region / Fc domain in the present invention are according to EU numbering (Edelman et al., Proc Natl Acad Sci US A. 1969 May;63(1):78-85; Kabat et al., Sequences of proteins of immunological interest. 5th Edition - 1991 NIH Publication No. 91-3242). However, amino acid residues of CH of isotypes other than human IgG1 may alternatively be referred to at the corresponding amino acid positions of a wild-type human IgG1 heavy chain, in which the amino acid residues are numbered according to the EU index. Specifically, the corresponding amino acid positions can be identified as shown in FIG. 1, i.e., by (a) aligning the amino acid sequence of the non-IgG1 constant region (or a segment thereof) with the amino acid sequence of a human IgG1 heavy chain (or a segment thereof), in which the amino acid residues are numbered according to the EU index, and (b) identifying which amino acid position in the IgG1 heavy chain the amino acid residue aligns to. Thus, such an amino acid residue position may be referred to herein as "an amino acid residue at a position corresponding to" followed by the amino acid position of a wild-type human IgG1 heavy chain numbered according to the EU index. When referring to one or more of several different amino acid positions, this may be referred to herein as "a mutation of one or more amino acid residues at a position selected from the group consisting of positions corresponding to", "a mutation of one or more amino acid residues at a position corresponding to" or simply "a mutation of one or more amino acid residues selected from the group corresponding to" followed by two or more amino acid positions of a human wild-type IgG1 heavy chain in which the amino acid residues are numbered according to the EU index (e.g., E430, E345 and S440).

[0026] The term "hinge region" as used herein is intended to refer to the hinge region of an immunoglobulin heavy chain. Thus, for example, the hinge region of a human IgG1 antibody corresponds to amino acids 216-230 according to EU numbering.

[0027] The term "CH2 region" or "CH2 domain" as used herein is intended to refer to the CH2 region of an immunoglobulin heavy chain. Thus, for example, the CH2 region of a human IgG1 antibody corresponds to amino acids 231-340 according to EU numbering. However, the CH2 region may also be of any of the other subtypes described herein.

[0028] The term "CH3 region" or "CH3 domain" as used herein is intended to refer to the CH3 region of an immunoglobulin heavy chain. Thus, for example, the CH3 region of a human IgG1 antibody corresponds to amino acids 341-447 according to EU numbering. However, the CH3 region may also be of any of the other subtypes described herein.

[0029] 2 (WO2008 / 003116), and dual scFv-fusions. The term antibody, unless otherwise specified, is to be understood to include: monoclonal antibodies (such as human monoclonal antibodies), polyclonal antibodies, chimeric antibodies, humanized antibodies, monospecific antibodies (such as bivalent monospecific antibodies), bispecific antibodies, antibodies of any isotype and / or allotype; antibody mixtures (recombinant polyclonal), for example produced by technology developed by Symphogen and Merus (Oligoclonics), multimeric Fc proteins as described in WO2015 / 158867, and fusion proteins as described in WO2014 / 031646. Although these different antibody fragments and formats are generally included in the meaning of antibodies, they collectively and each independently are unique features of the present invention and exhibit different biological properties and utilities.

[0030] As used herein, a "CD38 antibody" or "anti-CD38 antibody" is an antibody that specifically binds to the antigen CD38.

[0031] The term "human antibody" as used herein is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the invention may contain amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations, insertions or deletions introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, the term "human antibody" as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[0032] As used herein, the terms "monoclonal antibody", "monoclonal Ab", "monoclonal antibody composition", "mAb" and the like refer to a preparation of Ab molecules of a single molecular composition. A monoclonal antibody composition exhibits a single binding specificity and affinity for a particular epitope. Thus, the term "human monoclonal antibody" refers to an Ab exhibiting a single binding specificity having variable and constant regions derived from human germline immunoglobulin sequences. Human mAbs can be produced from hybridomas, which are fused to immortalized cells from B cells obtained from a transgenic or transchromosomal non-human animal, such as a transgenic mouse, whose genome includes human heavy and light chain transgene repertoires rearranged to produce functional human antibodies.

[0033] As used herein, "isotype" refers to the immunoglobulin class encoded by the heavy chain constant region genes and includes, for example, IgG1, IgG2, IgG3, IgG4, IgD, IgA1, IgA2, IgE, and IgM, as well as any allotypes thereof, such as IgG1m(z), IgG1m(a), IgG1m(x), IgG1m(f), etc., and mixed allotypes thereof, such as IgG1m(za), IgG1m(zax), IgG1m(fa), etc. (see, e.g., de Lange, Experimental and Clinical Immunogenetics 1989;6(1):7-17).

[0034] Furthermore, each heavy chain isotype can be combined with either a kappa (κ) or lambda (λ) light chain. As used herein, the term "mixed isotype" refers to an immunoglobulin Fc region that is obtained by combining structural features of one isotype with a similar region from another isotype to generate a hybrid isotype. A mixed isotype comprises an Fc region having a sequence of two or more isotypes selected from the following: IgG1, IgG2, IgG3, IgG4, IgD, IgA1, IgGA2, IgE, or IgM, thereby generating combinations such as IgG1 / IgG3, IgG1 / IgG4, IgG2 / IgG3, IgG2 / IgG4, or IgG1 / IgA.

[0035] The term "full length antibody" as used herein refers to an antibody (e.g., a parent antibody or a variant antibody) that contains all heavy and light chain constant and variable domains that normally correspond to those found in a wild-type antibody of the isotype in question.

[0036] A "full-length bivalent monospecific monoclonal antibody" as used herein refers to a bivalent, monospecific antibody (e.g., a parent antibody or a variant antibody) formed by a pair of identical HC and a pair of identical LC, in which the constant and variable domains correspond to those normally found in antibodies of the particular isotype in question.

[0037] As used herein, the term "antigen-binding region", "binding region" or antigen-binding domain refers to the region of an antibody capable of binding to an antigen. This binding region is typically defined by the VH and VL domains of an antibody, which can be further subdivided into regions of hypervariability (i.e., hypervariable regions that may be hypervariable in sequence and / or in the form of structurally defined loops), also called complementarity determining regions (CDRs), sandwiched between more conserved regions called framework regions (FRs). An antigen can be any molecule, such as a polypeptide, present on a cell, for example.

[0038] The term "target" as used herein refers to a molecule to which the antigen-binding region of an antibody binds. Targets include any antigen against which an antibody is raised. The terms "antigen" and "target" can be used interchangeably in the context of an antibody and may constitute the same meaning and purpose with respect to any aspect or embodiment of the present invention.

[0039] The term "epitope" refers to a protein determinant capable of specific binding to an antibody variable domain. Epitopes usually consist of surface groupings of molecules such as amino acids, sugar side chains, or combinations thereof, and usually have specific three-dimensional structural characteristics as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents. Epitopes may include amino acid residues that are directly involved in binding (also called immunodominant components of the epitope) and other amino acid residues that are not directly involved in binding.

[0040] "Variant" as used herein refers to a protein or polypeptide sequence that differs from a parent or reference sequence by one or more amino acid residues. A variant may, for example, have at least 80%, for example, 90%, 95%, 97%, 98%, or 99% sequence identity to a parent or reference sequence. Additionally or alternatively, a variant may differ from a parent or reference sequence by 12 or fewer mutations, for example, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutation, for example, substitution, insertion, or deletion, of amino acid residues. Thus, "variant antibody" or "antibody variant", as used interchangeably herein, refers to an antibody that differs from a parent or reference antibody by one or more amino acid residues, for example, in the antigen-binding region, the Fc region, or both. Similarly, a "variant Fc region" or "Fc region variant" refers to an Fc region that differs in one or more amino acid residues compared to a parent or reference Fc region, and optionally differs from the parent or reference Fc region amino acid sequence by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 mutation, e.g., substitution, insertion or deletion, of amino acid residues. The parent or reference Fc region is typically an Fc region of a human wild-type antibody, and may be of a particular isotype, depending on the context. The variant Fc region may be in a dimerized form, either homodimeric or heterodimeric, e.g., one of the amino acid sequences of the dimerized Fc region contains a mutation, while the other is identical to the parent or reference wild-type amino acid sequence. Examples of amino acid sequences of wild-type (usually parent or reference sequence) IgG CH and variant IgG constant regions, including the amino acid sequence of the Fc region, are shown in Table 1.

[0041] In the context of the present invention, conservative substitutions may be defined as substitutions within the following classes of amino acids: - Acidic residues: Asp (D) and Glu (E) - Basic residues: Lys (K), Arg (R), and His (H) - Hydrophilic uncharged residues: Ser (S), Thr (T), Asn (N), and Gln (Q) - Aliphatic uncharged residues: Gly (G), Ala (A), Val (V), Leu (L), and Ile (I) - Non-polar uncharged residues: Cys (C), Met (M), and Pro (P) - Aromatic residues: Phe (F), Tyr (Y), and Trp (W)

[0042] Alternative conservative amino acid residue substitution classes: 1. AST 2. DE 3. NQ 4. RK 5. ILM 6. FYW

[0043] Alternative physical and functional classification of amino acid residues: - Alcohol group-containing residues: S and T - Aliphatic residues: I, L, V, and M - Cycloalkenyl related residues: F, H, W, and Y - Hydrophobic residues: A, C, F, G, H, I, L, M, R, T, V, W, and Y - Negatively charged residues: D and E - Polar residues: C, D, E, H, K, N, Q, R, S, and T - Positively charged residues: H, K, and R - Small residues: A, C, D, G, N, P, S, T, and V - Very small residues: A, G, and S - Residues involved in turn formation: A, C, D, E, G, H, K, N, Q, R, S, P, and T - Flexible residues: Q, T, K, S, G, N, D, E, and R

[0044] As used herein, "sequence identity" refers to the percent identity between two sequences as a function of the number of identical positions shared by the two sequences, taking into account the number of gaps that need to be introduced for optimal alignment of the two sequences and the length of each gap (i.e., percent homology = number of identical positions / total number of positions x 100). The percent identity between two nucleotide or amino acid sequences can be determined, for example, using the algorithm of E. Meyers and W. Miller, Comput. Appl. Biosci 4, 11-17 (1988) as incorporated into the ALIGN program (version 2.0), with a PAM 120 weight residue table, gap length penalty 12, and gap penalty 4. Additionally, the percent identity between two amino acid sequences can be determined using the algorithm of Needleman and Wunsch, J. Mol. Biol. 48, 444-453 (1970). Other tools for sequence alignment are publicly available on the internet and include, but are not limited to, Clustal Omega and EMBOSS Needle on the EMBL-EBI website at www.ebi.ac.uk. Typically, default settings may be used.

[0045] In the context of the present invention, unless otherwise indicated, the following notation is used to describe the mutations: the name of the mutated amino acid, followed by the number of the position where it is mutated, followed by what the mutation involves. Thus, if the mutation is a substitution, the name of the amino acid replacing the previous one is included, if an amino acid is deleted it is indicated with a "*", if the mutation is an addition, the added amino acid is included after the original amino acid. The amino acid name may be a one-letter code or a three-letter code. Thus, for example, a substitution of glutamic acid at position 430 with glycine is indicated as E430G, a substitution of glutamic acid at position 430 with any amino acid is indicated as E430X, a deletion of glutamic acid at position 430 is indicated as E430*, and an addition of proline after glutamic acid at position E430 is indicated as E430EP.

[0046] As used herein, "immunosuppressive cells" refers to immune cells that can suppress immune responses in a subject, for example, by suppressing the activity of effector T cells and / or inhibiting the proliferation of T cells. Examples of such immune suppressive cells include, but are not limited to, regulatory T cells (Tregs), regulatory B cells (Bregs), and myeloid-derived suppressor cells (MDSCs). In addition, there are immune suppressive NK cells, NKT cells, macrophages, and antigen-presenting cells (APCs). One example of the phenotype of an immune suppressive NK cell is CD56 bright CD16 - It is.

[0047] "Regulatory T cells" or "Tregs" or "Treg" refers to T lymphocytes that regulate the activity of other T cells and / or other immune cells, usually by suppressing their activity. An example of a Treg phenotype is the CD3 + CD4 + CD25 + CD127 dim Tregs may further express Foxp3. It is understood that Tregs may not be entirely restricted to this phenotype.

[0048] "Effector T cells" or "Teffs" or "Teff" refers to T lymphocytes that carry out functions of the immune response, such as killing tumor cells and / or activating anti-tumor immune responses that result in the clearance of tumor cells from the body. Examples of Teff phenotypes include CD3 + CD4 + and CD3 + CD8 + Teffs can secrete, contain, or express markers such as IFNγ, Granzyme B, ICOS, etc. It is understood that Teffs may not be entirely restricted to these phenotypes.

[0049] "Myeloid-derived suppressor cells" or "MDSCs" or "MDSC" refers to a specific population of cells of hematopoietic lineage that express the macrophage / monocyte marker CD11b and the granulocyte marker Gr-1 / Ly-6G. An example of an MDSC phenotype is CD11b + HLA-DR - CD14 - CD33 + CD15 + MDSCs also typically show low or undetectable expression of mature antigen-presenting cell markers MHC class II and F480. MDSCs are immature cells of the myeloid lineage that can further differentiate into other cell types, such as macrophages, neutrophils, dendritic cells, monocytes, and granulocytes. MDSCs are naturally found in normal adult bone marrow in humans and animals, or at normal hematopoietic sites, such as the spleen.

[0050] "Regulatory B cells" or "Breg" or "Bregs" refer to B lymphocytes that suppress immune responses. An example of a Breg phenotype is the CD19 + CD24 + CD38 + Bregs can suppress immune responses by inhibiting T cell proliferation mediated by IL-10 secreted by Bregs. Of course, other Breg subsets exist, as described, for example, in Ding et al., (2015) Human Immunology 76: 615-621.

[0051] The term "effector cell" as used herein refers to an immune cell that participates in the effector phase of an immune response. Exemplary immune cells include cells of myeloid or lymphoid origin, such as lymphocytes (such as B cells and T cells, including cytolytic T cells (CTLs)), killer cells, natural killer cells, macrophages, monocytes, eosinophils, polymorphonuclear cells, such as neutrophils, granulocytes, mast cells, basophils, and the like. Some effector cells express Fc receptors (FcRs) or complement receptors to perform specific immune functions. In some embodiments, effector cells, such as natural killer cells, can induce ADCC. For example, monocytes, macrophages, neutrophils, dendritic cells, and Kupffer cells that express FcRs are involved in the specific killing of target cells and / or the presentation of antigens to other components of the immune system, or binding to cells that present antigens. In some embodiments, ADCC can be further enhanced by antibody-driven classical complement activation, resulting in the deposition of activated C3 fragments on target cells. C3 cleavage products are ligands for complement receptors (CRs), such as CR3, expressed on myeloid cells. Recognition of complement fragments by CRs on effector cells can promote the enhancement of Fc receptor-mediated ADCC. In some embodiments, antibody-driven classical complement activation directs C3 fragments onto target cells. These C3 cleavage products can promote direct complement-dependent cytotoxicity (CDCC). In some embodiments, effector cells can phagocytose target antigens, target particles, or target cells, which depends on antibody binding and can be mediated by FcγRs expressed by effector cells. The expression of certain FcRs or complement receptors on effector cells can be controlled by humoral factors, such as cytokines. For example, expression of FcγRI has been shown to be upregulated by interferon gamma (IFNγ) and / or G-CSF. This enhanced expression increases the cytotoxicity of FcγRI-bearing cells against targets. Effector cells can phagocytose target antigens and phagocytose or lyse target cells.In some embodiments, antibody-driven classical complement activation results in C3 fragments on target cells, and these C3 cleavage products can promote direct phagocytosis by effector cells or indirectly by enhancing antibody-mediated phagocytosis.

[0052] As used herein, the term "Fc effector function" is intended to refer to a function that is a result of a polypeptide or antibody binding to its target, such as an antigen, on a cell membrane, where the Fc effector function is dependent on the Fc region of the polypeptide or antibody. Examples of Fc effector functions include: (i) C1q binding, (ii) complement activation, (iii) complement dependent cytotoxicity (CDC), (iv) antibody dependent cellular cytotoxicity (ADCC), (v) Fcγ receptor (FcγR) binding, (vi) antibody dependent cellular phagocytosis (ADCP), (vii) complement dependent cytotoxicity (CDCC), (viii) complement enhanced cytotoxicity, (ix) antibody mediated opsonization antibody binding to complement receptor, (x) opsonization, (xi) trogocytosis, and (xii) any combination of (i)-(xi).

[0053] The term "complement activation" as used herein refers to activation of the classical complement pathway, which is initiated by a large macromolecular complex called C1 that binds to antibody-antigen complexes on a surface. C1 is a complex composed of six recognition proteins C1q and the serine protease heterotetramer C1r2C1s2. C1 is the first protein complex in the early events of the classical complement cascade, which involves a series of cleavage reactions starting with the cleavage of C4 to C4a and C4b, and C2 to C2a and C2b. C4b is deposited and forms an enzymatically active convertase called C3 convertase together with C2a; the C3 convertase cleaves complement component C3 to C3b and C3a to form C5 convertase. The C5 convertase splits C5 into C5a and C5b, the last component being deposited on the membrane; which then triggers the late events of complement activation, in which the terminal complement components C5b, C6, C7, C8, and C9 assemble into the membrane attack complex (MAC). This complement cascade results in the formation of pores in the cell membrane and cell lysis, also known as complement-dependent cytotoxicity (CDC). Complement activation can be assessed using the potency of C1q, the CDC kinetics, the CDC assay (described in WO2013 / 004842, WO2014 / 108198), or by the method Cellular deposition of C3b and C4b described in Beurskens et al., J Immunol April 1, 2012 vol. 188 no. 7, 3532-3541.

[0054] The term "complement-dependent cytotoxicity" (CDC) as used herein is intended to refer to the process of antibody-mediated complement activation that results in lysis of cells to which the antibody is bound, which is believed, without being bound by theory, to be the result of membrane pores formed by the assembly of the so-called membrane attack complex (MAC). Suitable assays for assessing CDC are known in the art and include, for example, in vitro assays using normal human serum as a source of complement, as described in Example 3. A non-limiting example of an assay for determining the maximum lysis of CD38-expressing cells mediated by CD38 antibodies, or EC50 value, may include the following steps: (a) plating approximately 100,000 CD38-expressing cells per well in 40 μL of medium supplemented with 0.2% BSA in a multiwell plate; (b) pre-incubating the cells with 40 μL of serially diluted CD38 antibodies (0.0002–10 μg / mL) for 20 min; (c) incubating each well with 20% pooled normal human serum at 37° C. for 45 minutes; (d) adding a viability dye and measuring the percentage of cell lysis with a flow cytometer; (e) determining maximum lysis and / or calculating EC50 values ​​using non-linear regression.

[0055] As used herein, the term "antibody-dependent cell-mediated cytotoxicity" or "antibody-dependent cellular cytotoxicity" ("ADCC") is intended to refer to the mechanism of killing of antibody-coated target cells by cells expressing Fc receptors that recognize the constant region of the bound antibody. Suitable assays for assessing ADCC are known in the art and include, for example, the assay described in Example 4. Non-limiting examples of assays for examining ADCC of CD38-expressing cells mediated by CD38 antibodies are described below. 51 The method may include a Cr release assay or a reporter assay step.

[0056] 51 ADCC by Cr release assay (a) In a multiwell plate, approximately 5,000 cells were placed in 50 μL of medium containing 0.2% BSA per well. 51 plating Cr-labeled CD38-expressing cells (e.g., Daudi cells); (b) pre-incubating the cells with 50 μL of serially diluted CD38 antibodies (0.0002-10 μg / mL) for 15 min; (c) incubating each well with 500,000 freshly isolated peripheral blood mononuclear cells (PBMCs) per well at 37° C. for 4 hours; (d) 75 μL of the supernatant was counted in a gamma counter. 51 measuring the amount of Cr released; (e) calculating the percentage of cell lysis as (cpm sample-cpm spontaneous lysis) / (cpm maximum lysis-cpm spontaneous lysis), where cpm is counts per minute.

[0057] ADCC by reporter assay (a) plating approximately 5,000 CD38 expressing cells (e.g. Daudi cells) in 10 μL in standard medium (e.g. RPMI 1640) supplemented with 25% low IgG serum in a multi-well plate suitable for optical reading (e.g. 384-well OptiPlates from PerkinElmer); (b) incubating each well with 10 μL of genetically engineered Jurkat cells stably expressing the FcγRIIIa receptor, the V158 (high affinity) variant, and an NFAT response element driving the expression of firefly luciferase as effector cells, and 10 μL of serially diluted CD38 antibodies (0.0002-10 μg / mL) for 6 hours at 37° C.; (c) Incubating each well with 30 μL of luciferase substrate for 5 minutes at room temperature and measuring luminescence.

[0058] The term "antibody-dependent cellular phagocytosis" ("ADCP") as used herein is intended to refer to a mechanism of elimination of antibody-coated target cells by internalization by phagocytes. The internalized antibody-coated target cells are contained within vesicles called phagosomes, which then fuse with one or more lysosomes to form phagolysosomes. Suitable assays for evaluating ADCP are known in the art and include, for example, in vitro cytotoxicity assays using macrophages as effector cells, and video microscopy as described by van Bij et al. in Journal of Hepatology Volume 53, Issue 4, October 2010, Pages 677-685, and the in vitro cytotoxicity assay described in Example 5. A non-limiting example of an assay for investigating ADCP of CD38-expressing cells mediated by CD38 antibodies may include the following steps: (a) Differentiation of freshly isolated monocytes into macrophages by incubation in GM-CSF-containing medium for 5 days; (b) plating approximately 100,000 macrophages per well in a multi-well plate in dendritic cell medium containing GM-CSF; (c) adding 20,000 common fluorescent membrane dye-labeled CD38 antibody-opsonized CD38 expressing cells (e.g., Daudi cells) per well for 45 minutes at 37°C; (d) Measuring the percentage of CD14 positive, CD19 negative, membrane dye positive macrophages using a flow cytometer.

[0059] As used herein, "trogocytosis" refers to a process characterized by the transfer of cell surface molecules from donor cells to acceptor cells, such as effector cells. Exemplary acceptor cells include T cells, B cells, monocytes / macrophages, dendritic cells, neutrophils, and NK cells. The transfer of cell surface molecules, such as CD38, from donor cells to acceptor cells via trogocytosis can also result in the transfer of antibody-antigen complexes from donor cells to acceptor cells, i.e., antibody-antigen complexes in which the antibody is bound to the cell surface molecule. In particular, a special form of trogocytosis can occur when the acceptor cell is an effector cell that expresses Fcγ receptors (FcγR); such acceptor cells can take up and internalize donor cell-associated immune complexes consisting of a specific antibody bound to a target antigen on the donor cell, usually after FcγR binding to the Fc region of the antibody. Suitable assays for assessing trogocytosis are known in the art and include, for example, the assay described in Example 8. Non-limiting examples of assays to examine trogocytosis of CD38-expressing cells mediated by CD38 antibodies include the following.

[0060] Trogocytosis (Daudi cells): (a') Differentiation of freshly isolated monocytes into macrophages with GM-CSF for 5 days; (b') plating approximately 100,000 macrophages per well in dendritic cell medium containing GM-CSF; (c') adding approximately 20,000 CD38 antibody-opsonized Daudi cells labeled with a common fluorescent membrane dye per well for 45 min at 37°C; (d') Measuring CD38 expression on Daudi cells with a flow cytometer, where a decrease in CD38 on CD38 antibody-opsonized Daudi cells compared to controls indicates trogocytosis.

[0061] Trogocytosis (Treg): (a) plating approximately 500,000 freshly isolated PBMCs per well in cell culture medium overnight at 37°C; (b) adding approximately 100,000 CD38 antibody-opsonized Tregs labeled with a common fluorescent intracellular amine dye per well overnight at 37° C.; and (c) measuring CD38 expression on Tregs by flow cytometry, whereby a decrease in CD38 on CD38 antibody-opsonized Tregs compared to controls indicates trogocytosis.

[0062] The control can be selected by the skilled artisan based on the particular purpose of the study or assay in question. However, non-limiting examples of controls include (i) the absence of an antibody, and (ii) an isotype control antibody. One example of an isotype control antibody is antibody b12 having the VH and VL sequences set forth in Table 1. In some embodiments where it is desired to evaluate the trogocytosis effect of the antibody variants described herein, the control can be (iii) a parent or reference antibody having a different antigen-binding region and / or a different Fc region.

[0063] In some embodiments, in step (b), Tregs are labeled with a general fluorescent membrane dye in addition to or instead of a fluorescent intracellular amine dye.

[0064] In some embodiments, the reduction of CD38 antibody on donor cells can also be measured in steps (d') and (c) of the trogocytosis assay outlined above. For example, if the CD38 antibody is a human IgG (huIgG) antibody, a secondary antibody can be used to detect huIgG.

[0065] In addition to Daudi cells (ATCC CCL-213), tumor cells suitable for the first assay include, but are not limited to, those listed in Table 2, particularly those with high CD38 expression.

[0066] In addition to Tregs, CD38-expressing cells suitable for the second assay include immune cells such as, for example, NK cells, B cells, T cells, monocytes, and tumor cells as described in Table 2, particularly those with low CD38 expression levels.

[0067] The term "vector" as used herein is intended to refer to a nucleic acid molecule capable of inducing transcription of a nucleic acid segment linked to the vector. One type of vector is a "plasmid", which is in the form of a circular double-stranded DNA loop. Another type of vector is a viral vector, in which a nucleic acid segment can be ligated to a viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication, and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of the host cell upon introduction into the host cell, and are thereby replicated along with the host genome. In addition, certain vectors are capable of inducing expression of genes operably linked to the vector. Such vectors are referred to herein as "recombinant expression vectors" (or simply "expression vectors"). In general, expression vectors useful in recombinant DNA techniques are often in the form of plasmids. As used herein, "plasmid" and "vector" may be used interchangeably, since plasmids are the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (eg, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

[0068] The term "recombinant host cell" (or simply "host cell") as used herein is intended to refer to a cell into which one or more expression vectors have been introduced. For example, the HC and LC of the antibody variants described herein may both be encoded by the same expression vector, and the host cell is transfected with the expression vector. Alternatively, the HC and LC of the antibody variants described herein may be encoded by different expression vectors, and the host cell is co-transfected with the expression vectors. Of course, the term "host cell" is intended to refer not only to the particular subject cell, but also to the progeny of such a cell. Such progeny may not actually be identical to the parent cell, since certain modifications may occur in subsequent generations due to mutations or environmental influences, but are nevertheless included within the scope of the term "host cell" as used herein. Recombinant host cells include, for example, transfectomas such as CHO cells, HEK-293 cells, PER.C6 cells, NS0 cells, lymphocytic cells, prokaryotic cells such as E. coli, and other eukaryotic hosts such as plant cells, fungi, etc.

[0069] As used herein, the term "transfectoma" includes recombinant eukaryotic host cells expressing an Ab or a target antigen, e.g., CHO cells, PER.C6 cells, NS0 cells, HEK-293 cells, plant cells, or fungi such as yeast cells.

[0070] The term "treatment" refers to the administration of an effective amount of a therapeutically active antibody variant of the invention with the purpose of alleviating, ameliorating, preventing or eradicating (cure) a symptom or condition.

[0071] The term "effective amount" or "therapeutically effective amount" refers to an amount effective, at the dosage and for the period of time necessary, to achieve the desired therapeutic result. The therapeutically effective amount of an antibody may vary depending on factors such as the individual's medical condition, age, sex, and weight, and the ability of the antibody to elicit a desired response in the individual. A therapeutically effective amount is also an amount in which the therapeutically beneficial effects of the antibody variant outweigh its toxic or adverse effects.

[0072] Specific Aspects of the Invention As described herein, the present invention relates to variants of CD38 antibodies for use in therapy, in particular antibody variants that provide trogocytosis-mediated depletion of CD38 expressed on CD38-expressing cells.

[0073] As shown in Example 8, CD38 expression on Daudi cells was significantly reduced by co-culture with macrophages and CD38 antibody; however, the reduction in CD38 expression was stronger with the E430G mutant antibody. Surprisingly, CD38 expression on regulatory T cells (Tregs) co-cultured with PBMCs was reduced only after incubation with the E430G mutant CD38 antibody; no reduction in CD38 expression was observed when Tregs were incubated with parental antibody B, i.e., antibody B without the E430G mutation. Without being limited by theory, the ability of the antibody variants described herein to induce trogocytosis of non-cancerous immune cells expressing CD38, particularly immunosuppressive cells, may result in an increased immune response against tumor cells in cancer patients, regardless of whether the tumor cells express CD38 or not.

[0074] Thus, in one aspect the invention provides an antibody variant for use in treating cancer in a subject, wherein the antibody variant comprises: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells.

[0075] In one aspect, the invention provides an antibody variant for use in promoting an immune response in a subject, wherein the antibody variant comprises: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells.

[0076] In one aspect, the invention provides an antibody variant for use in treating cancer in a subject, wherein the antibody variant comprises: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and It induces the loss of CD38 via trogocytosis on CD38-expressing tumor cells.

[0077] In one aspect, the invention provides a method of treating cancer in a subject comprising administering to the subject an antibody variant, wherein the antibody variant: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells.

[0078] Typically, the antibody variant is administered in a therapeutically effective amount and / or for a period of time sufficient to treat the disease.

[0079] In one aspect, the invention provides a method of promoting an immune response in a subject comprising administering to the subject an antibody variant, wherein the antibody variant: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells.

[0080] Typically, the antibody variant is administered in a therapeutically effective amount and / or for a period of time sufficient to treat the disease.

[0081] In one aspect, the invention provides a method of treating cancer in a subject comprising administering to the subject an antibody variant, wherein the antibody variant: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and It induces the loss of CD38 via trogocytosis on CD38-expressing tumor cells.

[0082] Typically, the antibody variant is administered in a therapeutically effective amount and / or for a period of time sufficient to treat the disease.

[0083] Suitable assays for examining induction of CD38 reduction via trogocytosis on CD38-expressing immune cells are known in the art and include the assay described in Example 8. A non-limiting example of an assay for examining trogocytosis of CD38-expressing immune cells mediated by CD38 antibody variants includes the following steps, using Tregs as representative immune cells: (a) plating approximately 500,000 freshly isolated PBMCs per well in cell culture medium overnight at 37°C; (b) adding approximately 100,000 CD38 antibody-opsonized Tregs labeled with a common fluorescent intracellular amine dye per well overnight (O / N) at 37° C.; and (c) measuring CD38 expression on Tregs by flow cytometry, whereby a decrease in CD38 on CD38 antibody-opsonized Tregs compared to controls indicates trogocytosis.

[0084] In one embodiment, the immune cells are Tregs, and thus the antibody variants induce a reduction of CD38 via trogocytosis in CD38-expressing Tregs. In a further embodiment, the antibody variants reduce the number of CD38 molecules on Tregs in the presence of peripheral blood lymphocytes (PBMCs), optionally as measured by the assays described above.

[0085] The antibody variants described herein typically result in a reduction of CD38 expression on CD38-expressing cells via trogocytosis, compared to a control. Preferably, the reduction is statistically significant. Using this or another assay to examine the reduction of CD38 via trogocytosis on CD38-expressing immunosuppressive cells, immune cells, such as Tregs or other immunosuppressive cells, the antibody variants described herein typically reduce CD38 expressed on immune cells by at least about 5%, such as at least about 10%, such as at least about 15%, such as at least about 25%, such as at least about 50%, such as at least about 75%, such as 100%, compared to a control, using the antibody variant. As described elsewhere, suitable controls include (i) the absence of antibody, (ii) an isotype control antibody, and (iii) a parent or reference antibody with a different antigen-binding region and / or a different Fc region.

[0086] In one embodiment, the antibody variant for use according to any aspect or embodiment disclosed herein results in a reduction of CD38 via trogocytosis on CD38 expressing immune cells, e.g. immunosuppressant cells, compared to an isotype control antibody comprising the sequences of the VH and VL regions of antibody b12, i.e., SEQ ID NO:57 and SEQ ID NO:61, respectively, and the sequences of the CH and CL regions identical to the antibody variant.

[0087] In one embodiment, an antibody variant for use according to any aspect or embodiment disclosed herein results in a decrease in CD38 expression via trogocytosis on CD38-expressing immune cells, such as immunosuppressive cells, compared to a reference antibody, which has an identical amino acid sequence (typically heavy and light chain amino acid sequences) to the antibody variant, except for one or more mutations at E430, E345 and / or S440 in the variant antibody (said amino acid residues are numbered according to the EU index).

[0088] As used herein, an immune cell, e.g., an immune suppressor cell, expresses CD38 if CD38 expression on the tested cell population is statistically significant compared to a control, e.g., expression detected with an anti-CD38 antibody using known methods compared to expression detected with an isotype control antibody. This can be tested, for example, by taking a biological sample containing immune cells, such as a blood sample, a bone marrow sample, or a tumor biopsy, and testing CD38 expression in vitro using methods known in the art. Methods for identifying a particular type of immune cell, such as an immune suppressor cell, as disclosed herein, are well known in the art and include testing the expression of an antigen specific to the immune cell type in question. Examples of VH and VL sequences of anti-CD38 antibodies suitable for testing CD38 expression are shown in Table 1.

[0089] Some types of immune cells, such as regulatory T cells (Tregs), regulatory B cells (Bregs), myeloid-derived suppressor cells (MDSCs), immunosuppressive NK cells, etc., can express CD38 (Feng, Zhang et al., 2017; Patton, Wilson et al., 2011; Karakasheva, Waldron et al., 2015; Morandi, Horenstein et al., 2015; and Krejcik et al., 2016). In one embodiment, the immune cells expressing CD38 are immunosuppressive cells expressing CD38. Thus, in some embodiments, the immunosuppressive cells expressing CD38 include Tregs, Bregs, MDSCs, immunosuppressive NK cells, immunosuppressive NKT cells, immunosuppressive APCs, immunosuppressive macrophages, or any combination of two or more thereof. In certain embodiments, the immune suppressive cells expressing CD38 comprise, consist of, or consist essentially of Tregs. How to identify such cells, for example, by their phenotype and / or function, is known in the art. As described elsewhere herein, in some embodiments, Tregs can be characterized by the expression of a combination of specific antigens. Thus, in one embodiment, Tregs have the phenotype CD38. + CD4 + CD25 + CD127 dim In one embodiment, the Tregs further express Foxp3.

[0090] Preferably, the reduction of CD38 on CD38-expressing immune cells via trogocytosis promotes an immune response, such as an immune response that can kill a desired target cell. Intended target cells include, for example, tumor cells, virions, virus-infected cells and bacterial cells, particularly tumor cells. Non-limiting immune responses that can be promoted by the reduction of CD38 on CD38-expressing immune cells include, for example, CD3 + CD4 + T cells, CD3 + CD8 +an increase in the number of effector T cells, such as CD8 T cells, or both; an increase in the clonal expansion of T cells; and + One example is an increase in memory cells.

[0091] In some embodiments, the reduction of CD38 on CD38-expressing immunosuppressive cells via trogocytosis reduces their immunosuppressive activity. For example, Tregs with high CD38 expression are more immunosuppressive compared to Tregs with low or moderate CD38 expression (Krejcik et al., 2016). Thus, in a preferred embodiment, the CD38-expressing immunosuppressive cells comprise, consist of, or essentially consist of CD38-expressing Tregs, and the reduction of CD38 on CD38-expressing immunosuppressive cells via trogocytosis reduces their suppressive activity. The suppressive activity of Tregs can be assessed by methods known to those skilled in the art, for example, as described in Krejcik et al. (2016). Therefore, the sorted effector T cells were labeled with CFSE (a common DNA dye) and stimulated with anti-CD3 / CD28 coated beads + / - CD38+ or CD38- Tregs (Treg to effector cell ratio 1:1) in RPMI containing 10% fetal bovine serum, and after 72 hours, flow cytometry was performed; the percentage dilution of CFSE was used as a surrogate for T cell proliferation.

[0092] In one embodiment, trogocytosis occurs by effector cells expressing Fc gamma receptors (FcγR). In some embodiments, the Fcγ receptor expressing cells include macrophages, monocytes, or a combination thereof. In one embodiment, the Fcγ receptor expressing cells include macrophages. In one embodiment, the Fcγ receptor expressing cells consist of, or consist essentially of, macrophages. In one embodiment, the Fcγ receptor expressing cells include monocytes. In one embodiment, the Fcγ receptor expressing cells consist of, or consist essentially of, monocytes. For example, a convenient source of Fcγ receptor expressing cells suitable for in vitro trogocytosis assays is peripheral blood mononuclear cells (PBMCs), from which macrophages can be prepared as described in Example 8.

[0093] In some embodiments, the immune response promoted by the reduction of CD38 on CD38-expressing immune cells via trogocytosis comprises an effector T cell (Teff) response. + CD4 + T cells, CD3 + CD8 + Examples of Teff responses include CD3 + CD4 + T cells, CD3 + CD8 + Increased numbers of effector T cells, such as CD3 T cells, or both + CD4 + T cells, CD3 + CD8 + increased proliferation of T cells, or both; increased T cell clonal expansion; T cell activation; and CD8 + These include, but are not limited to, an increase in memory cells.

[0094] CD3 + CD4 + and / or CD3 + CD8 +The increase in the number of T cells can be observed in vivo, for example, by taking a biological sample from the subject before and after use according to the invention and comparing the number of T cells, for example using FACS analysis. The biological sample can be, for example, a blood sample, a bone marrow sample, or a tumor biopsy.

[0095] T cell proliferation can be assessed, for example, by measuring the rate of DNA synthesis in T cells using tritiated thymidine, measuring interferon gamma (IFN gamma) production in vitro, or by measuring the absolute number or percentage of T cells in a cell population from a patient sample using known methods.

[0096] Clonal expansion of T cells can be assessed, for example, by sequencing the T cell receptor (TCR) from a pool of T cells using known methods.

[0097] CD8 + The formation of memory cells can be performed by, for example, using FACS to isolate naive T cells (CD45RO - / CD62L + ) versus memory T cells (CD45RO + / CD62L high ) can be evaluated.

[0098] In this context, "enhancing" an immune response, such as a Teff response, typically means increasing the immune response in a test sample by at least about 5%, at least about 10%, at least about 25%, at least about 50%, at least about 75%, at least about 100%, or more, compared to a control, in an in vitro or in vivo assay using methods described herein or known in the art. For example, immune responses can be measured in a subject, e.g., a patient, before and after administration of an antibody variant described herein, e.g., 1 hour before and 1 hour, 6 hours, 12 hours, 1 day, 2 days, and 3 days after administration, in a biological sample taken from the patient to ascertain an increased immune response. Alternatively, in vitro assays can be used to ascertain an increase in a particular immune response obtained using an antibody variant described herein, compared to a control. A control can be selected by one of skill in the art based on the particular purpose of the study or assay in question. However, non-limiting examples of controls include: (i) an isotype control antibody; (ii) the absence of an antibody; (iii) a reference antibody having identical amino acid sequences (typically heavy and light chain amino acid sequences) to the antibody variant, except for one or more mutations at E430, E345 and / or S440 in the variant antibody; or (iv) a baseline value, for example, from a textbook or other reference. Preferably, the increase is statistically significant.

[0099] CD38-binding antibody variants In addition to inducing trogocytosis-mediated reduction of CD38 on CD38-expressing immune cells, antibody variants for use according to the present invention may be further characterized by one or more other functionalities, or combinations of functionalities, which may be advantageous for therapeutic applications, e.g., improved Fc effector function, effective inhibition of CD38 enzymatic activity, or a combination of any two or more thereof.

[0100] For example, as shown in Example 3, the introduction of the E430G mutation enhanced CDC for all three CD38 IgG1 antibodies A, B and C tested. However, surprisingly, the magnitude of CDC enhancement differed between the antibody clones tested. Without the E430G mutation, IgG1-B was already a good inducer of CDC, whereas IgG1-C and IgG1-A induced moderate or no CDC, respectively. However, after the introduction of the E430G mutation, IgG1-C-E430G induced more effective CDC compared to IgG1-B-E430G. Notably, the EC50 value of IgG1-C-E430G was lower than that of IgG1-B-E430G in tumor cells and T regulatory cells with low levels of CD38 expression.

[0101] Furthermore, the antibody variants according to the invention can also demonstrate ADCC. For example, as shown in Example 4, IgG1-C: 51 The IgG1-A and IgG1-B antibodies achieved a higher percent maximum lysis in a Cr release assay compared to IgG1-B, and increased FcγRIIIa binding in an ADCC reporter assay compared to IgG1-B. 51 IgG1-C-E430G reduced the percent maximum lysis in a Cr release assay and reduced FcγRIIIa binding in an ADCC reporter assay compared to IgG1-B-E430G and IgG1-A-E430G. 51 They induced similar percent maximal lysis in a Cr release assay and similar FcγRIIIa binding in an ADCC reporter assay.

[0102] Furthermore, the ability of anti-CD38 antibodies to inhibit CD38 cyclase activity may be retained in the form of antibody variants according to the invention. For example, as shown in Example 7, IgG1-C-E430G showed stronger inhibition of CD38 cyclase activity compared to IgG1-B-E430G, the former resulting in about 40% inhibition and the latter about 25% inhibition. Without being limited by theory, it is believed that the stronger inhibition of CD38 cyclase activity is due to the release of Ca from the cytosol. 2+This may decrease the production of cADPR, a potent second messenger that regulates Ca mobilization and, in turn, 2+ This may lead to reduced recruitment and signaling of downstream pathways that control various biological processes such as proliferation and insulin secretion. Thus, without being limited by theory, it is possible that stronger inhibition of CD38 cyclase activity may affect, e.g., reduce, the ability of immune suppressor cells to suppress immune responses.

[0103] The antibody variants of the invention may also be able to kill tumor cells in vivo, as shown in Example 9, where twice weekly administration of IgG1-C-E430G reduced tumor growth in two of five DLBCL PDX models tested that showed the highest CD38 mRNA expression.

[0104] In further embodiments, said antibody variants may also or alternatively be characterized by their binding to human CD38, by particular amino acid sequences in the variable regions, by particular mutations in the antigen binding region or Fc region, and / or by their ability to induce effector functions or modulate CD38 enzymatic activity, as further described below.

[0105] antigen binding region The antigen-binding region typically comprises one or more antibody variable domains that enable specific binding to human CD38 (SEQ ID NO:83), such as a VH region and a VL region.

[0106] In some embodiments, antibody variants are characterized by their ability to bind (or not bind) to specific variants of human CD38. Soluble versions of human CD38, such as His-tagged soluble CD38 (SEQ ID NO:84) or its HA-tagged variant with N-terminal His-tag replaced by YPYDVPDYA (SEQ ID NO:85), can also be used in such studies. Suitable assays for assessing the binding of CD38 antibodies to human CD38 or its variants are known in the art and described, for example, in WO 2011 / 154453 A1 (see, for example, Example 6) and WO 2006 / 099875 A1 (see, for example, Example 17).

[0107] Thus, in one embodiment, the antibody variant does not bind to a variant of human CD38 in which Asp at position 202 is replaced by Gly to the same extent as it binds to human CD38; i.e., the binding of the antibody variant to said CD38 variant is reduced compared to its binding to human CD38. For example, the antibody variant may bind to said CD38 variant with an EC50 that is higher than the EC50 with which it binds to human CD38.

[0108] In one embodiment the antibody variant binds to a variant of human CD38 in which Gln at position 272 is substituted with Arg to the same extent as it binds to human CD38.

[0109] In one embodiment the antibody variant binds to a variant of human CD38 in which Ser at position 274 is substituted with Phe to the same extent as it binds to human CD38.

[0110] In one aspect, the antibody variant does not bind to a variant of human CD38 in which Ser at position 274 is substituted with Phe to the same extent as it binds to human CD38; i.e., binding of the antibody variant to the CD38 variant is reduced compared to its binding to human CD38.

[0111] In one embodiment, the antibody variant does not bind to a variant of human CD38 in which Gln at position 272 is substituted with Arg to the same extent as it binds to human CD38; i.e., the binding of the antibody variant to said CD38 variant is reduced compared to its binding to human CD38. For example, the antibody variant may bind to said CD38 variant with an EC50 that is higher than the EC50 it binds to human CD38.

[0112] In one embodiment the antibody variant binds to a variant of human CD38 in which Thr at position 237 is substituted with Ala to the same extent as it binds to human CD38.

[0113] In one aspect, an antibody that binds to a variant of human CD38 to the same extent as it binds to human CD38 may, for example, bind to the variant with an EC50 that is at least 80%, such as at least 90%, for example at least 95%, for example at least 98% of the EC50 of the antibody's binding to human CD38.

[0114] Thus, in one embodiment, the antibody variant does not bind to a variant of human CD38 in which Asp at position 202 is replaced by Gly, (ii) binds to a variant of human CD38 in which Gln at position 272 is replaced by Arg, (iii) binds to a variant of human CD38 in which Ser at position 274 is replaced by Phe, and (iv) binds to a variant of human CD38 in which Thr at position 237 is replaced by Ala. These CD38 binding properties are hereinafter referred to as "CD38 binding group 1".

[0115] In another embodiment, the antibody variant does not bind to the same extent to a variant of human CD38 in which Ser at position 274 is substituted with Phe, and does not bind to the same extent to a variant of human CD38 in which Gln at position 272 is substituted with Arg. These CD38 binding properties are hereinafter referred to as "CD38 binding group 2".

[0116] In another embodiment, the antibody variant binds to a variant of human CD38 in which Ser at position 274 is substituted with Phe to the same extent as it binds to human CD38, to a variant of human CD38 in which Gln at position 272 is substituted with Arg to the same extent as it binds to human CD38, and to a variant of human CD38 in which Thr at position 237 is substituted with Ala to the same extent as it binds to human CD38. These CD38 binding properties are hereinafter referred to as "CD38 binding group 3".

[0117] In some embodiments, the antibody variant binds to the region SKRNIQFSCKNIYR (SEQ ID NO:86) and the region EKVQTLEAWVIHGG (SEQ ID NO:87), and optionally further has binding group 2 or 3 binding properties.

[0118] Advantageously, the CDRs, VH regions and / or VL regions of the antibody variant are similar or identical to those of any one of antibodies AH, as set forth in Table 1.

[0119] Thus, in one aspect, the invention provides an antibody variant that binds to human CD38, the antibody variant comprising an antigen-binding region comprising the VH and VL CDRs of any of Antibodies A-H listed in Table 1, and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain; wherein the amino acid residues are numbered according to the EU index.

[0120] In one preferred embodiment, the antibody variant comprises an antigen-binding region comprising the VH and VL CDRs of antibody A, depicted as SEQ ID NO:2 (VH-3003-A_CDR1), SEQ ID NO:3 (VH-3003-A_CDR2), SEQ ID NO:4 (VH-3003-A_CDR3), SEQ ID NO:6 (VL-3003-A_CDR1), AAS (VL-3003-A_CDR2) and SEQ ID NO:7 (VL-3003-A_CDR3). In another preferred embodiment, the VH and VL sequences are those of antibody A, i.e. the VH region comprises the sequence of SEQ ID NO:1 (VH-3003-A) and the VL region comprises the sequence of SEQ ID NO:5 (VL-3003-A).

[0121] In one preferred embodiment, the antibody variant comprises an antigen-binding region comprising the VH and VL CDRs of antibody B, depicted as SEQ ID NO:9 (VH-3003-B_CDR1), SEQ ID NO:10 (VH-3003-B_CDR2), SEQ ID NO:11 (VH-3003-B_CDR3), SEQ ID NO:13 (VL-3003-B_CDR1), DAS (VL-3003-B_CDR2) and SEQ ID NO:14 (VL-3003-B_CDR3). In another preferred embodiment, the VH and VL sequences are those of antibody B, i.e. the VH region comprises the sequence of SEQ ID NO:8 (VH-3003-B) and the VL region comprises the sequence of SEQ ID NO:12 (VL-3003-B).

[0122] In one preferred embodiment, the antibody variant comprises an antigen-binding region comprising the VH and VL CDRs of antibody C, depicted as SEQ ID NO:37 (VH-3003-C_CDR1), SEQ ID NO:38 (VH-3003-C_CDR2), SEQ ID NO:39 (VH-3003-C_CDR3), SEQ ID NO:41 (VL-3003-C_CDR1), AAS (VL-3003-C_CDR2) and SEQ ID NO:42 (VL-3003-C_CDR3). In another preferred embodiment, the VH and VL sequences are those of antibody C, i.e. the VH region comprises the sequence of SEQ ID NO:36 (VH-3003-C) and the VL region comprises the sequence of SEQ ID NO:40 (VL-3003-C).

[0123] In one preferred embodiment, the antibody variant comprises an antigen-binding region comprising the VH and VL CDRs of antibody D, depicted as SEQ ID NO:16 (VH-3003-D_CDR1), SEQ ID NO:17 (VH-3003-D_CDR2), SEQ ID NO:18 (VH-3003-D_CDR3), SEQ ID NO:20 (VL-3003-D_CDR1), DAS (VL-3003-D_CDR2) and SEQ ID NO:21 (VL-3003-D_CDR3). In another preferred embodiment, the VH and VL sequences are those of antibody D, i.e. the VH region comprises the sequence of SEQ ID NO:15 (VH-3003-D) and the VL region comprises the sequence of SEQ ID NO:19 (VL-3003-D).

[0124] In one preferred embodiment, the antibody variant comprises an antigen-binding region comprising the VH and VL CDRs of antibody E, depicted as SEQ ID NO:23 (VH-3003-E_CDR1), SEQ ID NO:24 (VH-3003-E_CDR2), SEQ ID NO:25 (VH-3003-E_CDR3), SEQ ID NO:27 (VL-3003-E_CDR1), AAS (VL-3003-E_CDR2) and SEQ ID NO:28 (VL-3003-E_CDR3). In another preferred embodiment, the VH and VL sequences are those of antibody E, i.e. the VH region comprises the sequence of SEQ ID NO:22 (VH-3003-E) and the VL region comprises the sequence of SEQ ID NO:26 (VL-3003-E).

[0125] In one preferred embodiment, the antibody variant comprises an antigen-binding region comprising the VH and VL CDRs of antibody F, depicted as SEQ ID NO:30 (VH-3003-F_CDR1), SEQ ID NO:31 (VH-3003-F_CDR2), SEQ ID NO:32 (VH-3003-F_CDR3), SEQ ID NO:34 (VL-3003-F_CDR1), AAS (VL-3003-F_CDR2) and SEQ ID NO:35 (VL-3003-F_CDR3). In another preferred embodiment, the VH and VL sequences are those of antibody F, i.e. the VH region comprises the sequence of SEQ ID NO:29 (VH-3003-F) and the VL region comprises the sequence of SEQ ID NO:33 (VL-3003-F).

[0126] In one preferred embodiment, the antibody variant comprises an antigen-binding region comprising the VH and VL CDRs of antibody G, depicted as SEQ ID NO:44 (VH-3003-G_CDR1), SEQ ID NO:45 (VH-3003-G_CDR2), SEQ ID NO:46 (VH-3003-G_CDR3), SEQ ID NO:48 (VL-3003-G_CDR1), AAS (VL-3003-G_CDR2) and SEQ ID NO:49 (VL-3003-G_CDR3). In another preferred embodiment, the VH and VL sequences are those of antibody G, i.e. the VH region comprises the sequence of SEQ ID NO:43 (VH-3003-G) and the VL region comprises the sequence of SEQ ID NO:47 (VL-3003-G).

[0127] In one preferred embodiment, the antibody variant comprises an antigen-binding region comprising the VH and VL CDRs of antibody H, depicted as SEQ ID NO:51 (VH-3003-H_CDR1), SEQ ID NO:52 (VH-3003-H_CDR2), SEQ ID NO:53 (VH-3003-H_CDR3), SEQ ID NO:55 (VL-3003-H_CDR1), AAS (VL-3003-H_CDR2) and SEQ ID NO:56 (VL-3003-H_CDR3). In another preferred embodiment, the VH and VL sequences are those of antibody H, i.e. the VH region comprises the sequence of SEQ ID NO:50 (VH-3003-H) and the VL region comprises the sequence of SEQ ID NO:54 (VL-3003-H).

[0128] However, as is well known in the art, the VH and VL of an antibody can be mutated, for example, to increase the affinity of the antibody for its target antigen, to reduce its potential immunogenicity, and / or to increase the yield of the antibody expressed by a host cell. Thus, in some embodiments, antibodies comprising variants of the CDR, VH and / or VL sequences of any one of antibodies A-H are also contemplated, in particular antibodies comprising functional variants of the VL and / or VH regions of such antibodies. A functional variant may differ by one or more amino acids compared to the parent VH and / or VL sequence, for example in one or more CDRs, but its antigen-binding region still retains at least a substantial portion (at least about 50%, 60%, 70%, 80%, 90%, 95% or more) of the affinity and / or specificity of the parent antibody. Typically, such functional variants retain substantial sequence identity to the parent sequence. Exemplary variants include those that differ from the respective parent VH or VL regions by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 mutations, e.g., substitutions, insertions or deletions, of amino acid residues. Exemplary variants include those that differ from the VH and / or VL and / or CDR regions of the parent sequences primarily by conservative amino acid substitutions; for example, 12 of the amino acid substitutions of the variants, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1, can be conservative. In some cases, antibodies that include a variant of the VH and / or VL of any of antibodies A-H may be associated with higher affinity and / or specificity than the parent antibody. For purposes of the present invention, VH and / or VL variants that retain or improve the affinity and specificity of the antibody in binding to CD38 are particularly preferred.

[0129] For example, as shown in Figure 14, the amino acid sequences of the CDR, VH and VL regions of antibodies C, E, F, G and H are similar but differ at certain positions, i.e., positions not indicated with an "*" symbol. These positions therefore represent potential positions at which mutations can be made in the CDR, VH and VL sequences while retaining or improving the affinity and specificity of the antibody in binding to CD38. In particular, positions in the VH and VL CDRs that can be mutated in functional variants of the VH and VL of antibodies C, E, F, G or H are shown in SEQ ID NOs:88-92.

[0130] Thus, in one embodiment, an antibody variant comprising an antigen binding region comprising a functional variant of the VH and VL of any one of antibodies C, E, F, G or H comprises the VH and VL CDRs set forth as SEQ ID NO:88 (VH CDR1), SEQ ID NO:89 (VH CDR2), SEQ ID NO:90 (VH CDR3), SEQ ID NO:91 (VL CDR1), AAS (VL CDR2) and SEQ ID NO:92 (VL CDR3). Such antibody variants may maintain the original framework regions of the antibody in question or may contain mutations in the framework regions, optionally at one or more framework positions not indicated with an "* symbol" in Figure 14.

[0131] In another embodiment, no mutations are made in the CDRs, i.e. functional variants of the VH and / or VL regions retain the sequences of VH CDR1-3 and / or VL CDR1-3 of antibodies A, B, C, D, E, F, G or H as set forth in Table 1. Such antibody variants may maintain the original framework regions of the antibody in question or may contain mutations in said framework regions. Functional variants of the VH and VL regions of antibodies C, E, F, G and H may optionally contain mutations in one or more framework positions not indicated with an "* symbol" in Figure 14.

[0132] In one embodiment, the VH region comprises SEQ ID NO:1 or comprises an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:1 (VH-3003-A). For example, the VH may differ from SEQ ID NO:1 by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutation, e.g., substitution, insertion, or deletion, of amino acid residues. In one embodiment, the VH region differs from SEQ ID NO:1 by only 12 or fewer, e.g., 5 or fewer, e.g., 5, 4, 3, 2, or 1 amino acid substitutions. The amino acid substitutions may, for example, be conservative amino acid substitutions as described elsewhere herein. In certain embodiments, no mutations are made in the VH CDRs, i.e. the variant VH retains the CDR sequences of antibody A shown in SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4.

[0133] In such an embodiment, the VL region may comprise SEQ ID NO:5 or an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:5 (VL-3003-A). For example, the VL may differ from SEQ ID NO:5 by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutation, e.g., substitution, insertion, or deletion, of amino acid residues. In one embodiment, the VL region differs from SEQ ID NO:5 by only 12 or fewer, e.g., 5 or fewer, e.g., 5, 4, 3, 2, or 1 amino acid substitutions. The amino acid substitutions may, for example, be conservative amino acid substitutions as described elsewhere herein. In certain embodiments, no mutations are made in the VL CDRs, i.e., the variant VL retains the CDR sequences of antibody A shown in SEQ ID NO:6, AAS, and SEQ ID NO:7. In certain embodiments, the antigen-binding region has CD38 binding properties of CD38-binding group 3.

[0134] In one such embodiment, the antigen binding region may comprise a VH region having the sequence set forth in SEQ ID NO:1 and a VL region having the sequence set forth in SEQ ID NO:5.

[0135] In one embodiment, the VH region comprises SEQ ID NO:8 or comprises an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:8 (VH-3003-B). For example, the VH may differ from SEQ ID NO:8 by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutation, e.g., substitution, insertion, or deletion, of amino acid residues. In one embodiment, the VH region differs from SEQ ID NO:8 by only 12 or fewer, e.g., 5 or fewer, e.g., 5, 4, 3, 2, or 1 amino acid substitutions. The amino acid substitutions may, for example, be conservative amino acid substitutions as described elsewhere herein. In a particular embodiment, no mutations are made in the VH CDRs, i.e. the variant VH retains the CDR sequences of antibody B shown in SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11.

[0136] In such an embodiment, the VL region may comprise SEQ ID NO:12 or an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:12 (VL-3003-B). For example, the VL may differ from SEQ ID NO:12 by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutation, e.g., substitution, insertion, or deletion, of amino acid residues. In one embodiment, the VL region differs from SEQ ID NO:12 by only 12 or fewer, e.g., 5 or fewer, e.g., 5, 4, 3, 2, or 1 amino acid substitutions. The amino acid substitutions may, for example, be conservative amino acid substitutions as described elsewhere herein. In certain embodiments, no mutations are made in the VL CDRs, i.e., the variant VL retains the CDR sequences of antibody B shown in SEQ ID NO: 13, DAS, and SEQ ID NO: 14. In certain embodiments, the antigen-binding region has CD38 binding properties of CD38-binding group 2.

[0137] In one such embodiment, the antigen binding region may comprise a VH region having the sequence set forth in SEQ ID NO:8 and a VL region having the sequence set forth in SEQ ID NO:12.

[0138] In one embodiment, the VH region comprises SEQ ID NO:36 or comprises an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:36 (VH-3003-C). For example, the VH may differ from SEQ ID NO:36 by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutation, e.g., substitution, insertion, or deletion, of amino acid residues. In one embodiment, the VH region differs from SEQ ID NO:36 by only 12 or fewer, e.g., 5 or fewer, e.g., 5, 4, 3, 2, or 1 amino acid substitutions. The amino acid substitutions may, for example, be conservative amino acid substitutions as described elsewhere herein. In certain embodiments, no mutations are made in the VH CDRs, i.e., the variant VH retains the CDR sequences of antibody C shown in SEQ ID NO:37, SEQ ID NO:38, and SEQ ID NO:39.

[0139] In such an embodiment, the VL region may comprise SEQ ID NO:40 or an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:40 (VL-3003-C). For example, the VL may differ from SEQ ID NO:40 by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutation, e.g., substitution, insertion, or deletion, of amino acid residues. In one embodiment, the VL region differs from SEQ ID NO:40 by only 12 or fewer, e.g., 5 or fewer, e.g., 5, 4, 3, 2, or 1 amino acid substitutions. The amino acid substitutions may, for example, be conservative amino acid substitutions as described elsewhere herein. In certain embodiments, no mutations are made in the VL CDRs, i.e., the variant VL retains the CDR sequences of antibody C shown in SEQ ID NO:41, AAS, and SEQ ID NO:42. In certain embodiments, the antigen-binding region has CD38 binding properties of CD38-binding group 1.

[0140] In one such embodiment, the antigen binding region may comprise a VH region having the sequence set forth in SEQ ID NO:36 and a VL region having the sequence set forth in SEQ ID NO:40.

[0141] In one embodiment, the VH region comprises SEQ ID NO:15 or comprises an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:15 (VH-3003-D). For example, the VH may differ from SEQ ID NO:15 by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutation, e.g., substitution, insertion, or deletion, of amino acid residues. In one embodiment, the VH region differs from SEQ ID NO:15 by only 12 or fewer, e.g., 5 or fewer, e.g., 5, 4, 3, 2, or 1 amino acid substitutions. The amino acid substitutions may, for example, be conservative amino acid substitutions as described elsewhere herein. In certain embodiments, no mutations are made in the VH CDRs, i.e., the variant VH retains the CDR sequences of antibody D shown in SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18.

[0142] In such an embodiment, the VL region may comprise SEQ ID NO:19 or an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:19 (VL-3003-D). For example, the VL may differ from SEQ ID NO:19 by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutation, e.g., substitution, insertion, or deletion, of amino acid residues. In one embodiment, the VL region differs from SEQ ID NO:19 by only 12 or fewer, e.g., 5 or fewer, e.g., 5, 4, 3, 2, or 1 amino acid substitutions. The amino acid substitutions may, for example, be conservative amino acid substitutions as described elsewhere herein. In a particular embodiment, no mutations are made in the VL CDRs, i.e., the variant VL retains the CDR sequences of antibody D shown in SEQ ID NO:20, DAS, and SEQ ID NO:21.

[0143] In one such embodiment, the antigen binding region may comprise a VH region having the sequence set forth in SEQ ID NO:15 and a VL region having the sequence set forth in SEQ ID NO:19.

[0144] In one embodiment, the VH region comprises SEQ ID NO:22 or comprises an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:22 (VH-3003-E). For example, the VH may differ from SEQ ID NO:22 by 12 or less mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutation, e.g., substitution, insertion, or deletion, of amino acid residues. In one embodiment, the VH region differs from SEQ ID NO:22 by only 12 or less, e.g., 5 or less, e.g., 5, 4, 3, 2, or 1 amino acid substitutions. The amino acid substitutions may, for example, be conservative amino acid substitutions as described elsewhere herein. In certain embodiments, no mutations are made in the VH CDRs, i.e., the variant VH retains the CDR sequences of antibody E shown in SEQ ID NO:23, SEQ ID NO:24, and SEQ ID NO:25.

[0145] In such an embodiment, the VL region may comprise SEQ ID NO:26 or an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:26 (VL-3003-E). For example, the VL may differ from SEQ ID NO:26 by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutation, e.g., substitution, insertion, or deletion, of amino acid residues. In one embodiment, the VL region differs from SEQ ID NO:26 by only 12 or fewer, e.g., 5 or fewer, e.g., 5, 4, 3, 2, or 1 amino acid substitutions. The amino acid substitutions may, for example, be conservative amino acid substitutions as described elsewhere herein. In certain embodiments, no mutations are made in the VL CDRs, i.e., the variant VL retains the CDR sequences of antibody E shown in SEQ ID NO:27, AAS, and SEQ ID NO:28. In certain embodiments, the antigen-binding region has CD38 binding properties of CD38-binding Group 1.

[0146] In one such embodiment, the antigen binding region may comprise a VH region having the sequence set forth in SEQ ID NO:22 and a VL region having the sequence set forth in SEQ ID NO:26.

[0147] In one embodiment, the VH region comprises SEQ ID NO:29 or comprises an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:29 (VH-3003-F). For example, the VH may differ from SEQ ID NO:29 by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutation, e.g., substitution, insertion, or deletion, of amino acid residues. In one embodiment, the VH region differs from SEQ ID NO:29 by only 12 or fewer, e.g., 5 or fewer, e.g., 5, 4, 3, 2, or 1 amino acid substitutions. The amino acid substitutions may, for example, be conservative amino acid substitutions as described elsewhere herein. In certain embodiments, no mutations are made in the VH CDRs, i.e., the variant VH retains the CDR sequences of antibody F shown in SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32.

[0148] In such an embodiment, the VL region may comprise SEQ ID NO:33 or an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:33 (VL-3003-F). For example, the VL may differ from SEQ ID NO:33 by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutation, e.g., substitution, insertion, or deletion, of amino acid residues. In one embodiment, the VL region differs from SEQ ID NO:33 by only 12 or fewer, e.g., 5 or fewer, e.g., 5, 4, 3, 2, or 1 amino acid substitutions. The amino acid substitutions may, for example, be conservative amino acid substitutions as described elsewhere herein. In certain embodiments, no mutations are made in the VL CDRs, i.e., the variant VL retains the CDR sequences of antibody F shown in SEQ ID NO:34, AAS, and SEQ ID NO:35. In certain embodiments, the antigen-binding region has CD38 binding properties of CD38-binding group 1.

[0149] In one such embodiment, the antigen binding region may comprise a VH region having the sequence set forth in SEQ ID NO:29 and a VL region having the sequence set forth in SEQ ID NO:33.

[0150] In one embodiment, the VH region comprises SEQ ID NO:43 or comprises an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:43 (VH-3003-G). For example, the VH may differ from SEQ ID NO:43 by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutation, e.g., substitution, insertion, or deletion, of amino acid residues. In one embodiment, the VH region differs from SEQ ID NO:43 by only 12 or fewer, e.g., 5 or fewer, e.g., 5, 4, 3, 2, or 1 amino acid substitutions. The amino acid substitutions may, for example, be conservative amino acid substitutions as described elsewhere herein. In certain embodiments, no mutations are made in the VH CDRs, i.e., the variant VH retains the CDR sequences of antibody G shown in SEQ ID NO:44, SEQ ID NO:45, and SEQ ID NO:46.

[0151] In such an embodiment, the VL region may comprise SEQ ID NO:47 or an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:47 (VL-3003-G). For example, the VL may differ from SEQ ID NO:47 by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutation, e.g., substitution, insertion, or deletion, of amino acid residues. In one embodiment, the VL region differs from SEQ ID NO:47 by only 12 or fewer, e.g., 5 or fewer, e.g., 5, 4, 3, 2, or 1 amino acid substitutions. The amino acid substitutions may, for example, be conservative amino acid substitutions as described elsewhere herein. In certain embodiments, no mutations are made in the VL CDRs, i.e., the variant VL retains the CDR sequences of antibody G shown in SEQ ID NO:48, AAS, and SEQ ID NO:49. In certain embodiments, the antigen-binding region has CD38 binding properties of CD38-binding group 1.

[0152] In one such embodiment, the antigen binding region may comprise a VH region having the sequence set forth in SEQ ID NO:43 and a VL region having the sequence set forth in SEQ ID NO:47.

[0153] In one embodiment, the VH region comprises SEQ ID NO:50 or comprises an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:50 (VH-3003-H). For example, the VH may differ from SEQ ID NO:50 by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 mutation, e.g., substitution, insertion or deletion, of amino acid residues. In one embodiment, the VH region differs from SEQ ID NO:50 by only 12 or fewer, e.g., 5 or fewer, e.g., 5, 4, 3, 2 or 1 amino acid substitutions. The amino acid substitutions may, for example, be conservative amino acid substitutions as described elsewhere herein. In certain embodiments, no mutations are made in the VH CDRs, i.e., the variant VH retains the CDR sequences of antibody H shown in SEQ ID NO:51, SEQ ID NO:52, and SEQ ID NO:53.

[0154] In such an embodiment, the VL region may comprise SEQ ID NO:54 or an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:54 (VL-3003-H). For example, the VL may differ from SEQ ID NO:54 by 12 or fewer mutations, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutation, e.g., substitution, insertion, or deletion, of amino acid residues. In one embodiment, the VL region differs from SEQ ID NO:54 by only 12 or fewer, e.g., 5 or fewer, e.g., 5, 4, 3, 2, or 1 amino acid substitutions. The amino acid substitutions may, for example, be conservative amino acid substitutions as described elsewhere herein. In certain embodiments, no mutations are made in the VL CDRs, i.e., the variant VL retains the CDR sequences of antibody H shown in SEQ ID NO:55, AAS, and SEQ ID NO:56. In certain embodiments, the antigen-binding region has CD38 binding properties of CD38-binding Group 1.

[0155] In one such embodiment, the antigen binding region may comprise a VH region having the sequence set forth in SEQ ID NO:50 and a VL region having the sequence set forth in SEQ ID NO:54.

[0156] In yet other embodiments, the antigen binding region is selected from the group consisting of a CD38 antibody described in WO 2007 / 042309 A2 (e.g., the antibody designated "3087" having sequences of VH and VL regions corresponding to the sequences set forth in WO 2007 / 042309 A2 as SEQ ID NOs:21 and 51); a CD38 antibody described in WO 2008 / 047242 A2 (e.g., the antibody designated 38SB19 having a VH region comprising CDR1, CDR2 and CDR3 as set forth in WO 2008 / 047242 A2 as SEQ ID NOs:13, 14 and 15, respectively, and a VL region comprising CDR1, CDR2 and CDR3 as set forth in WO 2008 / 047242 A2 as SEQ ID NOs:16, 17 and 18, respectively); or a CD38 antibody described in WO 2012 / 092612 A1 (e.g., the antibody designated "3087" having sequences of VH and VL regions corresponding to the sequences set forth in WO 2007 / 042309 A2 as SEQ ID NOs:21 and 51, respectively). and US Pat. No. 6,399,343, issued Dec. 2012 / 092612, and which is incorporated herein by reference in its entirety; the VH and VL CDRs, or VH and VL sequences, of an antibody designated as "Ab19" or "Ab79," having the sequences of the VH and VL regions set forth in SEQ ID NOs:11 and 12 for Ab19, and SEQ ID NOs:9 and 10 for Ab79, respectively; all of which publications are incorporated herein by reference in their entireties.

[0157] Thus, in one embodiment, the antibody variant comprises an antigen binding region comprising the VH CDR1, VH CDR2 and VH CDR3 sequences of the VH region of antibody 3087 (SEQ ID NO:93) and the VL CDR1, VL CDR2 and VL CDR3 sequences of the VL region of antibody 3087 (SEQ ID NO:94) as shown in Table 1. In another embodiment, the sequences of the VH and VL regions comprise SEQ ID NOs:93 and 94, respectively, as shown in Table 1.

[0158] In one embodiment, the antibody variant comprises an antigen binding region comprising the VH CDR1, VH CDR2 and VH CDR3 sequences of the VH region of antibody 38SB19 (SEQ ID NO:95) and the VL CDR1, VL CDR2 and VL CDR3 sequences of the VL region of antibody 38SB19 (SEQ ID NO:96), as shown in Table 1. In another embodiment, the sequences of the VH and VL regions comprise SEQ ID NOs:95 and 96, respectively, as shown in Table 1.

[0159] In one embodiment, the antibody variant comprises an antigen-binding region comprising the VH CDR1, VH CDR2 and VH CDR3 sequences of the VH region of antibody Ab19 (SEQ ID NO:97) and the VL CDR1, VL CDR2 and VL CDR3 sequences of the VL region of antibody Ab19 (SEQ ID NO:98), as shown in Table 1. In another embodiment, the sequences of the VH and VL regions comprise SEQ ID NOs:97 and 98, respectively, as shown in Table 1.

[0160] In one embodiment, the antibody variant comprises an antigen-binding region comprising the VH CDR1, VH CDR2 and VH CDR3 sequences of the VH region of antibody Ab79 (SEQ ID NO:99) and the VL CDR1, VL CDR2 and VL CDR3 sequences of the VL region of antibody Ab79 (SEQ ID NO:100), as shown in Table 1. In another embodiment, the sequences of the VH and VL regions comprise SEQ ID NOs:99 and 100, respectively, as shown in Table 1.

[0161] Variant Fc Regions Mutation of amino acid residues at positions corresponding to E430, E345, and S440 in the human IgG1 heavy chain (wherein the amino acid residues are numbered according to the EU index) can improve the ability of an antibody to induce CDC (see, e.g., Example 3). Without being bound by theory, it is believed that substituting one or more amino acids at these positions can stimulate oligomerization of the antibody, thereby modulating effector function, for example, to increase C1q binding, complement activation, CDC, ADCP, internalization, or other related functions that may result in in vivo efficacy.

[0162] As described herein, the amino acid position to be mutated in the Fc region can be provided relative to (i.e., "corresponding to") its position in the naturally occurring (wild-type) human IgG1 heavy chain when numbered according to the EU index. Thus, if the parent Fc region already contains one or more mutations and / or the parent Fc region contains, for example, an IgG2, IgG3 or IgG4 Fc region, the amino acid position corresponding to the amino acid residue, such as, for example, E430 of the human IgG1 heavy chain numbered according to the EU index, can be determined by alignment. Specifically, the parent Fc region is aligned with the wild-type human IgG1 heavy chain sequence to identify the residue at the position corresponding to E430 in the human IgG1 heavy chain sequence. Any wild-type human IgG1 constant region amino acid sequence can be useful for this purpose, including any one of the different human IgG1 allotypes listed in Table 1. This is illustrated in FIG. 1, which shows an alignment between two different human IgG1 allotypes (IgG1m(f) and IgG1m(a)) and wild-type human IgG2, IgG3 and IgG4, in particular the alignment of the segment corresponding to residues P247 to K447 of the human IgG1 heavy chain; said amino acid residues are numbered according to the EU index.

[0163] Accordingly, in the remaining paragraphs of this section and elsewhere in this specification, unless otherwise stated or contradicted by context, references to amino acid positions correspond to amino acid residues in a wild-type human IgG heavy chain, where the amino acid residues are numbered according to the EU index.

[0164] In separate and specific embodiments, the variant Fc region comprises a mutation at only one of E430, E345 and S440, at both E430 and E345, at both E430 and S440, at both E345 and S440, or at all of E430, E345 and S440. In some embodiments, the variant Fc region comprises a mutation at only one of E430, E345 and S440, at both E430 and E345, at both E430 and S440, at both E345 and S440, or at all of E430, E345 and S440, with the proviso that the mutation at S440 is S440W or S440Y. In other separate and specific embodiments, the mutation is an amino acid substitution. In one embodiment, the mutations are only one of E430X, E345X and S440X, both E430X and E345X, both E430X and S440X, both E345X and S440X, or all of the E430X, E345X and S440X amino acid substitutions, with the proviso that the S440X mutation is preferably S440Y or S440W. More preferably, the E430X, E345X and S440X mutations are independently selected from E430G, E345K, E430S, E430F, E430T, E345Q, E345R, E345Y, S440Y and S440W.

[0165] In one embodiment, the one or more amino acid residue mutations are selected from the group consisting of E430G, E345K, E430S, E430F, E430T, E345Q, E345R, E345Y, S440Y and S440W.

[0166] In a preferred embodiment, said mutation of one or more amino acid residues is selected from the group corresponding to E430G, E345K, E430S and E345Q.

[0167] In one embodiment, the mutation is a mutation of an amino acid residue corresponding to E430, such as an amino acid substitution E430X selected from those corresponding to E430G, E430S, E430F, or E430T. In one preferred embodiment, the mutation of one or more amino acid residues comprises E430G. In another preferred embodiment, the mutation of one or more amino acid residues comprises E430S, optionally without mutations at amino acid residues corresponding to E345 and S440. In a particularly preferred embodiment, the mutation of one or more amino acid residues consists of E430G, i.e. without mutations at amino acid residues corresponding to E345 and S440.

[0168] In one embodiment, the mutation is a mutation of the amino acid residue corresponding to E345, such as the amino acid substitution E345X, selected from those corresponding to E345K, E345Q, E345R and E345Y. In one preferred embodiment, the mutation of one or more amino acid residues comprises E345K. In another preferred embodiment, the mutation of one or more amino acid residues comprises E345Q, optionally without mutations at the amino acid residues corresponding to E430 and S440. In a particularly preferred embodiment, the mutation of one or more amino acid residues consists of E345K, i.e. without mutations at the amino acid residues corresponding to E430 and S440.

[0169] In one embodiment, the mutation is at the amino acid residue corresponding to S440, such as the amino acid substitution S440X, typically selected from those corresponding to S440Y and S440W. In one preferred embodiment, the mutation at one or more amino acid residues comprises S440W, optionally without mutations at the amino acid residues corresponding to E430 and E345. In one preferred embodiment, the mutation at one or more amino acid residues comprises S440Y, optionally without mutations at the amino acid residues corresponding to E430 and E345.

[0170] Preferably, the antibody variant comprises a variant Fc region according to any of the preceding sections, the variant Fc region being a variant of a human IgG Fc region selected from the group consisting of human IgG1, IgG2, IgG3 and IgG4 Fc regions. Thus, the variant Fc region is of human IgG1, IgG2, IgG3 or IgG4 isotype, or a mixed isotype thereof, except for the mutations listed. That is, the mutations of one or more amino acid residues corresponding to E430, E345 and S440 are made in a parent Fc region that is a human IgG Fc region selected from the group consisting of IgG1, IgG2, IgG3 and IgG4 Fc regions. Preferably, the parent Fc region is a naturally occurring (wild type) human IgG Fc region, such as a human wild type IgG1, IgG2, IgG3 or IgG4 Fc region, or a mixed isotype thereof. Thus, the variant Fc region can be of human IgG1, IgG2, IgG3 or IgG4 isotype, or a mixed isotype thereof, except for the mutations listed.

[0171] In one embodiment, the parent Fc region is a wild-type human IgG1 isotype. Thus, in one embodiment, the variant Fc region is a human IgG1 Fc region, except for the recited mutations.

[0172] In one embodiment, the parent Fc region is of the human IgG1m(f), IgG1m(a), IgG1m(x), IgG1m(z) allotype, or mixed allotypes thereof. Thus, in one embodiment, the variant Fc region is of the human IgG1m(f), IgG1m(a), IgG1m(x), IgG1m(z) allotype, or mixed allotypes thereof, except for the recited mutations.

[0173] In certain embodiments, the parent Fc region is of human wild-type IgG1m(f) isotype. Thus, in one embodiment, the variant Fc region is of human IgG1m(f) isotype, except for the recited mutations.

[0174] In certain embodiments, the parent Fc region is of human wild-type IgG1m(z) isotype. Thus, in one embodiment, the variant Fc region is of human IgG1m(z) isotype, except for the recited mutations.

[0175] In certain embodiments, the parent Fc region is of human wild-type IgG1m(a) isotype. Thus, in one embodiment, the variant Fc region is of human IgG1m(a) isotype, except for the recited mutations.

[0176] In certain embodiments, the parent Fc region is of human wild-type IgG1m(x) isotype. Thus, in one embodiment, the variant Fc region is of human IgG1m(x) isotype, except for the recited mutations.

[0177] In certain embodiments, the parent Fc region is a mixed allotype human wild type IgG1, e.g., IgG1m(za), IgG1m(zax), IgG1m(fa), etc. Thus, in one embodiment, the variant Fc region is a mixed allotype human IgG1, e.g., IgG1m(za), IgG1m(zax), IgG1m(fa), etc., except for the recited mutations.

[0178] In certain embodiments, the parent Fc region is of human wild type IgG1m(za) isotype. Thus, in one embodiment, the variant Fc region is of human IgG1m(za) isotype, except for the recited mutations.

[0179] In certain embodiments, the parent Fc region is of human wild-type IgG2 isotype. Thus, in one embodiment, the variant Fc region is of human IgG2 isotype, except for the recited mutations.

[0180] In certain embodiments, the parent Fc region is of human wild-type IgG3 isotype. Thus, in one embodiment, the variant Fc region is of human IgG3 isotype, except for the recited mutations.

[0181] In certain embodiments, the parent Fc region is of human wild-type IgG4 isotype. Thus, in one embodiment, the variant Fc region is of human IgG4 isotype, except for the recited mutations.

[0182] Specific example CH region amino acid sequences of wild-type human IgG isotypes and IgG1 allotypes are shown in Table 1. In some embodiments, the parent Fc region comprises the CH2-CH3, or optionally the hinge-CH2-CH3 segment, of such a wild-type CH region amino acid sequence.

[0183] Thus, in certain embodiments, the parent Fc region is a human wild-type IgG1 isotype comprising amino acid residues corresponding to 231-447 of the human IgG1 heavy chain according to EU numbering. For example, the parent Fc region may comprise amino acid residues 114 to 330 (direct numbering) of a sequence selected from the group consisting of SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, and SEQ ID NO:68. As described elsewhere herein for the production of therapeutic antibodies, the C-terminal amino acid K447 may also be deleted or removed. Thus, the parent Fc region may comprise amino acid residues 114 to 329 (direct numbering) of SEQ ID NO:101.

[0184] In certain embodiments, the parent Fc region is a human wild-type IgG1 isotype that comprises amino acid residues corresponding to 216-447 of the human IgG1 heavy chain according to EU numbering. For example, the parent Fc region may comprise amino acid residues 99 to 330 (direct numbering) of a sequence selected from the group consisting of SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, and SEQ ID NO:68. In another embodiment, the variant Fc region may comprise amino acid residues 99 to 329 (direct numbering) of SEQ ID NO:101.

[0185] In certain embodiments, the variant Fc region is a variant of the human wild-type IgG1 isotype comprising amino acid residues corresponding to 231-447 of the human IgG1 heavy chain according to EU numbering. For example, the variant Fc region may comprise amino acid residues 114 to 330 (direct numbering) of a sequence selected from the group consisting of SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77 and SEQ ID NO:78. In another embodiment, the variant Fc region may comprise amino acid residues 114 to 329 (direct numbering) of SEQ ID NO:102.

[0186] In certain embodiments, the variant Fc region is a variant of the human wild-type IgG1 isotype comprising amino acid residues corresponding to 216-447 of the human IgG1 heavy chain according to EU numbering. For example, the variant Fc region may comprise amino acid residues 99 to 330 (direct numbering) of a sequence selected from the group consisting of SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77 and SEQ ID NO:78. In another embodiment, the variant Fc region may comprise amino acid residues 99 to 329 (direct numbering) of SEQ ID NO:102.

[0187] Thus, the present invention is applicable to antibody molecules having a human IgG1 heavy chain, for example a human IgG1 heavy chain comprising the amino acid sequence of a human IgG1 CH region comprising SEQ ID NO:64 (IgGm(za)).

[0188] The present invention is also applicable to antibody molecules having a human IgG1 heavy chain, for example a human IgG1 heavy chain comprising the amino acid sequence of the human IgG1 CH region comprising SEQ ID NO:65 (IgGm(f)) or SEQ ID NO:101.

[0189] The present invention is also applicable to antibody molecules having a human IgG1 heavy chain, for example a human IgG1 heavy chain comprising the amino acid sequence of a human IgG1 CH region comprising SEQ ID NO:66 (IgGm(z)).

[0190] The present invention is also applicable to antibody molecules having a human IgG1 heavy chain, for example a human IgG1 heavy chain comprising the amino acid sequence of a human IgG1 CH region comprising SEQ ID NO:67 (IgGm(a)).

[0191] The present invention is also applicable to antibody molecules having a human IgG1 heavy chain, for example a human IgG1 heavy chain comprising the amino acid sequence of a human IgG1 CH region comprising SEQ ID NO:68 (IgG1m(x)).

[0192] The present invention is also applicable to antibody molecules having a human IgG2 heavy chain, for example a human IgG2 heavy chain comprising an amino acid sequence of a human IgG2 CH region comprising SEQ ID NO:79.

[0193] The present invention is also applicable to antibody molecules having a human IgG3 heavy chain, for example a human IgG3 heavy chain comprising an amino acid sequence of a human IgG3 CH region comprising SEQ ID NO:80.

[0194] The present invention is also applicable to antibody molecules having a human IgG4 heavy chain, for example a human IgG4 heavy chain comprising an amino acid sequence of a human IgG4 CH region comprising SEQ ID NO:81.

[0195] However, variant Fc regions that contain one or more additional mutations, i.e., mutations of one or more other amino acid residues other than those corresponding to E430, E345 and S440 in the human IgG1 heavy chain when numbered according to the EU index, are also contemplated as antibody variants disclosed herein. Additionally or alternatively, the Fc region may be of mixed isotype, where, for example, different CH regions are derived from different IgG isotypes. Thus, as described in more detail below, the parent Fc region may already contain one or more additional mutations compared to such a wild-type (naturally occurring) human IgG Fc region, or may be of mixed isotype.

[0196] In one embodiment, the parent Fc region into which mutations of one or more amino acid residues selected from the group corresponding to E430, E345 and S440 are introduced is a human IgG Fc region comprising one or more further mutations compared to wild-type human IgG1, IgG2, IgG3 and IgG4 Fc region, e.g. as shown in one of SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:79, SEQ ID NO:80 and SEQ ID NO:81. When expressed otherwise, a variant Fc region comprising mutations at E430, E345 and / or S440 may differ from a reference Fc region, such as a reference wild-type human IgG1, IgG2, IgG3 and IgG4 Fc region, for example as set forth in one of SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:79, SEQ ID NO:80 and SEQ ID NO:81, in terms of one or more additional mutations. For example, apart from the mutation of one or more amino acid residues selected from the group corresponding to E430, E345 and S440, the variant Fc region may differ from the wild-type Fc region by up to 12 mutations, for example 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 mutation, for example a substitution, insertion or deletion, of amino acid residues. For example, the C-terminal amino acid Lys (K) at position 447 (Eu numbering) may be deleted. Some host cells used to produce antibodies may contain an enzyme that can remove Lys at position 447, and such removal may not be homogeneous. Therefore, to increase the homogeneity of the product, therapeutic antibodies may be produced without a C-terminal Lys (K). Methods for producing antibodies without a C-terminal Lys (K) are well known to those skilled in the art and include genetic engineering of nucleic acids expressing the antibody, enzymatic methods, and the use of specific host cells. Thus, for example, the parent Fc region may comprise the sequence set forth in SEQ ID NO:101.

[0197] Preferably, such one or more additional mutations do not reduce the ability of the antibody disclosed herein, i.e., the antibody comprising one or more amino acid residue mutations selected from the group corresponding to E430, E345 and S440 in the human IgG1 heavy chain, to induce CDC and / or ADCC. Thus, in one embodiment, the variant Fc region can comprise one or more additional mutations that do not reduce both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) induced by the antibody variant that does not comprise one or more additional mutations. More preferably, such one or more additional mutations do not reduce the ability of the antibody to induce CDC. Most preferably, such one or more additional mutations do not reduce the ability of the antibody to induce either CDC or ADCC. Candidate one or more additional mutations can be tested in a CDC or ADCC assay, for example as disclosed herein in Examples 3 and 4. For example, CDC of an antibody described herein, e.g., IgG1-C-E430G, can be tested in the assay described in Example 3 or in the next section (or a similar assay) in the presence and absence of one or more particular candidate further mutations to ascertain the effect of the candidate further mutations on the ability of the antibody to induce CDC. Similarly, ADCC of an antibody described herein, e.g., IgG1-C-E430G, can be tested in the assay described in Example 4 or in the next section (or a similar assay) in the presence and absence of the particular candidate further mutations to ascertain the effect of the candidate further mutations on the ability of the antibody to induce ADCC.

[0198] Preferably, in an antibody variant comprising two HCs and two LCs, the Fc regions of the first and second HCs are identical, and as a result, the Fc region in the dimerized form is a homodimer.

[0199] However, in some embodiments, in antibody variants comprising two HCs and two LCs, the Fc region of the first HC may differ from the Fc region of the second HC by one or more amino acids, resulting in a heterodimer in the dimerized form of the Fc region. For example, mutations of one or more amino acid residues selected from the group corresponding to E430, E345 and S440 in the IgG1 heavy chain (the amino acid residues are numbered according to the EU index) may be present in only one of the Fc regions. Thus, in some embodiments, one Fc region may be SEQ ID NO:101, or a human wild-type IgG Fc region selected from SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:79, SEQ ID NO:80 and SEQ ID NO:81, and the other Fc region may be identical except for a mutation of one or more amino acid residues selected from the group corresponding to E430, E345, and S440 in the IgG1 heavy chain, when numbered according to the EU index.

[0200] In one embodiment, the antibody variant according to any aspect or embodiment herein is a human antibody, except for the recited mutations.

[0201] In one embodiment, the antibody variant according to any aspect or embodiment herein is a full length antibody, e.g., a full length human antibody, except for the recited mutations.

[0202] In one embodiment, the antibody variant according to any aspect or embodiment herein is a bivalent antibody, e.g., a human bivalent antibody, e.g., a human bivalent full-length antibody, except for the recited mutations.

[0203] In one embodiment, the antibody variant according to any aspect or embodiment herein is a monoclonal antibody, e.g., a human monoclonal antibody, e.g., a human bivalent monoclonal antibody, e.g., a human bivalent full length monoclonal antibody, except for the recited mutations.

[0204] In a preferred embodiment, the antibody variant according to any aspect or embodiment herein is an IgG1 antibody, such as a full length IgG1 antibody, such as a human full length IgG1 antibody, such as a human monoclonal full length bivalent IgG1,κ antibody, such as a human monoclonal full length bivalent IgG1m(f),κ antibody, except for the recited mutations.

[0205] The antibody variant according to the present invention is advantageously a bivalent monospecific format, comprising two antigen-binding regions that bind to the same epitope.However, a bispecific format is also contemplated, in which one of the antigen-binding regions binds to a different epitope.Therefore, the antibody variant according to any aspect or embodiment of the present specification can be either a monospecific antibody or a bispecific antibody, unless the context is inconsistent.

[0206] Thus, in one embodiment the antibody variant according to any aspect or embodiment herein is a monospecific antibody, e.g. a human monospecific antibody, e.g. a human full length monospecific antibody, e.g. a human full length monospecific bivalent monoclonal antibody, e.g. a human full length bivalent monospecific monoclonal antibody, except for the recited mutations.

[0207] In another embodiment, the antibody variant according to any aspect or embodiment herein is a bispecific antibody, such as a full length bispecific antibody, optionally a full length bispecific bivalent IgG1,κ antibody, except for the recited mutations.

[0208] In certain embodiments, the antibody variant that binds to human CD38 comprises: (a) a heavy chain comprising a VH region comprising the amino acid sequences of VH CDR1, VH CDR2 and VH CDR3 of an antibody selected from the group consisting of A to H, as set forth in Table 1, and a human IgG1 CH region having mutations at one or more of E430, E345 and S440, wherein the amino acid residues are numbered according to the EU index; (b) a light chain comprising a VL region comprising the amino acid sequences of VL CDR1, VL CDR2 and VL CDR3 of a selected antibody as set forth in Table 1; Includes.

[0209] In another particular embodiment, the antibody variant that binds to human CD38 is (a) a heavy chain comprising the amino acid sequence of a VH region of an antibody selected from the group consisting of A to H and a human IgG1 CH region having one or more mutations at E430, E345 and S440, as set forth in Table 1, wherein the amino acid residues are numbered according to the EU index; (b) a light chain comprising the amino acid sequence of the VL region of the selected antibody, as set forth in Table 1; Includes.

[0210] In a separate and specific embodiment, the human IgG1 CH region may be of human IgG1m(f), IgG1m(a), IgG1m(x) and IgG1m(z) allotypes, or a mixed allotype of one or more thereof. In other separate and specific embodiments, the CH may comprise the sequence of SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68 and SEQ ID NO:101, except for the mutations listed. In other separate and specific embodiments, the CH region comprises an amino acid sequence selected from the group consisting of SEQ ID NO:69 to SEQ ID NO:78 and SEQ ID NO:101. In a specific embodiment, the CH region comprises SEQ ID NO:69 (IgG1m(f)-E430G) or SEQ ID NO:102, and optionally the light chain comprises a CL comprising SEQ ID NO:82. In certain embodiments, the antibody variants are monospecific antibodies that comprise two HCs with identical amino acid sequences and two LCs with identical amino acid sequences.

[0211] In one aspect, the antibody variant for use according to any aspect or embodiment herein is conjugated to a drug, cytotoxic agent, toxin, radiolabel or radioisotope.

[0212] Adjusting functions In addition to inducing trogocytosis, the antibody variants for use according to any aspect or embodiment herein are typically also capable of inducing one or more, preferably all, of CDC, ADCC, ADCP, apoptosis and apoptosis, or any combination thereof, of target cells expressing human CD38, usually in the presence of complement and / or effector cells.

[0213] The antibody variant according to any aspect or embodiment herein is typically capable of modulating the enzymatic activity of CD38.

[0214] In a further embodiment, the antibody variant according to any aspect or embodiment herein, in addition to inducing trogocytosis, is capable of inducing one or more of CDC, ADCC, ADCP, apoptosis, or any combination thereof, and modulating the enzymatic activity of CD38.

[0215] In a further embodiment, the antibody variant according to any aspect or embodiment herein has an inhibitory effect on CD38 cyclase activity and is capable of inducing one or more of the following functions: CDC, ADCC, ADCP and apoptosis.

[0216] In a further embodiment, the antibody variant according to any aspect or embodiment herein has no inhibitory effect on CD38 cyclase activity and is capable of inducing one or more of the following functions: CDC, ADCC, ADCP and apoptosis.

[0217] Complement-dependent cytotoxicity (CDC): In one embodiment, the antibody variant induces CDC. In one embodiment, the antibody variant induces CDC of cells expressing human CD38. In particular, the antibody variant can mediate increased CDC when bound to CD38, e.g., on the surface or cell membrane of CD38-expressing cells, compared to a control. The control can be, for example, a reference antibody having the same amino acid sequence (typically heavy and light chain amino acid sequence) as the antibody variant, except for one or more mutations at E430, E345 and / or S440 in the variant antibody. Alternatively, the reference antibody can be an antibody that binds to the same target but has a different amino acid sequence. Alternatively, the control can be an isotype control antibody, e.g., whose VH and VL sequences are those of antibody b12 shown in Table 1.

[0218] Thus, in one embodiment, an antibody variant according to any aspect or embodiment disclosed herein induces higher CDC on CD38-expressing target cells than a reference antibody, wherein the reference antibody comprises the same VH and VL region sequences as the antibody variant, and the same CH and CL region sequences as the antibody variant except for one or more mutations at E430, E345 and / or S440.

[0219] In another embodiment, the antibody variant according to any aspect or embodiment disclosed herein induces higher CDC on CD38-expressing target cells than a reference antibody, wherein the reference antibody comprises the sequences of the VH and VL regions of antibody b12, i.e., SEQ ID NO:57 and SEQ ID NO:61, respectively, and the sequences of the CH and CL regions are identical to the antibody variant.

[0220] In one particular embodiment, the CDC response is expressed as maximum lysis, where higher maximum lysis reflects increased CDC.

[0221] In one particular embodiment, the CDC response is expressed as EC50 (the concentration at which half-maximal lysis is observed), where a lower EC50 indicates increased CDC.

[0222] In one particular embodiment, the CD38-expressing target cell is a tumor cell, such as a lymphoma cell. Non-limiting examples of lymphoma target cells include the following (commercial sources are indicated in parentheses): - Daudi cells (ATCC CCL-213); - Ramos cells (ATCC CRL-1596); - REH cells (DSMZ ACC 22); - Wien-133 cells (BioAnaLab, Oxford, UK); - RS4;1 cells (DSMZ ACC 508); - NALM-16 (DSMZ ACC 680); - U266 (ATCC TIB-196); - RC-K8(DSMZ ACC 561); - SU-DHL-8; - Oci-Ly-7; - Oci-Ly-19; - Oci-Ly-18; - Raji; - DOHH-2; - SU-DHL-4; - WSU-DLCL-2; - Z-138; - JVM-13; - Jeko-1; - 697; - Granta 519; - DB; - Pfeiffer.

[0223] The target cell expressing CD38 may also be an AML cell, such as, but not limited to, one selected from the group consisting of THP1, monomac6, Oci-AML3, KG-1, ML2, U937, Nomo-1, AML-193, MEGAL, MOLM13, HL-60 and Oci-M1.

[0224] In another specific embodiment, the CD38-expressing target cells are tumor cells, e.g., lymphoma or myeloma cells, and the approximate average number of CD38 molecules per cell, optionally as measured as described in Example 1, is in any of the following ranges: - 150,000-250,000, for example, about 200,000; - 200,000-300,000, for example, about 260,000; - 80,000-180,000, for example, about 130,000; - 50,000-150,000, for example, about 100,000; - 40,000-120,000, for example, about 80,000; - 30,000-70,000, for example, about 50,000; - 10,000-20,000, for example, about 15,000; - 5,000 to 15,000, for example, about 10,000.

[0225] In one embodiment, the antibody variant induces increased CDC against CD38-expressing target cells compared to a reference antibody, where the CDC response is maximal lysis, and the CD38-expressing target cells are selected from Daudi cells (ATCC CCL-213) and Ramos cells (ATCC CRL-1596).

[0226] In one embodiment, the antibody variant induces increased CDC against CD38-expressing target cells compared to a reference antibody, where the CDC response is an EC50 and the CD38-expressing target cells are selected from NALM-16 (DSMZ ACC 680), U266 (ATCC TIB-196) and RC-K8 (DSMZ ACC 561).

[0227] Any in vitro or in vivo method or assay known to those skilled in the art suitable for assessing the ability of an antibody, such as an IgG antibody, to induce CDC on CD38-expressing target cells can be used. Preferably, such an assay comprises, in relevant part, the steps of a CDC assay described in Example 3.

[0228] A non-limiting example of an assay for measuring the maximum lysis or EC50 value of CD38 expressing cells mediated by CD38 antibodies may include the following steps: (a) plating approximately 100,000 CD38-expressing cells per well in 40 μL of culture medium supplemented with 0.2% BSA in a multi-well plate; (b) pre-incubating the cells with 40 μL of serially diluted CD38 antibodies (0.0002–10 μg / mL) for 20 min; (c) incubating each well with 20% pooled normal human serum at 37° C. for 45 minutes; (d) adding a viability dye and measuring the percentage of cell lysis with a flow cytometer; (e) determining maximum lysis and / or calculating EC50 values ​​using non-linear regression.

[0229] Tumor cells suitable for this assay include, but are not limited to, those listed in Table 2, such as Daudi cells (ATCC CCL-213).

[0230] In a particular embodiment, the antibody variant induces CDC on Daudi cells (ATCC No. CCL-213) or Ramos cells (ATCC No. CRL-1596) and results in a maximum lysis that is at least 50%, such as at least 60%, such as at least 70% higher than the maximum lysis obtained with a reference antibody that differs only by the absence of a mutation in one or more amino acid residues selected from the group corresponding to E430, E435 and S440 in the human IgG1 heavy chain, where said amino acid residues are numbered according to the EU index. In one embodiment, the reference antibody comprises the sequences of the VH and VL regions of antibody C, i.e., SEQ ID NO:36 and SEQ ID NO:40, respectively, and the sequences of the CH and CL regions of SEQ ID NO:65 (IgGm(f)) and SEQ ID NO:82(kappa), respectively.

[0231] Antibody-dependent cellular cytotoxicity (ADCC): In one embodiment, the antibody variant for use according to any aspect or embodiment herein induces ADCC. In one embodiment, the antibody variant induces ADCC of cells expressing human CD38. In some embodiments, the antibody variant can mediate higher ADCC than the control when bound to CD38, for example on the surface or cell membrane of CD38-expressing cells. The control can be a reference antibody, such as an isotype control antibody, for example, whose VH and VL sequences are those of antibody b12 shown in Table 1.

[0232] Thus, in one embodiment, the antibody variant according to any aspect or embodiment disclosed herein induces higher ADCC against CD38-expressing target cells than an isotype control antibody, which comprises the VH and VL region sequences of antibody b12 and the same CH and CL region sequences as the antibody variant. In one particular embodiment, the ADCC response is maximal lysis, with higher maximal lysis reflecting higher ADCC. In one particular embodiment, the ADCC response is assessed in an assay that measures FcγRIIIa binding, where higher binding indicates higher ADCC. In one particular embodiment, the CD38-expressing target cells are tumor cells. Non-limiting examples of target cells include tumor cell lines listed in Table 2, such as Daudi cells, Wien-133 cells, Granta 519 cells, and MEC-2 cells.

[0233] Any in vitro or in vivo method or assay known to those skilled in the art suitable for assessing the ability of an antibody, such as an IgG antibody, to induce ADCC against CD38-expressing target cells can be used. Preferably, the assay is, in relevant part, the method described in Example 4. 51 The assay includes a Cr release antibody-dependent cytotoxicity assay or an ADCC reporter bioassay. Non-limiting examples of assays for investigating ADCC of CD38-expressing cells mediated by CD38 antibodies are described below. 51 The method may include a Cr release assay or a reporter assay step.

[0234] 51 ADCC via Cr release: (a) In a multiwell plate, approximately 5,000 cells were cultured in 50 μL of culture medium containing 0.2% BSA per well. 51 plating Cr-labeled CD38-expressing cells (e.g., Daudi cells); (b) pre-incubating the cells with 50 μL of serially diluted CD38 antibodies (0.0002-10 μg / mL) for 15 min; (c) incubating each well with 500,000 freshly isolated peripheral blood mononuclear cells (PBMCs) per well at 37° C. for 4 hours; (d) 75 μL of the supernatant was counted in a gamma counter. 51 measuring the amount of Cr released; (e) calculating the percentage of cell lysis as (cpm sample-cpm spontaneous lysis) / (cpm maximum lysis-cpm spontaneous lysis), where cpm is counts per minute.

[0235] ADCC by reporter assay: (a) plating approximately 5,000 Daudi cells in 10 μL in standard medium (e.g. RPMI 1640) supplemented with 25% low IgG serum in a multi-well plate suitable for optical reading (e.g. 384-well OptiPlate from PerkinElmer); (b) incubating each well with 10 μL of genetically engineered Jurkat cells stably expressing the FcγRIIIa receptor, the V158 (high affinity) variant, and an NFAT response element driving the expression of firefly luciferase as effector cells, and 10 μL of serially diluted CD38 antibodies (0.0002-10 μg / mL) for 6 hours at 37° C.; (c) Incubating each well with 30 μL of luciferase substrate for 5 minutes at room temperature and measuring luminescence.

[0236] Antibody-dependent cellular phagocytosis (ADCP): In one embodiment, the antibody variant for use according to any aspect or embodiment herein induces ADCP. In some embodiments, the antibody variant of the present invention can mediate higher ADCP than the control when bound to CD38, for example on the surface or cell membrane of a CD38-expressing cell. In one embodiment, the control is a reference antibody that has the same amino acid sequence (typically heavy and light chain amino acid sequence) as the antibody variant, except for one or more mutations at E430, E345 and / or S440 of the variant antibody. In another embodiment, the control is a reference antibody that is an isotype control antibody that has the same amino acid sequence (typically heavy and light chain amino acid sequence) as the antibody variant, except for different VH and VL sequences. For example, the isotype control antibody has the VH and VL sequences of antibody b12 shown in Table 1.

[0237] Thus, in one embodiment, an antibody variant according to any aspect or embodiment disclosed herein induces higher ADCP against CD38-expressing target cells than a reference antibody, where the reference antibody differs from the antibody variant only in one or more mutations at E430, E345 and / or S440 of the variant antibody. In another embodiment, the reference antibody comprises the sequences of the VH and VL regions of antibody b12 and the same CH and CL region sequences as the antibody variant.

[0238] In one particular embodiment, the CD38-expressing target cell is a tumor cell, such as a myeloma cell or a lymphoma cell. Non-limiting examples of target cells that are tumor cells include those listed in Table 2.

[0239] Any in vitro or in vivo method or assay known to those skilled in the art suitable for assessing the ability of an antibody, such as an IgG antibody, to induce ADCP against CD38-expressing target cells can be used. Preferably, the assay comprises, in relevant part, the steps of a macrophage-based ADCP assay described in Example 5. In particular, an assay for measuring ADCP of CD38-expressing cells mediated by CD38 antibodies may comprise the steps described below:

[0240] ADCP: (a) Differentiation of freshly isolated monocytes into macrophages by incubation in GM-CSF-containing medium for 5 days; (b) plating approximately 100,000 macrophages per well in a multi-well plate in dendritic cell medium containing GM-CSF; (c) adding 20,000 common fluorescent membrane dye-labeled CD38 antibody-opsonized CD38 expressing cells (e.g., Daudi cells) per well for 45 minutes at 37°C; (d) Measuring the percentage of CD14 positive, CD19 negative, membrane dye positive macrophages using a flow cytometer.

[0241] Apoptosis: Antibody variants for use according to the present invention may in one embodiment induce apoptosis in the absence of an Fc cross-linking agent.

[0242] An antibody variant for use according to the invention in one embodiment is not capable of inducing apoptosis in the absence of an Fc crosslinking agent, hi a further embodiment, the antibody variant is capable of inducing apoptosis in the presence of an Fc crosslinking agent but is not capable of inducing apoptosis in the absence of an Fc crosslinking agent.

[0243] In one embodiment, the Fc cross-linking agent is an antibody.

[0244] In one embodiment, apoptosis can be measured as described in Example 6.

[0245] Trogocytosis: The antibody variants for use according to the present invention induce trogocytosis, and induce trogocytosis of CD38 expressed on the surface of CD38-expressing cells, such as CD38-expressing immune cells and / or CD38-expressing tumor cells as described above. Representative immune cells include immune suppressive cells, such as Tregs. Representative acceptor cells include T cells, B cells, monocytes / macrophages, dendritic cells, neutrophils, and NK cells. Preferably, the acceptor cells are effector cells expressing Fc gamma receptors (FcγR), such as macrophages or PBMCs.

[0246] The antibody variants described herein typically result in a reduction of CD38 on CD38-expressing cells via trogocytosis, compared to at least one control. The control can be selected by the skilled artisan based on the specific purpose of the study or assay in question. However, non-limiting examples of controls include: (i) absence of antibody; (ii) isotype control antibody; or (iii) a parent or reference antibody that has the same amino acid sequence as the antibody variant, except for mutations of one or more amino acid residues corresponding to E430, E345 and S440 in the human IgG1 heavy chain, for example; wherein said amino acid residues are numbered according to the EU index.

[0247] Typically, the antibody variants described herein result in an increased reduction of CD38 expressed on CD38-expressing cells, for example an increased reduction of at least about 5%, such as at least about 10%, such as at least about 15%, such as at least about 25%, such as at least about 50%, such as at least about 75%, or 100% using the antibody variants compared to a control. Preferably, the reduction is statistically significant. In one embodiment, the control is (ii), i.e., an isotype control antibody. An example of an isotype control antibody is antibody b12 having the VH and VL sequences set forth in Table 1. In one embodiment, the control is (iii), i.e., a reference antibody having an identical amino acid sequence to the antibody variant, except for mutations of one or more amino acid residues corresponding to E430, E345 and S440 in the human IgG1 heavy chain; said amino acid residues are numbered according to the EU index.

[0248] Suitable assays for assessing trogocytosis are known in the art and include, for example, the assays described in Example 8 and elsewhere herein. Non-limiting examples of assays for measuring trogocytosis of CD38-expressing immune cells, such as immunosuppressive cells, are described elsewhere in this disclosure. The following is an example of an assay for measuring tumor cell trogocytosis mediated by CD38 antibodies:

[0249] Trogocytosis (Daudi cells): (a') Differentiation of freshly isolated monocytes into macrophages with GM-CSF for 5 days; (b') plating approximately 100,000 macrophages per well in dendritic cell medium containing GM-CSF; (c') adding approximately 20,000 common fluorescent membrane dye-labeled CD38 antibody-opsonized Daudi cells per well for 45 min at 37°C; (d') Measuring CD38 and huIgG expression on Daudi cells with a flow cytometer, where a decrease in CD38 and huIgG on CD38 antibody-opsonized Daudi cells indicates trogocytosis.

[0250] In addition to Daudi cells (ATCC CCL-213), suitable tumor cells include, but are not limited to, those listed in Table 2.

[0251] Thus, in one embodiment, an antibody variant for use according to any aspect or embodiment disclosed herein results in a trogocytosis-mediated reduction of CD38 expression on CD38-expressing target cells, such as CD38-expressing immunosuppressive cells or tumor cells, compared to a reference antibody, where the reference antibody has an identical amino acid sequence (typically heavy and light chain amino acid sequences) to the antibody variant, except for one or more mutations at E430, E345 and / or S440 in the variant antibody.

[0252] In one embodiment, the antibody variant for use according to any aspect or embodiment disclosed herein effects a trogocytosis-mediated reduction of CD38 expression on CD38-expressing target cells, such as CD38-expressing immunosuppressive cells or tumor cells, compared to an isotype control antibody, which comprises the sequences of the VH and VL regions of antibody b12, i.e., SEQ ID NO:57 and SEQ ID NO:61, respectively, and the sequences of the CH and CL regions identical to the antibody variant.

[0253] Regulation of CD38 enzyme activity Antibody variants for use according to any aspect or embodiment herein are typically capable of modulating one or more enzymatic activities of human CD38.

[0254] In one embodiment, the antibody variants disclosed herein have an inhibitory effect on CD38 cyclase activity. For example, the antibody variants may have an inhibitory effect on the cyclase activity of CD38 expressed by cells, such as tumor cells, and / or on isolated CD38, such as soluble fragments of CD38 (e.g., His-tagged CD38 or HA-tagged CD38). In some embodiments, the antibody variants are included in CD38 binding group 1 or 2.

[0255] In one embodiment, the antibody variants disclosed herein do not have an inhibitory effect on CD38 cyclase activity.For example, the antibody variants may not show significant inhibitory effect on the cyclase activity of CD38 expressed by cells such as tumor cells, and / or on isolated CD38, such as soluble fragments of CD38 (e.g., His-tagged CD38 or HA-tagged CD38).In some embodiments, the antibody variants are included in CD38 binding group 3.

[0256] Any in vitro or in vivo method or assay known to those skilled in the art that is suitable for assessing the ability of an anti-CD38 antibody to inhibit CD38 cyclase or hydrolase activity can be used. Exemplary assays are provided below.

[0257] Cyclase activity (NDG substrate): In one aspect, the antibody variants disclosed herein have an inhibitory effect on CD38 cyclase activity compared to a control, e.g., an isotype control antibody such as antibody b12. For example, the antibody variants may have an inhibitory effect on the cyclase activity of CD38 expressed by a cell, such as a tumor cell, and / or on isolated CD38, such as a soluble fragment of CD38 (e.g., SEQ ID NO:84).

[0258] Any in vitro or in vivo method or assay known to those skilled in the art suitable for evaluating the ability of anti-CD38 antibodies to inhibit CD38 cyclase activity can be used. Suitable assays for testing CD38 cyclase activity are described, for example, in WO 2006 / 099875 A1 and WO 2011 / 154453 A1. Preferably, the method comprises the steps of a specific assay described, in relevant part, in Example 6, and tests cyclase activity using nicotinamide guanine dinucleotide sodium salt (NGD) as a substrate for CD38. NGD, which is non-fluorescent, is cyclized by CD38 to cyclic GDP-ribose, a fluorescent cADPR analogue (see, for example, Comb, Chem High Throughput Screen. 2003 Jun;6(4):367-79A). A non-limiting example of an assay comprises the following steps for measuring inhibition of CD38 cyclase activity: (a) seeding 200,000 Daudi or Wien133 cells in 100 μL of 20 mM Tris-HCL per well in a multi-well plate; or seeding 0.6 μg / mL His-tagged soluble CD38 (SEQ ID NO:84) in 100 μL of 20 mM Tris-HCL per well; (b) adding 1 μg / mL of CD38 antibody and 80 μM of NGD to each well; (c) measuring the fluorescence until a plateau is reached (e.g., 5, 10, or 30 minutes); and (d) Determining the percent inhibition by comparison with a control, such as wells incubated with an isotype control antibody.

[0259] In one embodiment, in such an assay, the antibody variant can inhibit the cyclase activity of CD38, specifically the maximum NGD conversion percentage, by at least about 40%, such as at least about 50%, such as at least about 60%, such as between about 40% and about 60%, compared to the CD38 cyclase activity in the presence of a control, typically an isotype control antibody. For example, the isotype control antibody may comprise the sequences of the VH and VL regions of antibody b12, i.e., SEQ ID NO:57 and SEQ ID NO:61, respectively, and the sequences of the CH and CL regions identical to the antibody variant. In a particular embodiment, the assay utilizes hisCD38 (SEQ ID NO:84) to measure cyclase activity.

[0260] In one aspect, in such an assay, the parent antibody or antibody variant is capable of inhibiting the cyclase activity of CD38, specifically the maximum percent NGD conversion, by at least about 20%, such as at least about 40%, such as at least about 50%, such as at least about 60%, for example between about 20% and about 60%, compared to a control, typically an isotype control antibody. In a particular embodiment, the cyclase activity inhibited is that of hisCD38 (SEQ ID NO:84).

[0261] In one embodiment, a parent antibody or antibody variant that is capable of inhibiting the cyclase activity of hisCD38 in such an assay, in particular the maximum percent NGD conversion, by at least about 20%, such as at least about 40%, such as at least about 50%, such as at least about 60%, for example between about 20% and about 60%, compared to a control, belongs to CD38 binding group 1 or 2.

[0262] In one embodiment, a parent antibody or antibody variant that is capable of inhibiting the cyclase activity of hisCD38 in such an assay, in particular the maximum percent NGD conversion, by at least about 20%, such as at least about 40%, such as at least about 50%, such as at least about 60%, for example between about 20% and about 60%, compared to a control, comprises the VH CDRs and VL CDRs of antibodies B, C, E, F, G or H as set forth in Table 1.

[0263] In one aspect, a parent antibody or antibody variant capable of inhibiting the cyclase activity of hisCD38 in such an assay, in particular the maximum percent NGD conversion, by at least about 20%, such as at least about 40%, for example at least about 50%, for example at least about 60%, for example between about 20% and about 60%, compared to a control, comprises the amino acid sequence of the VH region and VH region of antibody B, C, E, F, G or H set forth in Table 1.

[0264] In one preferred embodiment, the parent antibody or antibody variant inhibits the cyclase activity of hisCD38 in such an assay, in particular the maximum percent NGD conversion, by at least about 40%, such as at least about 50%, such as at least about 60%, such as between about 40% and about 60%, and comprises an antigen binding region comprising the VH and VL CDRs of antibody C, designated as SEQ ID NO:37 (VH-3003-C_CDR1), SEQ ID NO:38 (VH-3003-C_CDR2), SEQ ID NO:39 (VH-3003-C_CDR3), SEQ ID NO:41 (VL-3003-C_CDR1), AAS (VL-3003-C_CDR2) and SEQ ID NO:42 (VL-3003-C_CDR3). In another preferred embodiment, the VH and VL sequences are those of antibody C, i.e., the VH region comprises the sequence of SEQ ID NO:36 (VH-3003-C) and the VL region comprises the sequence of SEQ ID NO:40 (VL-3003-C).

[0265] In another preferred embodiment, the parent antibody or antibody variant inhibits the cyclase activity of hisCD38 in such an assay, in particular the maximum percent NGD conversion, by at least about 20%, such as at least about 25%, and comprises an antigen-binding region comprising the VH and VL CDRs of antibody B, shown as SEQ ID NO:9 (VH-3003-B_CDR1), SEQ ID NO:10 (VH-3003-B_CDR2), SEQ ID NO:11 (VH-3003-B_CDR3), SEQ ID NO:13 (VL-3003-B_CDR1), DAS (VL-3003-B_CDR2) and SEQ ID NO:14 (VL-3003-B_CDR3). In another preferred embodiment, the VH and VL sequences are those of antibody B, i.e., the VH region comprises the sequence of SEQ ID NO:8 (VH-3003-B) and the VL region comprises the sequence of SEQ ID NO:12 (VL-3003-B).

[0266] In one embodiment the cyclase assay is the NGD assay described in example 8 of WO 2011 / 154453 A1: Briefly, the substrate NGD + (80 μM) is incubated with 0.6 μg / ml HisCD38 (SEQ ID NO:84) in a buffer containing 20 mM Tris-HCl (pH 7.0) and the production of cGDPR is monitored spectrophotometrically at an emission wavelength of 410 nm (excitation at 300 nm) with an excitation filter of 340 ± 60 nm and an emission filter of 430 ± 8 nm. The recombinant His-CD38 protein is preincubated with 3 μg / ml CD38 antibody at room temperature for 15 min, followed by incubation with the substrate NGD. + is added and the production of cyclic GDP-ribose (cGDPR) is recorded after 90 min.

[0267] In this assay, parental antibodies or antibody variants are able to reduce cGDPR production by 53-66% after 90 min.

[0268] Thus, in one aspect, in such an assay, the parent antibody or antibody variant can inhibit the cyclase activity of hisCD38, specifically the maximum percent NGD conversion, by at least about 40%, such as at least about 50%, for example at least about 60%, for example between about 53% and about 66%, compared to a control, typically an isotype control antibody.

[0269] In one aspect, a parent antibody or antibody variant capable of inhibiting the cyclase activity of hisCD38 in such an assay by at least about 40%, such as at least about 50%, such as at least about 60%, such as between about 53% and about 66%, compared to a control, belongs to CD38 binding group 1 or 2, such as CD38 binding group 1.

[0270] In one aspect, a parent antibody or antibody variant capable of inhibiting the cyclase activity of hisCD38 in such an assay, in particular the maximum percent NGD conversion, by at least about 40%, such as at least about 50%, for example at least about 60%, for example between about 53% and about 66%, compared to a control, comprises the VH and VL CDRs of antibodies C, E, F, G or H as set forth in Table 1.

[0271] In one aspect, a parent antibody or antibody variant capable of inhibiting the cyclase activity of hisCD38 in such an assay, in particular the maximum percent NGD conversion, by at least about 40%, such as at least about 50%, for example at least about 60%, for example between about 53% and about 66%, comprises the amino acid sequence of the VH region and VH region of antibody C, E, F, G or H set forth in Table 1.

[0272] In one preferred embodiment, the parent antibody or antibody variant is capable of inhibiting the cyclase activity of hisCD38 in such an assay, in particular the maximum percent NGD conversion, by at least about 40%, such as at least about 50%, such as at least about 60%, such as between about 53% and about 66%, and comprises an antigen binding region comprising the VH and VL CDRs of antibody C, designated as SEQ ID NO:37 (VH-3003-C_CDR1), SEQ ID NO:38 (VH-3003-C_CDR2), SEQ ID NO:39 (VH-3003-C_CDR3), SEQ ID NO:41 (VL-3003-C_CDR1), AAS (VL-3003-C_CDR2) and SEQ ID NO:42 (VL-3003-C_CDR3). In another preferred embodiment, the VH and VL sequences are those of antibody C, i.e., the VH region comprises the sequence of SEQ ID NO:36 (VH-3003-C) and the VL region comprises the sequence of SEQ ID NO:40 (VL-3003-C).

[0273] In some embodiments, a parent antibody or antibody variant has increased (i.e., more effective) inhibition of CD38 cyclase activity compared to a reference antibody that has identical amino acid sequences (typically heavy and light chain amino acid sequences) as the antibody variant, except for different VH and VL sequences as defined herein. Such a reference antibody can instead have the VH and VL sequences of Antibody A, e.g., as shown in Table 1.

[0274] Reverse cyclase activity The effect of the parent antibody or antibody variant described herein on the generation of cADPR from NAD by CD38 can be examined by a reverse cyclase reaction, which tests the reversibility of the reaction catalyzed by CD38. For example, in the presence of high concentrations of nicotinamide and cADPR, ADP-ribosyl cyclase, such as human CD38, can generate NAD. Any suitable reverse cyclase assay known in the art can be used. However, preferably, the assay comprises, in relevant part, the steps of the assay described in Example 8 of WO 2011 / 154453 A1:

[0275] CD38 antibody is diluted to 10 μg / ml in 20 mM Tris-HCl, 0.01% (v / v) BSA, pH 7.2 (Tris / BSA). Human recombinant CD38 was diluted to 2 μg / ml in Tris / BSA. CD38 antibody is preincubated with CD38 for 10 min at room temperature by mixing equal volumes (50 μL) of diluted antibody and diluted CD38. The reaction is started by transferring 25 μL of the CD38 / antibody mixture to 25 μL of a solution containing 1 mM cADPR and 10 mM nicotinamide. The reaction is allowed to proceed for 1-20 min at room temperature and stopped at the appropriate time by filtering the entire sample, for example through a Millipore MultiScreen-IP filter 96-well plate, to remove protein. NAD produced is measured by the method of Graeff and Lee (supra).

[0276] In this assay, 1 μg / ml of parent antibody or antibody variant can reduce cADPR production from NAD by at least 60%, such as about 67%, for example between about 40% and about 80%.

[0277] Thus, in one aspect, in such an assay the parent antibody or antibody variant is capable of inhibiting the reverse cyclase activity of CD38, such as hisCD38, by at least about 40%, such as at least about 50%, such as at least about 60%, such as about 67%, for example between about 40% and about 80%, compared to CD38 cyclase activity in the absence of a control, typically a CD38 antibody.

[0278] In one aspect, a parent antibody or antibody variant that is capable of inhibiting the reverse cyclase activity of CD38, such as hisCD38, in such an assay by at least about 40% compared to a control, such as at least about 50%, such as at least about 60%, such as about 67%, such as between about 40% and about 80%, belongs to CD38 binding group 1 or 2, such as CD38 binding group 1.

[0279] In one embodiment, a parent antibody or antibody variant that is capable of inhibiting the reverse cyclase activity of CD38, such as hisCD38, in such an assay by at least about 40%, such as at least about 50%, such as at least about 60%, such as about 67%, such as between about 40% and about 80% compared to a control comprises the VH and VL CDRs of antibody B, C, E, F, G or H as set forth in Table 1.

[0280] In one aspect, a parent antibody or antibody variant capable of inhibiting the reverse cyclase activity of CD38, such as hisCD38, in such an assay by at least about 40%, such as at least about 50%, such as at least about 60%, such as about 67%, such as between about 40% and about 80%, comprises the amino acid sequence of the VH region and VH region of antibody C, E, F, G or H as set forth in Table 1.

[0281] In one preferred embodiment, the antibody variant inhibits the reverse cyclase activity of CD38, such as hisCD38, in such an assay by at least about 40%, such as at least about 50%, such as at least about 60%, such as about 67%, such as between about 40% and about 80%, and comprises an antigen binding region comprising the VH and VL CDRs of antibody C, designated as SEQ ID NO:37 (VH-3003-C_CDR1), SEQ ID NO:38 (VH-3003-C_CDR2), SEQ ID NO:39 (VH-3003-C_CDR3), SEQ ID NO:41 (VL-3003-C_CDR1), AAS (VL-3003-C_CDR2) and SEQ ID NO:42 (VL-3003-C_CDR3). In another preferred embodiment, the VH and VL sequences are those of antibody C, i.e., the VH region comprises the sequence of SEQ ID NO:36 (VH-3003-C) and the VL region comprises the sequence of SEQ ID NO:40 (VL-3003-C).

[0282] In some embodiments, a parent antibody or antibody variant has increased (i.e., more effective) inhibition of CD38 reverse cyclase activity compared to a reference antibody that has identical amino acid sequences (typically heavy and light chain amino acid sequences) to the antibody variant except for different VH and VL sequences as defined herein. Such a reference antibody can instead have the VH and VL sequences of Antibody A, e.g., as shown in Table 1.

[0283] CD38 cyclase activity (8-amino-NAD (8NH2-NAD) substrate): Since the production of cADPR only accounts for about 1% of the products generated from NAD by CD38 (the remainder being ADPR), ribosyl cyclase activity can also be assessed using 8-amino-NAD (8NH2-NAD) as a substrate. Unlike NAD, a significant amount (about 8%) of the 8NH2-NAD substrate is cyclized to 8-amino-cADPR (8NH2-cADPR), which is detected by HPLC analysis. Preferably, the assay comprises, in relevant part, the steps of the assay described in Example 8 of WO 2011 / 154453 A1:

[0284] Briefly, CD38 antibody is diluted to 10 μg / ml in 20 mM Tris-HCl, 0.01% (v / v) BSA, pH 7.2 (Tris / BSA). Human recombinant CD38 was diluted to 2 μg / ml in Tris / BSA. CD38 antibody is pre-incubated with CD38 for 10 min at room temperature by mixing equal volumes (50 μL) of diluted CD38 antibody and diluted CD38. The reaction is started by transferring 25 μL of the CD38 / antibody mixture to 75 μL of 0.5 mM 8NH2-NAD. The reaction is allowed to proceed for 10 min at room temperature and stopped at the appropriate time by filtering the entire sample, for example through a Millipore MultiScreen-IP filter 96-well plate, to remove protein. The reaction products (8NH2-cADPR and 8NH2-ADPR) are analyzed by reverse-phase HPLC based on the system described, for example, in Schweitzer et al., Assay for ADP-ribosyl cyclase by reverse-phase high-performance liquid chromatography. Anal Biochem 2001;299:218-226.

[0285] In such an assay, the parent antibody or antibody variant can inhibit 8NH2-cADPR by 78%.

[0286] Thus, in one aspect, in such an assay the parent antibody or antibody variant can inhibit the cyclase activity of CD38, such as hisCD38, by at least about 40%, such as at least about 50%, such as at least about 60%, such as about 78%, for example between about 40% and about 90%, compared to CD38 cyclase activity in the absence of a control, typically a CD38 antibody.

[0287] In one aspect, a parent antibody or antibody variant that is capable of inhibiting the cyclase activity of CD38, such as hisCD38, in such an assay by at least about 40%, such as at least about 50%, such as at least about 60%, such as about 78%, such as between about 40% and about 90% compared to a control belongs to CD38 binding group 1 or 2, such as CD38 binding group 1.

[0288] In one embodiment, a parent antibody or antibody variant that is capable of inhibiting the cyclase activity of CD38, such as hisCD38, in such an assay by at least about 40%, such as at least about 50%, such as at least about 60%, such as about 78%, such as between about 40% and about 90% compared to a control comprises the VH and VL CDRs of antibody B, C, E, F, G or H as set forth in Table 1.

[0289] In one aspect, a parent antibody or antibody variant capable of inhibiting the cyclase activity of CD38, such as hisCD38, in such an assay by at least about 40%, such as at least about 50%, such as at least about 60%, such as about 67%, such as between about 40% and about 90%, comprises the amino acid sequence of the VH region and VH region of antibody C, E, F, G or H as set forth in Table 1.

[0290] In one preferred embodiment, the antibody variant inhibits the cyclase activity of CD38, such as hisCD38, in such an assay by at least about 40%, such as at least about 50%, such as at least about 60%, such as about 78%, such as between about 40% and about 90%, and comprises an antigen binding region comprising the VH and VL CDRs of antibody C, designated as SEQ ID NO:37 (VH-3003-C_CDR1), SEQ ID NO:38 (VH-3003-C_CDR2), SEQ ID NO:39 (VH-3003-C_CDR3), SEQ ID NO:41 (VL-3003-C_CDR1), AAS (VL-3003-C_CDR2) and SEQ ID NO:42 (VL-3003-C_CDR3). In another preferred embodiment, the VH and VL sequences are those of antibody C, i.e., the VH region comprises the sequence of SEQ ID NO:36 (VH-3003-C) and the VL region comprises the sequence of SEQ ID NO:40 (VL-3003-C).

[0291] In some embodiments, a parent antibody or antibody variant has increased (i.e., more effective) inhibition of CD38 cyclase activity compared to a reference antibody that has identical amino acid sequences (typically heavy and light chain amino acid sequences) to the antibody variant except for different VH and VL sequences as defined herein. Such a reference antibody can instead have the VH and VL sequences of Antibody A, e.g., as shown in Table 1.

[0292] Nucleic Acids and Combinations of Nucleic Acids Encoding Antibody Variants In one aspect, the antibody variants used in the present invention may be in the form of a nucleic acid or combination of nucleic acids encoding the antibody variants described herein. In one aspect, the antibody variants used in the present invention may be in the form of a delivery vehicle comprising a nucleic acid or combination of nucleic acids encoding the antibody variants described herein.

[0293] Antibodies are well known therapeutic agents that can be used to treat a variety of diseases. Another method for administering an antibody to a subject in need thereof includes administering a nucleic acid or a combination of nucleic acids encoding the antibody for in vivo expression of the antibody.

[0294] The antibody variant may be according to any aspect or embodiment disclosed herein.

[0295] In one embodiment, the antibody variants may be encoded by one nucleic acid. Thus, the nucleotide sequences encoding the antibody variants disclosed herein are present in one nucleic acid or are present in the same nucleic acid molecule.

[0296] In another embodiment, the antibody variant may be encoded by a combination of nucleic acids, typically by two nucleic acids, in one embodiment, said combination of nucleic acids comprises a nucleic acid encoding the heavy chain of said antibody variant and a nucleic acid encoding the light chain of said antibody variant.

[0297] As noted above, nucleic acids can be used as a means to deliver therapeutic proteins, such as antibodies, to a subject in need thereof.

[0298] In some embodiments, the nucleic acid can be deoxyribonucleic acid (DNA).DNA suitable for in vivo expression of therapeutic proteins such as antibodies and methods for its preparation are well known to those skilled in the art, including but not limited to those described in Patel A et al., 2018, Cell Reports 25, 1982-1993.

[0299] In some embodiments, the nucleic acid may be a ribonucleic acid (RNA), such as a messenger RNA (mRNA). In some embodiments, the mRNA contains only naturally occurring nucleotides. In some embodiments, the mRNA may contain modified nucleotides, where modified means nucleotides that are chemically different from naturally occurring nucleotides. In some embodiments, the mRNA may contain both naturally occurring and modified nucleotides.

[0300] Various nucleic acids suitable for the in vivo expression of therapeutic proteins, such as antibodies, in subjects are well known to those skilled in the art.For example, mRNA suitable for the expression of therapeutic antibodies in subjects often comprises an open reading frame (ORF) flanked by untranslated regions (UTRs) containing specific sequences, and the 5' and 3' ends are formed with cap structures and poly(A) tails (see, for example, Schlake et al., 2019, Molecular Therapy Vol. 27 No 4 April).

[0301] Examples of methods for optimizing RNA and RNA molecules, such as mRNA, for in vivo expression include, but are not limited to, those described in US9,254,311; US9,221,891; US20160185840 and EP3118224.

[0302] Naked nucleic acids administered to a subject for in vivo expression are prone to degradation and / or immunogenic responses in the subject. Furthermore, for in vivo expression of an antibody encoded by a nucleic acid, the nucleic acid is typically administered in a form suitable for the nucleic acid to enter the cells of the subject. There are various methods of delivering nucleic acids for in vivo expression, including both mechanical and chemical means. For example, such methods may include electroporation or tattooing of the nucleic acid into the skin (Patel et al., 2018, Cell Reports 25, 1982-1993). Other methods suitable for administering nucleic acids to a subject include administering the nucleic acid in a suitable formulation. Thus, the antibody variants disclosed herein may also be in the form of a delivery vehicle that includes a nucleic acid or combination of nucleic acids encoding the antibody variants disclosed herein.

[0303] The delivery vehicle may also be a mixture of delivery vehicles comprising a delivery vehicle comprising a nucleic acid encoding the heavy chain of an antibody variant disclosed herein and a delivery vehicle comprising a nucleic acid encoding the light chain of an antibody variant disclosed herein.

[0304] In some embodiments, the delivery vehicle can be a lipid formulation.The lipid of the formulation can be a particle, such as lipid nanoparticle (LNP).The nucleic acid or nucleic acid combination of the present invention can be encapsulated in the particle, for example in the LNP.

[0305] A variety of lipid formulations suitable for administering nucleic acid to a subject for in vivo expression are well known to those skilled in the art.For example, the lipid formulation can typically include lipid, ionizable amino lipid, PEG lipid, cholesterol, or any combination thereof.

[0306] Various forms of lipid formulations suitable for administering nucleic acid to subjects for the expression of therapeutic antibodies and their preparation methods are well known in the art.Examples of such lipid formulations include, but are not limited to, those described in US20180170866 (Arcturus), EP 2391343 (Arbutus), WO 2018 / 006052 (Protiva), WO2014152774 (Shire Human Genetics), EP 2 972 360 (Translate Bio), US10195156 (Moderna), and US20190022247 (Acuitas).

[0307] Production of variant antibodies The variant antibodies may advantageously be produced recombinantly, i.e., by host cells transformed or transfected with a nucleic acid encoding the antibody variant disclosed herein. The nucleic acid may, for example, be contained in an expression vector.

[0308] Suitable nucleic acid constructs, vectors and expression systems for antibodies and variants thereof are known in the art and include, but are not limited to, those described in the Examples. The nucleotide sequences encoding the HC and LC may be contained in different nucleic acids or expression vectors or may be contained in the same nucleic acid or expression vector.

[0309] A stable expression vector in the context of the present invention can be any suitable vector, for example, a chromosomal vector, a non-chromosomal vector, a synthetic nucleic acid vector (a nucleic acid sequence comprising an appropriate set of expression control elements), etc. Examples of such vectors include derivatives of SV40, bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA, and viral nucleic acid (RNA or DNA) vectors. In one embodiment, the nucleic acid is contained in a vector: a naked DNA or RNA vector, such as a linear expression element (e.g., as described in Sykes and Johnston, Nat Biotech 17, 355 59 (1997)), a compacted nucleic acid vector (e.g., as described in US 6,077,835 and / or WO 00 / 70087), a plasmid vector, such as pBR322, pUC 19 / 18, or pUC 118 / 119, a "midge" minimal size nucleic acid vector (e.g., as described in Schakowski et al., Mol Ther 3, 793 800 (2001)), or a precipitated nucleic acid vector construct, such as a CaP04 precipitated construct (e.g., as described in WO200046147; Benvenisty and Reshef, PNAS USA 83, 9551 55 (1986); Wigler et al., Cell 14, 725 731 (2001)). (1978); and Coraro and Pearson, Somatic Cell Genetics 7, 603 (1981). Such nucleic acid vectors and methods for their use are well known in the art (see, e.g., US 5,589,466 and US 5,973,972).

[0310] In one embodiment, the vector is suitable for expressing the antibody variant in a bacterial cell. Examples of such vectors include expression vectors such as BlueScript (Stratagene), pIN vectors (Van Heeke & Schuster, J Biol Chem 264, 5503 5509 (1989)), and pET vectors (Novagen, Madison WI).

[0311] Expression vector can also or alternatively be a vector suitable for expression in yeast system. Any vector suitable for expression in yeast system can be used. Suitable vectors include, for example, vectors that contain constitutive or inducible promoters, such as alpha factor, alcohol oxidase and PGH (reviewed in F. Ausubel et al., eds., Current Protocols in Molecular Biology, Greene Publishing and Wiley InterScience New York (1987); and Grant et al., Methods in Enzymol 153, 516 544 (1987)).

[0312] The expression vector may also, or alternatively, be a vector suitable for expression in mammalian cells, such as a vector containing glutamine synthetase as a selectable marker, such as the vector described in Bebbington (1992) Biotechnology (NY) 10:169-175.

[0313] The nucleic acid and / or vector may also contain a nucleic acid sequence encoding a secretion / localization sequence, which can target a polypeptide, such as a nascent polypeptide chain, to the periplasmic space or to the cell culture medium. Such sequences are known in the art and include secretory leaders or signal peptides.

[0314] The expression vector may contain or be accompanied by any suitable promoter, enhancer, and other expression promoting elements. Examples of such elements include a strong expression promoter (e.g., human CMV IE promoter / enhancer, as well as RSV, SV40, SL33, MMTV, and HIV LTR promoters), an effective poly(A) termination sequence, an origin of replication of the plasmid product in E. coli, an antibiotic resistance gene as a selection marker, and / or a convenient cloning site (e.g., polylinker). The nucleic acid may also contain an inducible promoter as opposed to a constitutive promoter such as CMV IE.

[0315] In one embodiment, an expression vector encoding the antibody variant may be positioned and / or delivered to a host cell or animal via a viral vector.

[0316] Typically, the host cell is transformed or transfected with the nucleic acid or vector. The claimed recombinant host cell can be, for example, a eukaryotic cell, a prokaryotic cell, or a microbial cell, such as a transfectoma. In one aspect, the host cell can be a eukaryotic cell. In one aspect, the host cell can be a prokaryotic cell. In some aspects, the antibody is a heavy chain antibody. However, in most aspects, the antibody variant comprises both a heavy chain and a light chain, and thus the host cell expresses constructs encoding both the heavy and light chains, on the same or different vectors.

[0317] Examples of host cells include yeast, bacteria, plants and mammalian cells, such as CHO, CHO-S, HEK, HEK293, HEK-293F, Expi293F, PER.C6, NS0 cells, Sp2 / 0 cells or lymphocytic cells. In one embodiment, the host cell is a CHO (Chinese Hamster Ovary) cell. For example, in one embodiment, the host cell can comprise a first and a second nucleic acid construct stably integrated into the cell genome, where the first nucleic acid construct encodes the heavy chain of the antibody variant disclosed herein and the second nucleic acid construct encodes the light chain. In another embodiment, the present invention provides a cell comprising a non-integrated nucleic acid, such as a plasmid, cosmid, phagemid, or linear expression element, comprising the first and second nucleic acid constructs as specified above.

[0318] In one embodiment, the host cell is a cell capable of Asn-linked glycosylation of proteins, e.g., a eukaryotic cell, e.g., a mammalian cell, e.g., a human cell. In a further embodiment, the host cell is a non-human cell genetically engineered to produce glycoproteins with human-like or human glycosylation. Examples of such cells are recombinant Pichia pastoris (Hamilton et al., Science 301 (2003) 1244-1246; Potgieter et al., J. Biotechnology 139 (2009) 318-325) and recombinant Lemna minor (Cox et al., Nature Biotechnology 12 (2006) 1591-1597).

[0319] In one embodiment, the host cell is a host cell that does not have the ability to efficiently remove the C-terminal lysine K447 residue from the antibody heavy chain. For example, Table 2 in Liu et al. (2008) J Pharm Sci 97: 2426 (hereby incorporated by reference) describes some such antibody production systems, such as Sp2 / 0, NS / 0, or transgenic mammary gland (goat), in which only partial removal of the C-terminal lysine is obtained. In one embodiment, the host cell is a host cell with modified glycosylation machinery. Such cells have been described in the art and can be used as host cells to express the variants of the present invention and thereby produce antibodies with modified glycosylation. See, e.g., Shields, RL et al. (2002) J. Biol. Chem. 277:26733-26740; Umana et al. (1999) Nat. Biotech. 17:176-1; as well as EP1176195; WO03 / 035835; and WO99 / 54342. Additional methods for generating engineered glycoforms are known in the art and include, but are not limited to, those described in: Davies et al., 2001, Biotechnol Bioeng 74:288-294; Shields et al, 2002, J Biol Chem 277:26733-26740; Shinkawa et al., 2003, J Biol Chem 278:3466-3473; US6602684; WO00 / 61739A1; WO01 / 292246A1; WO02 / 311140A1; WO 02 / 30954A1; Potelligent™ technology (Biowa, Princeton, NJ); GlycoMAb™ glycosylation engineering technology (GLYCART biotechnology AG, Zurich, Switzerland); US 20030115614; Okazaki et al., 2004, JMB, 336: 1239-49; and WO2018 / 114877; WO2018 / 114878 and WO2018 / 114879.

[0320] Compositions and kit-of-parts In one aspect, the antibody variant for use according to the invention is provided as a composition, e.g. a pharmaceutical composition. The pharmaceutical composition comprises: - an antibody variant as defined in any of the aspects and embodiments disclosed herein; and - A pharma- ceutically acceptable carrier may include.

[0321] Pharmaceutical compositions can be formulated according to conventional techniques, such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition, Edited by Gennaro, Mack Publishing Co., Easton, PA, 1995. Pharmaceutical compositions of the present invention can include, for example, diluents, fillers, salts, buffers, surfactants (e.g., non-ionic surfactants such as Tween-20 or Tween-80), stabilizers (e.g., sugars or protein-free amino acids), preservatives, tissue fixatives, solubilizing agents, and / or other materials suitable for inclusion in a pharmaceutical composition.

[0322] Pharmaceutically acceptable carriers include any and all suitable solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonicity agents, antioxidants, absorption delaying agents, etc. that are physiologically compatible with the antibody variants of the present invention. Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions of the present invention include water, saline, phosphate buffered saline, ethanol, dextrose, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils, carboxymethylcellulose colloidal solutions, tragacanth gum, injectable organic esters such as ethyl oleate, and / or various buffers. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0323] The pharmaceutical compositions may also contain pharma- ceutically acceptable antioxidants, including, for example, (1) water-soluble antioxidants, such as ascorbic acid, cysteine ​​hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelators, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

[0324] The pharmaceutical compositions may also include isotonic agents, such as sugars, polyalcohols, for example, mannitol, sorbitol, glycerol, or sodium chloride in the composition.

[0325] Pharmaceutical compositions may also contain one or more auxiliary agents suitable for a given route of administration, such as preservatives, wetting agents, emulsifying agents, dispersing agents, preservatives or buffers, which may enhance the shelf life or effectiveness of pharmaceutical compositions. Pharmaceutical compositions of the present invention may be prepared with carriers that protect the antibody from rapid release, such as controlled release formulations, for example, implants, transdermal patches, microencapsulated delivery systems, etc. Such carriers include gelatin, glyceryl monostearate, glyceryl distearate, biodegradable, biocompatible polymers, such as ethylene-vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid, alone or with wax, or other materials well known in the art. Methods for preparing such formulations are generally known to those skilled in the art.

[0326] Sterile injectable solution can be prepared by incorporating the required amount of active compound into a suitable solvent, which contains one or a combination of the components as listed above, as required, followed by sterilization filtration.Generally, dispersion is prepared by incorporating active compound into a sterile vehicle that contains a basic dispersion medium and other components as listed above.For the case of sterile powder for preparing sterile injectable solution, the example of preparation method is vacuum drying and freeze-drying (lyophilization), which produces a powder of active ingredient and any additional desired ingredient from the solution that has been previously sterile-filtered.

[0327] The actual dosage level of the active ingredient in the pharmaceutical composition can be varied to obtain an amount of the active ingredient effective to achieve the desired therapeutic response for a particular patient, composition, and method of administration without causing toxicity to the patient.The dosage level selected will depend on various pharmacokinetic factors, including the activity of the particular composition of the present invention used, the route of administration, the time of administration, the rate of excretion of the particular compound used, the duration of treatment, other drugs, compounds and / or materials used in combination with the particular composition used, the age, sex, weight, symptoms, general health and previous medical history of the patient being treated, and similar factors well known in the medical field.

[0328] Pharmaceutical compositions can be administered by any suitable route and method. In one embodiment, the pharmaceutical compositions of the present invention are administered parenterally. As used herein, "administered parenterally" refers to administration methods other than enteral and topical administration, usually by injection, including epidermal, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intrathecal, transtracheal, subcutaneous, subcuticular, intraarticular, subcutaneous, subarachnoid, intraspinal, intracranial, intrathoracic, epidural, and intrasternal injection and infusion.

[0329] In one embodiment, the pharmaceutical composition is administered by intravenous or subcutaneous injection or infusion.

[0330] In some embodiments, the antibody variants are provided as a kit-of-parts for simultaneous, separate or sequential use in therapy, optionally the kit-of-parts comprising two or more doses of the antibody variant. The kit-of-parts may comprise such antibody variants or compositions in one or more containers, e.g., vials.

[0331] Therapeutic Applications The antibody variants disclosed herein have numerous therapeutic utilities, including the treatment of diseases and disorders involving target cells and / or immune cells expressing CD38 in a subject.

[0332] The term "subject" as used herein is intended to include humans and non-human animals that may benefit from or respond to an antibody.Subjects include, for example, human patients, who have a disease or disorder that can be treated or ameliorated by modulating CD38 function, such as enzyme activity, and / or by inducing lysis of CD38-expressing cells, and / or by removing / reducing the number of CD38-expressing cells, and / or by reducing the amount of CD38 on cell membranes.Thus, the antibody variants can be used to elicit one or more of the following biological activities in vivo or in vitro: CDC of CD38-expressing cells in the presence of complement; inhibition of CD38 cyclase activity; phagocytosis or ADCC of CD38-expressing cells in the presence of human effector cells; and trogocytosis of CD38-expressing cells, such as tumor cells or immunosuppressive cells.

[0333] The antibody variants disclosed herein can be used to treat or prevent diseases or disorders in subjects who can benefit from an immune response against target cells associated with the disease or disorder, particularly where the immune response against the target cells can be promoted by reduced immunosuppression as described herein. In some aspects, the disease or disorder is cancer and the target cells are tumor cells. In some aspects, the disease or disorder is a viral disease or infection and the target cells are virions or virus-infected cells. In some aspects, the disease or disorder is a bacterial infection and the target cells are bacterial cells.

[0334] Thus, in one aspect, the invention provides an antibody variant for use in enhancing an immune response in a subject, the antibody variant comprising: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index; and It induces the loss of CD38 on CD38-expressing immunosuppressive cells via trogocytosis.

[0335] In one aspect, the invention provides a method of enhancing an immune response in a subject comprising administering to the subject an antibody variant comprising: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index; and It induces the loss of CD38 on CD38-expressing immunosuppressive cells via trogocytosis. Typically, the antibody variant is administered in a therapeutically effective amount and / or for a period of time sufficient to treat the disease.

[0336] In one embodiment, the disease or disorder involving cells expressing CD38 is cancer, i.e., a tumorigenic disorder, e.g., a disorder characterized by the presence of tumor cells and / or immune cells expressing CD38.

[0337] Thus, in one aspect the invention provides an antibody variant for use in treating cancer in a subject, the antibody variant comprising: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells.

[0338] In one aspect, the invention provides an antibody variant for use in treating cancer in a subject, the antibody variant comprising: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index; and It induces the loss of CD38 via trogocytosis on CD38-expressing tumor cells.

[0339] In one aspect, the invention provides a method of treating cancer in a subject comprising administering to the subject an antibody variant comprising: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells. Typically, the antibody variant is administered in a therapeutically effective amount and / or for a period of time sufficient to treat the disease.

[0340] In one aspect, the invention provides a method of treating cancer in a subject comprising administering to the subject an antibody variant comprising: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index; and It induces the loss of CD38 via trogocytosis on CD38-expressing tumor cells. Typically, the antibody variant is administered in a therapeutically effective amount and / or for a period of time sufficient to treat the disease.

[0341] As noted above, the antibody variant may also be in the form of a nucleic acid, a combination of nucleic acids, or a delivery vehicle comprising a nucleic acid or a combination of nucleic acids, where the nucleic acid or combination of nucleic acids encodes an antibody variant disclosed herein.

[0342] Therefore, in one aspect, the present invention also relates to a nucleic acid or a combination of nucleic acids for use in the treatment of cancer in a subject, said nucleic acid or combination of nucleic acids encoding an antibody variant comprising an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index, and said antibody variant induces reduction of CD38 via trogocytosis on CD38-expressing immune cells.

[0343] In one aspect, the present invention also relates to a nucleic acid or a combination of nucleic acids for use in enhancing an immune response in a subject, said nucleic acid or combination of nucleic acids encoding an antibody variant comprising an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index, and wherein said antibody variant induces reduction of CD38 via trogocytosis on CD38-expressing immune cells.

[0344] In one aspect, the present invention also relates to a nucleic acid or a combination of nucleic acids for use in treating cancer in a subject, said nucleic acid or combination of nucleic acids encoding an antibody variant comprising an antigen binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index, and wherein said antibody variant induces a reduction of CD38 via trogocytosis on tumor cells expressing CD38.

[0345] In one aspect, the invention also relates to a method for treating cancer in a subject comprising administering to the subject a nucleic acid or a combination of nucleic acids that encodes an antibody variant comprising an antigen-binding region that binds to CD38 and a variant Fc region that comprises mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index, and wherein the antibody variant induces reduction of CD38 via trogocytosis on CD38-expressing immune cells.

[0346] In one aspect, the present invention also relates to a method for enhancing an immune response in a subject comprising administering to the subject a nucleic acid or a combination of nucleic acids that encodes an antibody variant comprising an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index, and wherein the antibody variant induces reduction of CD38 via trogocytosis on CD38-expressing immune cells.

[0347] In one aspect, the invention also relates to a method of treating cancer in a subject comprising administering to the subject a nucleic acid or a combination of nucleic acids that encodes an antibody variant comprising an antigen-binding region that binds to CD38 and a variant Fc region that comprises mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index, and wherein the antibody variant induces reduction of CD38 via trogocytosis on tumor cells expressing CD38.

[0348] In one aspect, the present invention also relates to a delivery vehicle comprising a nucleic acid or a combination of nucleic acids for use in enhancing an immune response in a subject, wherein the nucleic acid or combination of nucleic acids encodes an antibody variant comprising an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index, and wherein the antibody variant induces reduction of CD38 via trogocytosis on CD38-expressing immune cells.

[0349] In one aspect, the present invention also relates to a delivery vehicle comprising a nucleic acid or a combination of nucleic acids for use in treating cancer in a subject, said nucleic acid or combination of nucleic acids encoding an antibody variant comprising an antigen binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index, and said antibody variant induces reduction of CD38 via trogocytosis on tumor cells expressing CD38.

[0350] In one aspect, the invention also relates to a method of treating cancer in a subject comprising administering to the subject a delivery vehicle comprising a nucleic acid or combination of nucleic acids that encodes an antibody variant comprising an antigen binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index, and wherein the antibody variant induces reduction of CD38 via trogocytosis on CD38-expressing immune cells.

[0351] In one aspect, the present invention also relates to a method of enhancing an immune response in a subject comprising administering to the subject a delivery vehicle comprising a nucleic acid or a combination of nucleic acids encoding an antibody variant comprising an antigen binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index, and wherein the antibody variant induces reduction of CD38 via trogocytosis on CD38-expressing immune cells.

[0352] In one aspect, the present invention also relates to a method of treating cancer in a subject comprising administering to the subject a delivery vehicle comprising a nucleic acid or combination of nucleic acids that encodes an antibody variant comprising an antigen binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index, and wherein the antibody variant induces reduction of CD38 via trogocytosis on tumor cells expressing CD38.

[0353] In some embodiments, the cancer comprises tumor cells that express CD38.

[0354] In some embodiments, the CD38-expressing immune cells are CD38-expressing immunosuppressive cells.

[0355] In some embodiments, the cancer comprises CD38-expressing immunosuppressive cells, e.g., non-cancerous CD38-expressing immunosuppressive cells.

[0356] In some embodiments, the cancer comprises both tumor cells and immunosuppressive cells that express CD38.

[0357] In some embodiments, the cancer comprises immunosuppressive cells that express CD38 and tumor cells that do not express CD38.

[0358] In some embodiments, the use further comprises determining the presence of CD38-expressing immunosuppressive cells in a biological sample taken from the subject prior to use.

[0359] In some embodiments, the use further comprises determining the presence of CD38-expressing tumor cells in a biological sample obtained from the subject prior to use.

[0360] In some embodiments, the use further comprises determining the presence of CD38-expressing Tregs in a biological sample taken from the subject prior to use.

[0361] Non-limiting examples of biological samples include blood samples, bone marrow samples, and tumor biopsies.

[0362] As used herein, immune cells, such as immunosuppressive cells, express CD38 if the expression of CD38 in the tested immune cell population is statistically significant compared to a control, for example, expression detected with an anti-CD38 antibody and expression detected with an isotype control antibody using well-known methods. This can be tested, for example, by taking a biological sample containing immune cells, for example, a blood sample, a bone marrow sample, or a tumor biopsy. Methods for identifying a specific type of immune suppressive cell or other immune cell as disclosed herein are well known in the art and include testing for the expression of an antigen specific to the type of immune cell in question. Examples of VH and VL sequences of anti-CD38 antibodies suitable for testing CD38 expression are shown in Table 1.

[0363] In one embodiment, tumor cells of cancer express CD38. As used herein, tumor cells express CD38 if the expression of CD38 in the tested target cell population is statistically significant compared to a control, for example, by comparing the expression detected by anti-CD38 antibody with the expression detected by an isotype control antibody using known methods. This can be tested, for example, by taking a biological sample containing target cells, for example, a blood sample, a bone marrow sample or a tumor biopsy. Examples of VH and VL sequences of anti-CD38 antibodies suitable for testing CD38 expression are shown in Table 1.

[0364] In some embodiments, tumor cells lack detectable CD38 expression. Tumor cells lack detectable CD38 expression if CD38 expression on tumor cells isolated from a patient is not statistically significant compared to a control, for example, expression detected with anti-CD38 antibody and expression detected with an isotype control antibody using known methods. This can be tested, for example, by taking a biological sample containing tumor cells from a subject, for example, a patient. For example, a tumor biopsy can be obtained from a patient with a solid tumor, and a blood or bone marrow sample can be obtained from a patient with a blood cancer.

[0365] In some embodiments, the subject has Tregs that express CD38. Tregs may exhibit high expression of CD38, and Tregs with high CD38 expression are more immunosuppressive than Tregs with moderate CD38 expression (Krejcik J. et al. Blood 2016 128:384-394). Thus, without being limited by theory, the ability of the antibody variants according to the invention to reduce the amount of CD38 expressed on Tregs via trogocytosis allows for the treatment of cancer, particularly in cancer patients with CD38-expressing Tregs. Tregs express CD38 if the expression of CD38 on Tregs is statistically significant compared to a control, e.g., expression detected with an anti-CD38 antibody compared to expression detected with an isotype control antibody using well-known methods. This can be tested, for example, by taking a biological sample, such as a blood sample, a bone marrow sample, or a tumor biopsy.

[0366] In some embodiments, a method for promoting an immune response in a subject is provided, comprising the steps of: (i) identifying a subject as having immunosuppressive cells that express CD38; and (ii) administering a therapeutically effective amount of an antibody variant according to any aspect or embodiment herein, wherein the antibody variant induces a decrease in CD38 via trogocytosis on immune suppressive cells expressing CD38. Includes.

[0367] In some embodiments, a method for treating cancer in a subject is provided, comprising the steps of: (iii) identifying the subject as having immunosuppressive cells that express CD38; and (iv) administering a therapeutically effective amount of an antibody variant according to any aspect or embodiment herein, wherein the antibody variant induces a decrease in CD38 via trogocytosis on immune suppressive cells expressing CD38. Includes.

[0368] In some embodiments, a method for treating cancer in a subject is provided, comprising the steps of: (i) identifying a subject as having tumor cells that express CD38; and (ii) administering a therapeutically effective amount of an antibody variant according to any aspect or embodiment herein, wherein the antibody variant induces a decrease in CD38 via trogocytosis on immune suppressive cells expressing CD38. Includes.

[0369] Blood cancers: In one aspect, the cancer is a blood cancer, and thus the subject has a blood cancer. Examples of such blood cancers include: B cell lymphoma / leukemia, such as precursor B cell lymphoblastic leukemia / lymphoma and B cell non-Hodgkin's lymphoma; acute promyelocytic leukemia, acute lymphoblastic leukemia, and mature B cell neoplasms, such as B cell chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL), B cell acute lymphocytic leukemia, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, mantle cell lymphoma (MCL), follicular lymphoma, and lymphomas of the genotype, such as leukemia, ... and cutaneous follicle center lymphoma (FL), such as low-grade, intermediate-grade, high-grade FL, cutaneous follicle center lymphoma, marginal zone B-cell lymphoma (MALT type, nodal and splenic type), hairy cell leukemia, diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (adult) (AML), Burkitt lymphoma, plasmacytoma, plasma cell myeloma, plasma cell leukemia, post-transplant lymphoproliferative disorder, Waldenstrom's macroglobulinemia, plasma cell leukemia, and anaplastic large cell lymphoma (ALCL).

[0370] Examples of B-cell non-Hodgkin's lymphomas are lymphomatoid granulomatosis, primary effusion lymphoma, intravascular large B-cell lymphoma, mediastinal large B-cell lymphoma, heavy chain disease (including gamma chain disease, mu chain disease, and alpha chain disease), lymphomas induced by treatment with immunosuppressants, e.g., cyclosporine-induced lymphoma, and methotrexate-induced lymphoma.

[0371] In one aspect of the invention, the cancer is Hodgkin's lymphoma.

[0372] Other examples of disorders involving CD38 expressing cells include malignancies derived from T cells and NK cells, including: mature T cell and NK cell neoplasms such as T cell prolymphocytic leukemia, T cell large granular lymphocytic leukemia, aggressive NK cell leukemia, adult T cell leukemia / lymphoma, extranodal NK / T cell lymphoma, nasal type, enteropathy type T cell lymphoma, hepatosplenic T cell lymphoma, subcutaneous panniculitis-like T cell lymphoma, blastic NK cell lymphoma, mycosis fungoides / Sezary syndrome, primary cutaneous CD30 positive T cell lymphoproliferative disorders (primary cutaneous anaplastic large cell lymphoma C-ALCL, lymphomatoid papulosis, borderline lesions), angioimmunoblastic T cell lymphoma, peripheral T cell lymphoma not otherwise specified, and anaplastic large cell lymphoma.

[0373] Examples of malignancies derived from bone marrow cells include acute myeloid leukemias, such as acute promyelocytic leukemia, and chronic myeloproliferative disorders, such as chronic myeloid leukemia.

[0374] In some embodiments, the cancer is selected from the group consisting of multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (adult) (AML), mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

[0375] In some embodiments, the cancer is selected from the group consisting of multiple myeloma (MM), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute myeloid leukemia (adult) (AML), diffuse large B-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), and follicular lymphoma (FL).

[0376] In one embodiment, the cancer is multiple myeloma (MM).

[0377] In some embodiments, the cancer is chronic lymphocytic leukemia (CLL).

[0378] In some embodiments, the cancer is mantle cell lymphoma (MCL).

[0379] In some embodiments, the cancer is diffuse large B-cell lymphoma (DLBCL).

[0380] In one embodiment, the cancer is follicular lymphoma (FL).

[0381] In one embodiment, the cancer is acute myeloid leukemia (adult) (AML).

[0382] In one embodiment, the cancer is acute lymphoblastic leukemia (ALL).

[0383] Solid tumor malignancies: In one aspect, the cancer comprises a solid tumor, i.e., the patient suffering from cancer has a solid tumor.

[0384] Examples of solid tumors include, but are not limited to, melanoma, lung cancer, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, colorectal cancer, prostate cancer, castration-resistant prostate cancer, stomach cancer, ovarian cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, squamous cell carcinoma of the head and neck, cancer of the esophagus or gastrointestinal tract, breast cancer, fallopian tube cancer, brain tumor, urethral cancer, genitourinary cancer, endometrial cancer, cervical cancer, lung adenocarcinoma, renal cell carcinoma (RCC) (e.g., renal clear cell carcinoma or renal papillary cell carcinoma), mesothelioma, nasopharyngeal carcinoma (NPC), cancer of the esophagus or gastrointestinal tract, or metastatic lesions of any of these.

[0385] In one embodiment, the solid tumor is a melanoma.

[0386] In one embodiment, the solid tumor is lung cancer.

[0387] In one embodiment, the solid tumor is squamous non-small cell lung cancer (NSCLC).

[0388] In one embodiment, the solid tumor is non-squamous NSCLC.

[0389] In one embodiment, the solid tumor is colorectal cancer.

[0390] In one embodiment, the solid tumor is prostate cancer.

[0391] In one embodiment, the solid tumor is castration-resistant prostate cancer.

[0392] In one embodiment, the solid tumor is stomach cancer.

[0393] In one embodiment, the solid tumor is ovarian cancer.

[0394] In one embodiment, the solid tumor is gastric cancer.

[0395] In one embodiment, the solid tumor is liver cancer.

[0396] In one embodiment, the solid tumor is pancreatic cancer.

[0397] In one embodiment, the solid tumor is thyroid cancer.

[0398] In one embodiment, the solid tumor is squamous cell carcinoma of the head and neck.

[0399] In some embodiments, the solid tumor is a cancer of the esophagus or gastrointestinal tract.

[0400] In one embodiment, the solid tumor is breast cancer.

[0401] In one embodiment, the solid tumor is fallopian tube cancer.

[0402] In one embodiment, the solid tumor is a brain tumor.

[0403] In one embodiment, the solid tumor is a urethral cancer.

[0404] In some embodiments, the solid tumor is a genitourinary cancer.

[0405] In one embodiment, the solid tumor is endometrial cancer.

[0406] In one embodiment, the solid tumor is cervical cancer.

[0407] Metabolic disorders: In one aspect, the disease or disorder involving cells expressing CD38 is a metabolic disorder, eg, a disorder characterized by the presence of immune cells expressing CD38.

[0408] Thus, in one aspect, the invention provides an antibody variant for use in treating a metabolic disease in a subject, the antibody variant comprising: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells.

[0409] In one aspect, the invention provides a method of treating a metabolic disease in a subject comprising administering to the subject an antibody variant comprising: an antigen-binding region that binds to CD38 and a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein said amino acid residues are numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells.

[0410] In some embodiments, the metabolic disorder is amyloidosis. Amyloidosis is a vast group of diseases defined by the presence of insoluble protein deposits in tissues. Its diagnosis is based on histological findings. In further embodiments, the amyloidosis can be AL amyloidosis.

[0411] In some embodiments, the CD38-expressing immune cells are CD38-expressing immunosuppressive cells.

[0412] In some embodiments, the use further comprises determining the presence of CD38-expressing immunosuppressive cells in a biological sample taken from the subject prior to use.

[0413] In some embodiments, the use further comprises determining the presence of CD38-expressing Tregs in a biological sample taken from the subject prior to use.

[0414] Non-limiting examples of biological samples include blood samples, bone marrow samples, and tumor biopsies.

[0415] As used herein, immune cells, such as immunosuppressive cells, express CD38 if the expression of CD38 in the tested immune cell population is statistically significant compared to a control, for example, expression detected with an anti-CD38 antibody and expression detected with an isotype control antibody using well-known methods. This can be tested, for example, by taking a biological sample containing immune cells, for example, a blood sample, a bone marrow sample, or a tumor biopsy. Methods for identifying a specific type of immune suppressive cell or other immune cell as disclosed herein are well known in the art and include testing the expression of an antigen specific to the type of immune cell in question. Examples of VH and VL sequences of anti-CD38 antibodies suitable for testing CD38 expression are shown in Table 1.

[0416] patient: The antibody variants of the invention may be for the treatment or prevention of a disease or disorder in a subject who has previously received at least one treatment for the same disease or disorder with one or more compounds; wherein the one or more compounds are different from the antibody variants of the invention. In one embodiment, the disease or disorder may be any disease or disorder described herein, for example, a cancer, an inflammatory and / or autoimmune disease or disorder involving cells expressing CD38, or a metabolic disorder involving cells expressing CD38.

[0417] For example, in some embodiments, the antibody variant of the present invention can be for treating or preventing disease or disorder in a subject who has previously been treated with a proteasome inhibitor (PI) and / or an immunomodulatory drug (IMiD). Examples of proteasome inhibitors include, but are not limited to, bortezomib, carfilzomib and ixazomib. Examples of IMiDs include, but are not limited to, thalidomide, lenalidomide and pomalidomide. In further embodiments, the disease or disorder can be cancer or tumor, such as multiple myeloma, mantle cell lymphoma or myelodysplastic syndrome (MDS). Thus, the subject can be a cancer patient, such as a patient with multiple myeloma, mantle cell lymphoma or myelodysplastic syndrome (MDS).

[0418] The antibody variant of the present invention can be for treating or preventing disease or disorder in a subject who has not been previously treated with anti-CD38 antibody. Usually, such a subject or patient is called anti-CD38 antibody naive patient. In one embodiment, the anti-CD38 antibody is daratumumab; that is, the subject or patient has not been previously treated with daratumumab. Therefore, in one embodiment, the subject or patient is a daratumumab naive subject / patient. The disease or disorder can be a cancer or tumor according to any aspect or embodiment disclosed herein, or a metabolic disease such as amyloidosis.

[0419] The present invention also provides the antibody variants for use in the treatment or prevention of a disease or disorder in a subject who has previously received at least one treatment involving a CD38 antibody.

[0420] The present invention also provides antibody variants for use in treating cancer patients who have previously received at least one treatment comprising a CD38 antibody. The present invention also provides antibody variants for use in treating patients with metabolic diseases, such as amyloidosis, who have previously received at least one treatment comprising a CD38 antibody. Such previous treatments may have been one or more cycles of a planned treatment program comprising a CD38 antibody, such as one or more planned cycles of a CD38 antibody in monotherapy or combination therapy, as well as a planned course of treatment. In one embodiment, the previous treatment was a CD38 antibody monotherapy. In one embodiment, the previous treatment was a combination therapy comprising a CD38 antibody. For example, the previous treatment may have been a CD38 antibody in combination with a proteasome inhibitor (PI) and an immunomodulatory agent. In one embodiment, the CD38 antibody is daratumumab.

[0421] In some aspects, the cancer patient may also be a patient in whom administration of daratumumab as a monotherapy has limited efficacy.

[0422] In some aspects, the cancer can be characterized as a cancer that is "refractory" or "relapsed" to previous treatment. In further embodiments, the previous treatment can include one or more of a PI, an IMiD, and a CD38 antibody, for example, the CD38 antibody is daratumumab. Typically, this indicates that the previous treatment did not achieve a complete response (CR), for example, the cancer was unresponsive to CD38 antibody monotherapy or combination therapy, or the cancer progressed within a predetermined period after the end of CD38 antibody therapy. Examples of such combination therapy include, but are not limited to, a combination of a CD38 antibody and a PI or an IMiD, or a combination of a PI and an IMiD. Similarly, it may indicate that the previous treatment did not achieve a complete response (CR), for example, the cancer was unresponsive to a PI, an IMiD, or combination therapy thereof, or the cancer progressed within a predetermined period after the end of said treatment. One of skill in the art can determine whether a cancer is refractory to previous treatments based on what is known in the art, including available guidelines for each cancer.

[0423] For example, in multiple myeloma, refractory and relapsed disease can be identified according to the guidelines published by Rajkumar, Harousseau et al. on behalf of the International Myeloma Workshop Consensus Panel, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel, Blood 2011;117:4691-4695:

[0424] Refractory myeloma can be defined as disease that is non-responsive during first-line or salvage therapy or that progresses within 60 days of the last treatment. Non-responsive disease is defined as achieving only a minimal response during treatment or developing progressive disease (PD). There can be two categories of refractory myeloma: "relapsed-refractory myeloma" and "primary refractory myeloma."

[0425] Relapsed / refractory myeloma can be defined as disease that is non-responsive during salvage therapy or that progresses within 60 days of last treatment in patients who previously achieved at least a minimal response (MR) at some point but then progressed during their disease course.

[0426] Primary refractory myeloma can be defined as non-responsive disease in patients who have never achieved more than a minimal response to any therapy. It includes patients who never achieve more than MR, who have no significant changes in M ​​protein and no evidence of clinical progression, and primary refractory PD in which patients meet the criteria for true PD. When reporting efficacy in primary refractory patients, efficacy in these two subgroups (non-responding / non-progressing and progressive) should be described separately.

[0427] Relapsed myeloma can be defined as previously treated myeloma that has progressed and requires the initiation of salvage therapy, but does not meet the criteria for either the "primary refractory myeloma" or "relapsed / refractory myeloma" categories.

[0428] For details on specific responses (CR, PR, etc.) in multiple myeloma and how to test for them, see Rajkumar, Harousseau et al., 2011 (supra).

[0429] Thus, in some embodiments, the antibody variant according to any aspect or embodiment herein, or the pharmaceutical composition comprising said antibody variant, is for use in treating a cancer that is refractory to a previous treatment comprising one or more of a PI, an IMiD, and a CD38 antibody. In one embodiment, the previous treatment comprises a CD38 antibody. In certain embodiments, the cancer is identified as a refractory cancer prior to use.

[0430] In another aspect, a method for treating cancer in a subject is provided, the method comprising the steps of: (i) identifying the subject as refractory to a prior therapy comprising one or more of a PI, an IMiD, and a CD38 antibody; and (ii) administering to the subject a therapeutically effective amount of an antibody variant according to any aspect or embodiment herein, or a pharmaceutical composition comprising said antibody variant. Includes.

[0431] In one embodiment, the previous treatment comprises a CD38 antibody.

[0432] In another aspect, there is provided a method for treating cancer refractory to a previous treatment comprising one or more of a PI, an IMiD and a CD38 antibody in a subject, comprising administering to the subject a therapeutically effective amount of an antibody variant according to any aspect or embodiment herein, or a pharmaceutical composition comprising said antibody variant. In one aspect, the previous treatment comprises a CD38 antibody.

[0433] In some embodiments, the PI is selected from the group consisting of bortezomib, carfilzomib, and ixazomib.

[0434] In some embodiments, the IMiD is selected from the group consisting of thalidomide, lenalidomide, and pomalidomide.

[0435] In some embodiments, the CD38 antibody is daratumumab.

[0436] In some embodiments, the antibody variant according to any aspect or embodiment herein, or the pharmaceutical composition comprising said antibody variant, is for use in treating cancer that has relapsed after a previous treatment comprising one or more of a PI, an IMiD, and a CD38 antibody. In one embodiment, the previous treatment comprises a CD38 antibody. In certain embodiments, the cancer is identified as a relapsed cancer prior to use.

[0437] In another aspect, a method for treating cancer in a subject is provided, the method comprising the steps of: (i) identifying the subject as having relapsed after a prior therapy comprising one or more of a PI, an IMiD, and a CD38 antibody; and (ii) administering to the subject a therapeutically effective amount of an antibody variant according to any aspect or embodiment herein, or a pharmaceutical composition comprising said antibody variant. Includes.

[0438] In one embodiment, the previous treatment comprises a CD38 antibody.

[0439] In another embodiment, there is provided a method for treating cancer that has relapsed after a previous treatment comprising one or more of a PI, an IMiD and a CD38 antibody in a subject, comprising administering to the subject a therapeutically effective amount of an antibody variant according to any aspect or embodiment herein, or a pharmaceutical composition comprising said antibody variant. In one embodiment, the previous treatment comprises a CD38 antibody.

[0440] In some embodiments, the PI is selected from the group consisting of bortezomib, carfilzomib, and ixazomib.

[0441] In some embodiments, the IMiD is selected from the group consisting of thalidomide, lenalidomide, and pomalidomide.

[0442] In some embodiments, the CD38 antibody is daratumumab.

[0443] In a particular embodiment, the antibody variant according to the invention is administered in a therapeutically effective amount and / or for a period of time sufficient to treat the refractory or relapsed cancer.

[0444] In some embodiments, the refractory or recurrent cancer is a hematological cancer.

[0445] In some embodiments, the refractory or recurrent cancer is selected from the group consisting of multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (adult) (AML), mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

[0446] In some embodiments, the refractory or recurrent cancer is selected from the group consisting of multiple myeloma (MM), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL).

[0447] In some embodiments, the refractory or recurrent cancer is multiple myeloma (MM).

[0448] In some embodiments, the refractory or recurrent cancer is chronic lymphocytic leukemia (CLL).

[0449] In some embodiments, the refractory or recurrent cancer is mantle cell lymphoma (MCL).

[0450] In some embodiments, the refractory or recurrent cancer is diffuse large B-cell lymphoma (DLBCL).

[0451] In some embodiments, the refractory or recurrent cancer is follicular lymphoma (FL).

[0452] In some embodiments, the refractory or recurrent cancer is a solid tumor. In some embodiments, the refractory or recurrent cancer is selected from the group consisting of melanoma, lung cancer, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, colorectal cancer, prostate cancer, castration-resistant prostate cancer, stomach cancer, ovarian cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, squamous cell carcinoma of the head and neck, esophageal or gastrointestinal cancer, breast cancer, fallopian tube cancer, brain tumor, urethral cancer, genitourinary cancer, endometrial cancer, and cervical cancer.

[0453] In some embodiments, the refractory or recurrent cancer is melanoma.

[0454] In some embodiments, the refractory or recurrent cancer is lung cancer.

[0455] In some embodiments, the refractory or recurrent cancer is squamous non-small cell lung cancer (NSCLC).

[0456] In some embodiments, the refractory or recurrent cancer is non-squamous NSCLC.

[0457] In some embodiments, the refractory or recurrent cancer is colorectal cancer.

[0458] In some embodiments, the refractory or recurrent cancer is prostate cancer.

[0459] In some embodiments, the refractory or recurrent cancer is castration-resistant prostate cancer.

[0460] In some embodiments, the refractory or recurrent cancer is stomach cancer.

[0461] In some embodiments, the refractory or recurrent cancer is ovarian cancer.

[0462] In some embodiments, the refractory or recurrent cancer is gastric cancer.

[0463] In some embodiments, the refractory or recurrent cancer is liver cancer.

[0464] In some embodiments, the refractory or recurrent cancer is pancreatic cancer.

[0465] In some embodiments, the refractory or recurrent cancer is thyroid cancer.

[0466] In some embodiments, the refractory or recurrent cancer is squamous cell carcinoma of the head and neck.

[0467] In some embodiments, the refractory or recurrent cancer is a cancer of the esophagus or gastrointestinal tract.

[0468] In some embodiments, the refractory or recurrent cancer is breast cancer.

[0469] In some embodiments, the refractory or recurrent cancer is fallopian tube cancer.

[0470] In some embodiments, the refractory or recurrent cancer is a brain tumor.

[0471] In some embodiments, the refractory or recurrent cancer is urethral cancer.

[0472] In some embodiments, the refractory or recurrent cancer is a genitourinary cancer.

[0473] In some embodiments, the refractory or recurrent cancer is endometrial cancer.

[0474] In some embodiments, the refractory or recurrent cancer is cervical cancer.

[0475] Dosage regimens and combinations The dosage regimen in the above-mentioned method of treatment and method of use is adjusted to obtain the optimum desired response (e.g., therapeutic response).For example, a single bolus can be administered, or several divided doses can be administered over time, or the dose can be proportionally reduced or increased according to the needs of the therapeutic situation.The parenteral composition can be formulated into a unit dosage form for ease of administration and uniformity of dosage.

[0476] The effective dosage and administration regimen of the antibody variants will vary depending on the disease or condition being treated and can be determined by one of skill in the art. An exemplary, non-limiting range of therapeutically effective amounts of the antibody variants of the present invention is about 0.001 to 30 mg / kg.

[0477] The antibody variants may also be administered prophylactically to reduce the risk of developing cancer, delay the onset of events in cancer progression, and / or reduce the risk of recurrence if the cancer is in remission.

[0478] The antibody variants may also be administered in combination therapy, ie, in combination with other therapeutic agents or treatments relevant to the disease or condition being treated.

[0479] Thus, in one embodiment, the antibody variant is for combination with one or more additional therapeutic agents, such as chemotherapeutic agents, anti-inflammatory agents, or immunosuppressants and / or immunomodulators, such as another therapeutic antibody.Such combination administration can be simultaneous, separate, or sequential.When administered simultaneously, the agents can be administered as one composition or as separate compositions, as required.

[0480] The antibody variants may also be used in combination with radiation therapy and / or surgery and / or autologous or allogeneic peripheral stem cell or bone marrow transplantation.

[0481] (Table 1) Amino acid sequence TIFF2024160275000001.tif246162TIFF2024160275000002.tif238162TIFF2024160275000003.tif231162 TIFF2024160275000004.tif242162TIFF2024160275000005.tif231162TIFF2024160275000006.tif170162 EXAMPLES

[0482] Example 1 This invention is further illustrated by the following examples, which should not be construed as limiting.

[0483] Example 1: Antibodies and cell lines Antibody expression constructs For expression of the human and humanized antibodies used herein, variable heavy (VH) and variable light (VL) chain sequences were prepared by gene synthesis (GeneArt Gene Synthesis; ThermoFisher Scientific) and cloned into the pcDNA3.3 expression vector (ThermoFisher Scientific) containing the constant region of the human IgG heavy chain (HC) (constant region human IgG1m(f) HC: SEQ ID NO:65) and / or the constant region of the human kappa light chain (LC): SEQ ID NO:82. The desired mutations were introduced by gene synthesis. The CD38 antibody variants of the present application have VH and VL sequences derived from previously described CD38 antibodies IgG1-A (WO 2006 / 099875 A1, WO 2008 / 037257 A2, WO 2011 / 154453 A1; VH:SEQ ID NO:1; VL:SEQ ID NO:5), IgG1-B (WO 2006 / 099875 A1, WO 2008 / 037257 A2, WO 2011 / 154453 A1; VH:SEQ ID NO:8; VL:SEQ ID NO:12), and IgG1-C (WO 2011 / 154453 A1; VH:SEQ ID NO:36; VL:SEQ ID NO:40). In some experiments, the human IgG1 antibody b12, an HIV gp120-specific antibody, was used as a negative control (Barbas et al., J Mol Biol. 1993 Apr 5;230(3):812-23; VH:SEQ ID NO:57; VL:SEQ ID NO:61).

[0484] Transiently expressed antibody constructs Plasmid DNA mixtures encoding both the heavy and light antibody chains were transiently transfected into Expi293F cells (Gibco, Cat. No. A14635) using 293fectin (Life Technologies) essentially as described by Vink et al. (Vink et al., 2014 Methods 65(1):5-10). Antibody concentrations in the supernatants were measured by absorbance at 280 nm. Antibody-containing supernatants were either used directly in in vitro assays or antibodies were purified as described below.

[0485] Antibody purification and quality assessment Antibodies were purified by protein A affinity chromatography. Culture supernatants were filtered through a 0.20 μM dead-end filter, loaded onto a 5 mL MabSelect SuRe column (GE Healthcare), washed, and eluted with 0.02 M sodium citrate-NaOH, pH 3. The eluate was loaded onto a HiPrep Desalting column (GE Healthcare) immediately after purification, and the antibodies were buffer exchanged into 12.6 mM NaH2PO4, 140 mM NaCl, pH 7.4 buffer (B. Braun or Thermo Fisher). After buffer exchange, samples were sterile filtered through a 0.2 μm dead-end filter. Purified proteins were analyzed by several biological assays, including capillary electrophoresis on sodium dodecyl sulfate-polyacrylamide gels (CE-SDS), high performance size exclusion chromatography (HP-SEC), and concentration was measured by absorbance at 280 nm. Purified antibodies were stored at 2–8 °C.

[0486] The cell lines used in the examples are listed below in Table 2. The average number of CD38 and CD59 molecules per cell was measured by quantitative flow cytometry (Qifi, DAKO).

[0487] Table 2. Overview of cell lines and expression of CD38 and CD59 TIFF2024160275000007.tif207149ABC=Antibodies Bound per Cell

[0488] The origin / source of the cell lines is as follows: TIFF2024160275000008.tif39128

[0489] Example 2: Binding of CD38 antibodies and their variants to cell surface expressed human and cynomolgus CD38 Binding to cell surface expressed CD38 on Daudi and NALM16 cells and on PBMCs from cynomolgus monkeys was measured by flow cytometry. Cells resuspended in RPMI containing 0.2% BSA were seeded at 100,000 cells / well in polystyrene 96-well round-bottom plates (Greiner bio-one) and centrifuged at 300 × g for 3 min at 4 °C. Serial dilutions of CD38 or control antibodies (final antibody concentrations of 0.005–10 μg / mL in 3-fold serial dilutions) were added and cells were incubated for 30 min at 4 °C. Plates were washed and centrifuged twice with FACS buffer (PBS / 0.1% BSA / 0.01% Na azide). Next, for analysis of cynomolgus monkey PBMCs, R-phycoerythrin (PE)-conjugated goat anti-human IgG F(ab') diluted 1 / 100 in PBS / 0.1% BSA / 0.01% Na azide was added. 2 (Jackson) or FITC-conjugated goat anti-human IgG (Southern Biotech) for 30 min at 4°C. Cells were washed / centrifuged twice with FACS buffer, resuspended in FACS buffer, and analyzed by measuring mean fluorescence intensity using a FACS_Fortessa (BD). Binding curves were generated using nonlinear regression (sigmoidal dose-response with variable slope) analysis within GraphPad Prism V6.04 software (GraphPad Software).

[0490] Figure 2 shows that the CD38 antibodies IgG1-B, IgG1-C, and IgG1-A bind to CD38-expressing NALM16 cells in a dose-dependent manner, and introduction of the hexamerization-promoting E430G mutation into these antibodies did not affect binding.

[0491] Figure 3 shows that CD38 antibody IgG1-A-E430G, but not IgG1-B-E430G and IgG1-C-E430G, binds to CD38 expressed on cynomolgus monkey PBMCs in a dose-dependent manner (A). Average binding to CD38 expressed on cynomolgus monkey B, T and NK cells is shown and gated based on FSC and SSC. As a positive control, binding to Daudi cells expressing high copy numbers of human CD38 is also shown (B).

[0492] Example 3: Complement-dependent cytotoxicity (CDC) by E430G mutant CD38 antibody CDC for tumor cell lines Daudi cells, Wien133 cells, Ramos cells, NALM16 cells, U266 cells, and RC-K8 cells were resuspended in RPMI containing 0.2% BSA and plated in a 96-well polystyrene round-bottom plate (Greiner bio-one) at 1 × 10 5 Cells were plated at a density of 100 cells / well (40 μL / well). CD38 antibodies, their variants, and isotype control antibodies were serially diluted (final antibody concentrations of 0.0002–10 μg / mL in 3-fold serial dilutions) and 40 μL of diluted antibodies were added per well. After preincubation of cells and antibodies for 20 min at room temperature, 20 μL of pooled normal human serum (Sanquin) was added to each well and incubated for an additional 45 min at 37°C. The plates were then centrifuged (3 min, 1200 rpm) and the supernatant was discarded. Cell pellets were resuspended in FACS buffer supplemented with 0.25 μM topro-3 iodide (Life Technologies) and lysis was detected by measuring the percentage of topro-3 iodine positive cells on a FACS_Fortessa (BD). CDC was depicted as percent lysis. Data shown are N = 3 (Daudi and NALM16), N = 2 (Wien133 and U266 cells), or N = 1 (RC-K8 and Ramos). Isotype control antibodies were included only in Daudi and Wien133 cells.

[0493] Figure 4 demonstrates that CD38 antibodies B, C, and A without the E430G mutation induced approximately 85%, approximately 50%, and 0% lysis of Ramos and Daudi cells. No significant lysis by these CD38 antibodies was observed in any of the other cell lines tested. Introducing the E430G mutation into these CD38 antibodies resulted in higher CDC activity at significantly lower antibody concentrations. All three antibodies with the E430G mutation induced up to 100% lysis of Ramos and Daudi cells. Furthermore, in cell lines with lower CD38 expression, the E430G mutant CD38 antibodies were able to induce maximal (Wien133) or partial (NALM16 and U266) CDC, whereas the CD38 antibodies without the E430G mutation did not induce CDC. These results indicate that CD38 antibodies carrying the E430G mutation induce stronger CDC and require less CD38 expression than CD38 antibodies without the E430G mutation. In tumor cells with low levels of CD38 expression (NALM-16, RS4;11, and REH), IgG1-C-E430G showed lower EC50 values ​​than IgG1-B-E430G.

[0494] Table 3: EC50 values ​​for lysis Some cell lines were tested only once (Ramos, RS4;11, REH). TIFF2024160275000009.tif61153

[0495] The above CDC assay was repeated with several additional tumor cell lines derived from B-cell tumors, e.g., DLBCL, Burkitt's lymphoma, FL, MCL, B-ALL, CLL, or MM, and with antibodies IgG1-B, IgG1-B-E430G, IgG1-C-E430G, IgG1-A-E430G, and isotype control antibodies. Percent lysis was plotted against antibody concentration, and maximum percent lysis and EC50 values ​​were calculated using Graphpad Prism (GraphPad Software Inc.; version 8.1.0) software and shown in Table 4. These results are also shown in Figure 15.

[0496] Figure 15 shows that wild-type CD38 mAb IgG1-B induced lysis of high CD38 expressing cell lines: SU-DHL-8, Oci-LY-7, Oci-LY-19, Ramos, Daudi, Oci-LY-18 and Raji, but not other cell lines expressing less CD38 molecules on the membrane. Introduction of the E430G mutation into IgG1-B resulted in high CDC activity at significantly lower Ab concentrations in cell lines that were already sensitive to wild-type IgG1-B, and also in lysis of additional cell lines with lower CD38 copy numbers that were insensitive to IgG1-B-induced CDC (e.g. DOHH2, SU-DHL-4, WSU-DLCL2, Z-138, JVM-13, REH, Jeko-1, Wien-133, 697, RS4;11, NALM-16 and JVM-3). Cell lines with very low CD38 expression (RC-K8 and Pfeiffer) or very high CD59 expression (DB and Granta-519) did not show lysis upon exposure to IgG1-B and IgG1-B-E430G. In almost all cell lines tested, IgG1-C-E430G induced cell lysis at lower antibody concentrations compared to IgG1-B-E430G, whereas IgG1-A-E430G induced lysis at much higher Ab concentrations. This is also reflected in the higher EC50 value of IgG1-A-E430G in Table 4. This indicates that the E430G mutant CD38 mAb induces stronger CDC compared to the wild-type CD38 antibody and induces CDC on tumor cells with low CD38 expression levels where the wild-type CD38 antibody does not induce CDC. Furthermore, the potency of E430G mutant CD38 antibodies to induce CDC may differ among different CD38-targeting antibody clones.

[0497] Figure 16 shows an overview of some of the EC50 values ​​shown in Table 4. The EC50 values ​​of CDC induced by antibodies IgG1-B, IgG1-B-E430G and IgG1-C-E430G in 20 different B cell tumor cell lines are shown. Each square, triangle or circle represents a different B cell tumor cell line. IgG1-B-E430G was not tested in AML cell lines, therefore the EC50 values ​​obtained in AML cell lines were not included.

[0498] CDC by IgG1-C-E430G was also evaluated in various acute myeloid leukemia (AML) cell lines (Figure 17). It was performed as described above for B cell tumor cell lines, the only difference being the tumor cell line.

[0499] Figure 17 shows that CDC was induced by IgG1-C-E430G in all CD38-expressing AML cell lines, whereas no CDC was observed in CD38-negative AML cell lines. CDC by IgG1-C-E430G occurred at a much lower EC50 value compared to IgG1-B, but maximum cell lysis was higher for IgG1-C-E430G compared to IgG1-B (Table 4).

[0500] Table 4: Maximum lysis and EC50 values ​​for lysis TIFF2024160275000010.tif201170

[0501] Furthermore, the induction of CDC by wild-type and E430G mutant CD38 antibodies using T regulatory cells was investigated. T regulatory cells were generated as described in Example 8 (Trogocytosis of CD38 from T regulatory cells) and tested in the CDC assay as described above for tumor cell lines. The percentage of lysis is shown in Figure 18 together with the EC50 value.

[0502] FIG. 18 shows that IgG1-B did not substantially induce lysis of T regulatory cells; whereas IgG1-B-E430G and IgG1-C-E430G induced lysis of T regulatory cells, with IgG1-C-E430G showing a lower EC50 value compared to IgG1-B-E430G.

[0503] CDC in whole blood Whole blood from healthy donors was collected in hirudin tubes to prevent coagulation without interfering with physiological calcium levels (necessary for CDC). 50 μL / well were plated in 96-well flat-bottom tissue culture plates (Greiner bio-one). CD38 antibodies, their variants and control antibodies were serially diluted in RPMI containing 0.2% BSA (final antibody concentrations 0.016–10 μg / mL in 5-fold serial dilutions) and 50 μL of diluted antibody was added per well and incubated overnight at 37°C. As a positive control for CDC on B cells, CD20 Ab IgG1-7D8 was tested in the presence and absence of 60 μg / mL eculizumab to block CDC. Cells were transferred to polystyrene 96-well round-bottom plates (Greiner bio-one, centrifuge type), centrifuged (3 min, 1200 rpm) and washed once with 150 μL PBS (B.Braun) per well. The cell pellet was resuspended in 80 μL of PBS containing 1:1000 diluted amine-reactive viability dye (BD) and incubated for 30 min at 4° C. The cells were then washed with 150 μL of PBS and incubated with 80 μL of PBS containing a cocktail of lymphocyte phenotyping antibodies (1:200 mouse anti-human CD3-EF450 [OKT3, ebioscience], 1:50 mouse anti-human CD19-BV711 [HIB19, Biolegend], and 1:100 mouse anti-human CD56-PE / CF594 [NCAM16.2, BD]) for 30 min at 4° C. Cells were washed with 150 μL of PBS and incubated with 150 μL of red blood cell lysis solution (10 mM KHCO3 [Sigma], 0.01 mM EDTA [Fluka], 155 mM NH4Cl [Sigma] in 1 L of H2O [B. Braun], adjusted to pH 7.2) for 10 min at 4 °C. Cells were washed with 150 μL of FACS buffer, resuspended in 100 μL of FACS buffer, and analyzed on a FACS_Fortessa (BD). Viable NK cells (CD56 pos , CD3 neg , Amine-reactive viability dyes neg ), T cells (CD3 pos , Amine-reactive viability dyes neg), and B cells (CD19 pos , Amine-reactive viability dyes neg ) are shown in Figure 5. Data are shown from one representative donor out of five tested.

[0504] Figure 5 shows that CD38 antibodies containing the E430G mutation induce minimal CDC of healthy blood lymphocytes. The positive control CD20 Ab IgG1-7D8 demonstrated specific CDC of CD20-positive B cells, which was completely blocked by the CDC inhibitor eculizumab. Wild-type IgG1 CD38 antibodies did not induce CDC of B cells, T cells and NK cells. Some CDC (approximately 40% NK cell lysis at the highest concentration of IgG1-B-E430G) was observed in NK cells after incubation with clones B and C containing the E430G mutation, but not in B and T cells.

[0505] Overall, these results indicate that E430G mutant CD38 antibodies have broad CDC activity against a panel of tumor cell lines with variable CD38 expression. CD38 antibodies containing the E430G mutation were also tested against lymphocytes obtained from healthy donors, but were shown to only induce lysis of up to 40% of NK cells. NK cells express an average of 15,000 CD38 / cell, which is similar to the MM cell line U266. Both cell types were equally susceptible to CDC by E430G mutant CD38 antibodies, indicating that CDC by E430G mutant CD38 antibodies correlates with CD38 expression. Without being limited by theory, based on these data, the threshold for CDC by E430G mutant CD38 antibodies appears to be approximately 15,000 CD38 molecules / cell. Most B cell tumor cell lines express high levels of CD38, ranging from 15,000 to 400,000 CD38 molecules / cell, whereas healthy lymphocytes express only 2,000 to 15,000 CD38 molecules / cell, making these cells less vulnerable to CDC by E430G mutant CD38 antibodies.

[0506] Example 4: Antibody-dependent cellular cytotoxicity (ADCC) by E430G mutant CD38 antibody The ability of the E430G mutant CD38 antibody to induce antibody-dependent cellular cytotoxicity (ADCC) was examined by chromium release assay. Daudi cells were harvested (5 × 10 6 cells / mL) plus 100 μCi 51 Cr (chromium-51; PerkinElmer) was added. The cells were incubated for 1 h with shaking in a 37°C water bath. After washing the cells (2 times in PBS at 1500 rpm for 5 min), the cells were resuspended in culture medium and counted by trypan blue exclusion. The cells were diluted to 1 × 10 5 The cells were diluted to a density of 1000 cells / mL, pipetted into a 96-well round-bottom microtiter plate (Greiner Bio-One), and 50 μL of a concentration series (final concentrations of 0.005–10 μg / mL in 3-fold dilutions) of CD38 or isotype control antibodies diluted in culture medium was added. Cells were preincubated with Abs for 15 min at room temperature (RT).

[0507] Meanwhile, peripheral blood mononuclear cells (PBMCs) (Sanquin) from healthy volunteers were isolated from 45 mL of freshly drawn heparinized blood (buffy coat) using lymphocyte separation medium (BioWhittaker) according to the manufacturer's instructions. After resuspending the cells in culture medium, the cells were counted by trypan blue exclusion and a total of 1 × 10 7 The cells were diluted to a density of 1000 cells / mL.

[0508] After preincubation of target cells with Ab, 50 μL of effector cells were added to give an effector to target cell ratio of 100:1. Cells were incubated at 37° C., 5% CO 2 To measure maximum lysis, 50 μL of 51 Cr-labeled Daudi cells (5,000 cells) were incubated with 100 μL of 5% Triton-X100; to measure spontaneous lysis (background lysis), 5,000 cells were 51Cr-labeled Daudi cells were incubated in 150 μL of medium without antibody or effector cells. The level of antibody-independent cytolysis was measured by incubating 5,000 Daudi cells with 500,000 PBMCs without antibody. The plate was centrifuged (1200 rpm, 10 min) and 75 μL of the supernatant was transferred to a micronic tube, after which the released 51 Cr was counted using a gamma counter. The percentage of antibody-mediated lysis was calculated as follows: % specific lysis = (cpm sample - cpm spontaneous lysis) / (cpm maximum lysis - cpm spontaneous lysis) where cpm is counts per minute.

[0509] Figure 6 shows that all CD38 antibodies were able to induce lysis of Daudi cells, as shown by the increased lysis seen with the CD38 antibody compared to the isotype control (IgG1-b12-E430G). Cell lysis was observed already at the lowest antibody concentration, suggesting that further dilution of the antibody was required to observe a dose-dependent effect. CD38 antibodies containing the E430G mutation showed lower maximum lysis compared to the wild-type antibody.

[0510] The above chromium release assay was repeated using peripheral blood mononuclear cells (effector cells) from various healthy volunteers, the following target cells: Daudi, Wien-133, Granta 519 and MEC-2, and the antibodies IgG1-B-E430G, IgG1-B, IgG1-C-E430G, IgG1-C and IgG1-b12-E430G. The results are shown in FIG.

[0511] Figure 19 shows that all CD38 antibodies were able to induce lysis of Daudi, Wien-133, Granta 519 and MEC-2 cells, as shown by the increased lysis seen with CD38 antibodies compared to the isotype control (IgG1-b12-E430G). In most cases, dose-dependent lysis of target cells was seen, although some variability was observed between different PBMC donors.

[0512] The ability of CD38 antibodies to induce ADCC was further evaluated using a luminescent ADCC reporter bioassay (Promega, Cat. No. G7018) that detects FcγRIIIa (CD16) crosslinking as a surrogate for ADCC. As effector cells, the kit provides Jurkat human T cells engineered to stably express high affinity FcγRIIIa (V158) and the nuclear factor of activated T cells (NFAT) response element driving the expression of firefly luciferase. Briefly, Daudi cells or T regulatory cells (5,000 cells / well) were plated in 384-well white Optiplates (Perkin Elmer) in ADCC assay buffer [RPMI-1640 medium supplemented with 3.5% low IgG serum (Lonza, catalog no. BE12-115F)] and incubated in a total volume of 30 μL containing a concentration series of antibodies (final concentrations 0.5–250 ng / mL in 3.5-fold dilutions) and thawed ADCC bioassay effector cells at 37°C / 5% CO. 2 Plates were incubated at RT for 6 h. After adjusting the plates to room temperature (RT) for 15 min, 30 μL of Bio Glo Assay Luciferase Reagent was added and the plates were incubated at RT for 5 min. Luciferase production was quantified by luminescence reading on an EnVision multilabel reader (Perkin Elmer). Background levels were measured from wells where only target cells and antibody were added (no effector cells). Wells containing only target and effector cells (no antibody) were used as negative controls.

[0513] Figure 7 shows the results obtained in Daudi cells, which show that CD38 antibodies are highly effective in inducing dose-dependent FcγRIIIa cross-linking as measured by reporter assay. CD38 antibodies containing the E430G mutation showed lower maximal cross-linking compared to the respective wild-type antibodies, which was consistent with the results obtained in the chromium release assay.

[0514] Figure 20 shows the results obtained with T regulatory cells, which show that CD38 antibodies are highly effective in inducing dose-dependent FcγRIIIa cross-linking as measured by reporter assay. CD38 antibodies containing the E430G mutation showed lower maximal cross-linking compared to the respective wild-type antibodies.

[0515] Example 5: Antibody-dependent cellular phagocytosis (ADCP) by E430G mutant CD38 antibody The ability of E430G mutant CD38 antibodies to induce antibody-dependent cellular phagocytosis was adapted from Overdijk MB et al. mAbs 7:2,311-320. Macrophages were obtained by isolating PBMCs (Sanquin) from healthy volunteers using lymphocyte separation medium (Bio Whittaker) according to the manufacturer's instructions. Monocytes were isolated from PBMCs by negative selection using the Dynabeads Untouched human monocyte isolation kit (Invitrogen). The isolated monocytes were cultured for 3 days in serum-free dendritic cell medium (CellGenix Gmbh) supplemented with 50 ng / mL GM-CSF (Invitrogen) and then for 2 days in serum-free dendritic cell medium supplemented with 100 ng / mL GM-CSF to induce macrophage differentiation. Differentiated macrophages were detached using Versen solution (Life Technologies) and cell scraping and characterized by flow cytometry for staining with CD1a-FITC (BD), CD14-PE / Cy7 (BD), CD40-APC / H7 (BD), CD80-APC (Miltenyi biotec), CD83-PE (BD), and CD86-PerCP-Cy5.5 (Biolegend). Macrophages were seeded at 100,000 cells per well in 96-well flat-bottom culture plates (Greiner bio-one) and allowed to adhere overnight at 37°C in serum-free dendritic cell medium supplemented with 100 ng / mL GM-CSF.

[0516] Target cells (Daudi) were labeled with PKH-26 (Sigma) according to the manufacturer's instructions, opsonized with 10 μg / mL CD38 antibody (30 min at 4 °C), washed three times with FACS buffer, and added to macrophages at an effector:target (E:T) ratio of 5:1. Plates were briefly spun at 300 rpm to bring effector and target cells into close proximity and incubated at 37 °C for 45 min. Macrophages were then harvested using Versen's solution and stained with CD14-BV605 (biolegend) and CD19-BV711 (biolegend). Phagocytosis was measured by flow cytometer (BD) and expressed as the percentage of macrophages that were CD14 positive and also positive for PKH-26, but negative for CD19 (to exclude macrophages that were only attached to Daudi cells).

[0517] FIG. 8 shows the PKH-29 expression seen with CD38 Ab compared to isotype controls (IgG1-b12 and IgG1-b12-E430G). pos , CD14 pos and CD19 neg These results show that all CD38 Abs were able to induce ADCP of Daudi cells, as indicated by an increase in the proportion of macrophages. Depending on the donor used, CD38 antibodies containing the E430G mutation were able to induce ADCP of Daudi cells, as compared to the wild-type antibody, PKH-29. pos , CD14 pos and CD19 neg showed a higher proportion of macrophages, suggesting that CD38-Ab-mediated phagocytosis could be increased by introducing the E430G mutation.

[0518] Example 6: Induction of apoptosis by CD38 antibodies in tumor cell lines Apoptosis induction by CD38 antibodies was examined by overnight incubation of tumor cell lines with CD38 antibodies followed by live / dead cell analysis on a flow cytometer. Cells resuspended in RPMI with 0.2% BSA were seeded at 100,000 cells / well in 96-well flat-bottom tissue culture plates (Greiner bio-one). Serial dilutions of CD38 antibodies or control antibodies (final antibody concentrations of 0.01–10 μg / mL in 4-fold serial dilutions) were added in the absence or presence of 10 μg / mL goat anti-human IgG1 (Jackson) to provide additional Fc cross-linking. Cells were incubated overnight at 37°C, washed / centrifuged twice with FACS buffer (PBS / 0.1% BSA / 0.01% Na azide) and resuspended in FACS buffer supplemented with a 1:4000 dilution of Topro-3 iodine (Life Technologies). The viability of cells was analyzed using FACS_Fortessa (BD) and expressed as the percentage of apoptotic (Topro-3 iodine positive) cells.

[0519] Figure 9 shows that wild-type CD38 antibody and E430G mutant CD38 antibody alone did not induce apoptosis, but the addition of Fc cross-linking antibody induced about 30% apoptosis. No difference was observed between wild-type CD38 antibody and E430G mutant CD38 antibody.

[0520] Example 7: Inhibition of CD38 enzyme activity in the absence of PBMCs Inhibition of CD38 cyclase activity CD38 is an ectoenzyme that converts NAD to cADPR and ADPR. 2 Depends on the presence of O. 2 In the presence of O, NAD is converted to ADPR (glycohydrolase activity) and cADPR is converted to ADPR (hydrolase activity). Approximately 95% of NAD is converted to ADPR via (glyco)hydrolase activity. H 2In the absence of O, CD38 utilizes its cyclase activity to convert NAD to cADPR. To measure inhibition of CD38 enzymatic activity, we used an NAD derivative that becomes fluorescent after processing by CD38.

[0521] FIG. 10 shows the enzyme activity of CD38.

[0522] First, inhibition of CD38 cyclase activity was measured using nicotinamide guanine dinucleotide sodium salt phosphodiesterase (NGD, Sigma) as a substrate for CD38. As a source of CD38, we used recombinant his-tagged CD38 extracellular domain (hisCD38) as well as tumor cell lines with different CD38 expression levels. Tumor cells (Daudi and Wien133) were harvested and washed with 20 mM Tris-HCL. Cells were resuspended in 20 mM Tris-HCL and 200,000 cells / well were plated in 100 μL / well in 96-well white opaque plates (PerkinElmer). hisCD38 was plated at 0.6 μg / mL in 100 μL / well of 20 mM Tris-HCL. CD38 antibody was diluted to 100 μg / mL in 20 mM Tris-HCL and 10 μL was added to the cells and hisCD38 (final concentration 9 μg / mL) and incubated for 20 min at room temperature. Control wells were incubated with b12 antibody instead of CD38 antibody or without any antibody. 10 μL (80 μM) of NGD diluted in 20 mM Tris-HCL was then added to the plate and fluorescence was immediately measured using an Envision multilabel reader (PerkinElmer) with excitation at 340 nm and emission at 430 nm. NGD conversion was followed in real time by measuring fluorescence at the time points indicated in Figure 11 until a plateau was reached. For hisCD38, fluorescence was measured every 3 min for 27 min, for Daudi cells, fluorescence was measured after 5, 15, 30, 60, 120 and 185 min, and for Wien133 cells, fluorescence was measured after 5, 15, 30, 60, 150, 220, 300 and 360 min. Inhibition of CD38 cyclase activity was expressed as percent inhibition compared to control; here, the control was a sample containing hisCD38 and NGD but no Ab. One representative experiment for each condition tested is shown.

[0523] Figure 11A shows that NGD was rapidly converted by hisCD38 cyclase activity. This conversion was complete after about 9 min. In the presence of CD38 Ab B, the maximum percent conversion of NGD was reduced by about 25%, and in the presence of CD38 Ab C, the maximum percent conversion of NGD was reduced by about 50%, while CD38 Ab A did not affect the total turnover of NGD. Inhibition of CD38 cyclase activity was not affected by the presence of the E430G mutation. Similar results were seen in Figures 11B and 11C, where the conversion rate of NGD by CD38 present on Daudi and Wien133 cells was measured. The kinetics of NGD conversion was a little slower in Daudi cells and especially in Wien133 cells, which may correlate with the presence of fewer CD38 molecules. Nevertheless, a 25% inhibition of CD38 cyclase activity was induced by Ab B (approximately 25% inhibition) and a approximate 40% inhibition of CD38 cyclase activity was induced by Ab C, whereas Ab A had no effect. The wild-type and E430G mutant antibodies showed similar results, indicating that the E430G mutation does not affect antibody-mediated inhibition of CD38 cyclase activity.

[0524] Example 8: Antibody-dependent trogocytosis by E430G mutant CD38 antibody Trogocytosis induced by E430G mutant CD38 antibody in Daudi cells: The ability of the E430G mutant CD38 antibody to induce trogocytosis in Daudi cells was evaluated. Macrophages were obtained by isolating PBMCs (Sanquin) from healthy volunteers using lymphocyte separation medium (Bio Whittaker) according to the manufacturer's instructions. Monocytes were isolated from PBMCs by negative selection using the Dynabeads Untouched human monocyte isolation kit (Invitrogen). The isolated monocytes were cultured for 3 days in serum-free dendritic cell medium (CellGenix Gmbh) supplemented with 50 ng / mL GM-CSF (Invitrogen) and then for 2 days in serum-free dendritic cell medium supplemented with 100 ng / mL GM-CSF to induce macrophage differentiation. Differentiated macrophages were detached using Versen solution (Life Technologies) and cell scraping and characterized by flow cytometry for staining with CD1a-FITC (BD), CD14-PE / Cy7 (BD), CD40-APC / H7 (BD), CD80-APC (Miltenyi biotec), CD83-PE (BD), and CD86-PerCP-Cy5.5 (Biolegend). Macrophages were seeded at 100,000 cells per well in 96-well flat-bottom culture plates (Greiner bio-one) and allow...

Claims

1. 1. An antibody variant for use in treating cancer in a subject, comprising: an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells, The antibody variant.

2. The antibody variant for use according to claim 1, wherein reduction of CD38 on said CD38-expressing immune cells via trogocytosis enhances the immune response.

3. 4. The antibody variant for use according to any one of the preceding claims, wherein the CD38-expressing immune cells are CD38-expressing immunosuppressive cells.

4. The antibody variant for use according to claim 3, wherein reduction of CD38 on said CD38-expressing immunosuppressive cells via trogocytosis reduces their immunosuppressive activity.

5. 5. The antibody variant for use according to claim 3 or 4, wherein the CD38-expressing immunosuppressive cells comprise regulatory T cells (Tregs), regulatory B cells (Bregs), myeloid-derived suppressor cells (MDSCs), immunosuppressive NK cells, immunosuppressive NKT cells, immunosuppressive antigen-presenting cells (APCs), immunosuppressive macrophages, or any combination of two or more thereof.

6. The antibody variant for use according to any one of claims 3 to 5, wherein said CD38-expressing immune suppressive cells comprise CD38-expressing Tregs.

7. The antibody variant for use according to any one of the preceding claims, wherein said trogocytosis is caused by effector cells expressing Fc gamma receptors (FcγR).

8. The antibody variant for use according to claim 7, wherein the effector cells expressing the Fcγ receptors comprise macrophages, monocytes, or a combination thereof.

9. 2. The antibody variant for use according to any one of the preceding claims, wherein reduction of CD38 via trogocytosis on said CD38 expressing immune cells promotes an immune response, including an effector T cell (Teff) response.

10. The Teff response is + CD4 + T cells, CD3 + CD8 + 10. The antibody variant for use according to claim 9, mediated by T cells, or both.

11. The antibody variant for use according to any one of the preceding claims, wherein reduction of CD38 via trogocytosis on said CD38-expressing immune cells promotes an immune response against tumor cells in a subject.

12. The antibody variant for use according to any one of the preceding claims, wherein tumour cells of the cancer lack detectable CD38 expression.

13. The antibody variant for use according to any one of claims 1 to 11, wherein tumour cells of said cancer express CD38.

14. 4. The antibody variant for use according to any one of the preceding claims, wherein the subject has a hematological cancer.

15. 14. The antibody variant for use according to claim 13, wherein the hematological cancer is selected from the group consisting of multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (adult) (AML), mantle cell lymphoma, follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

16. The antibody variant for use according to claim 14, wherein the cancer is CLL.

17. The antibody variant for use according to claim 14, wherein the cancer is mantle cell lymphoma.

18. The antibody variant for use according to claim 14, wherein the cancer is DLBCL.

19. The antibody variant for use according to claim 14, wherein the cancer is FL.

20. The antibody variant for use according to claim 14, wherein the cancer is MM.

21. 15. The antibody variant for use according to claim 14, wherein the cancer is acute myeloid leukemia (adult) (AML).

22. The antibody variant for use according to any one of claims 1 to 13, wherein the cancer comprises a solid tumour.

23. 23. The antibody variant for use according to claim 22, wherein the solid tumor is lung cancer, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, melanoma, colorectal cancer, prostate cancer, castration-resistant prostate cancer, stomach cancer, ovarian cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, squamous cell carcinoma of the head and neck, cancer of the esophagus or gastrointestinal tract, breast cancer, fallopian tube cancer, brain tumor, urethral cancer, genitourinary cancer, endometrial cancer, cervical cancer, lung adenocarcinoma, renal cell carcinoma (RCC) (e.g. renal clear cell carcinoma or renal papillary cell carcinoma), mesothelioma, nasopharyngeal carcinoma (NPC), cancer of the esophagus or gastrointestinal tract, or a metastatic lesion of any of them.

24. 24. The antibody variant for use according to any one of claims 1 to 23, wherein the cancer is refractory to a previous treatment comprising a CD38 antibody.

25. The antibody variant for use according to any one of claims 1 to 23, wherein the cancer relapses after a previous treatment comprising a CD38 antibody.

26. 26. The antibody variant for use according to claim 24 or 25, wherein the CD38 antibody is daratumumab.

27. The antibody variant for use according to any one of the preceding claims, further comprising determining the presence of CD38-expressing immune cells in a biological sample taken from the subject prior to use.

28. The antibody variant for use according to any one of the preceding claims, further comprising determining the presence of CD38-expressing Tregs in a biological sample taken from the subject prior to use.

29. 29. The antibody variant for use according to claim 27 or 28, wherein the biological sample is selected from a blood sample, a bone marrow sample and a tumor biopsy.

30. Optionally, the following steps: (a) plating approximately 500,000 freshly isolated PBMCs per well in cell culture medium overnight at 37°C; (b) adding approximately 100,000 CD38 antibody-opsonized Tregs labeled with a common fluorescent intracellular amine dye per well overnight at 37° C.; and (c) measuring CD38 expression on Tregs by flow cytometry, where a decrease in CD38 on CD38 antibody-opsonized Tregs compared to controls indicates trogocytosis. When measured in an assay including 4. An antibody variant for use according to any one of the preceding claims, which reduces the number of CD38 molecules on Tregs in the presence of peripheral blood lymphocytes (PBMCs).

31. 31. The antibody variant for use according to claim 30, wherein the control is an isotype control antibody.

32. 31. The antibody variant for use according to claim 30, which in said assay results in a decrease in CD38 expression on Tregs compared to a reference antibody having an identical amino acid sequence except for mutations of one or more amino acid residues corresponding to E430, E345 and S440 in the human IgG1 heavy chain, said amino acid residues being numbered according to the EU index.

33. 13. The antibody variant for use according to any one of the preceding claims, wherein the mutation of one or more amino acid residues is selected from the group consisting of E430G, E345K, E430S, E430F, E430T, E345Q, E345R, E345Y, S440Y and S440W.

34. 4. The antibody variant for use according to any one of the preceding claims, wherein the mutation of one or more amino acid residues is selected from the group corresponding to E430G, E345K, E430S and E345Q.

35. 4. The antibody variant for use according to any one of the preceding claims, wherein the mutation of one or more amino acid residues comprises E430G.

36. 4. The antibody variant for use according to any one of the preceding claims, wherein the mutation of one or more amino acid residues consists of E430G.

37. 5. The antibody variant for use according to any one of the preceding claims, wherein the variant Fc region comprises one or more further mutations which do not reduce both complement dependent cytotoxicity (CDC) and antibody dependent cellular cytotoxicity (ADCC) induced by an antibody variant that does not comprise said one or more further mutations.

38. 38. The antibody variant for use according to claim 37, wherein the one or more further mutations are 12 or fewer mutations, such as 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 mutation, such as a substitution, insertion or deletion, of amino acid residues.

39. 4. The antibody variant for use according to any one of the preceding claims, wherein said variant Fc region is of human IgG1, IgG2, IgG3 or IgG4 isotype, or mixed isotypes thereof, except for the mutations listed.

40. 4. The antibody variant for use according to any one of the preceding claims, wherein the variant Fc region is a human IgG1 Fc region, except for the mutations listed.

41. 6. The antibody variant for use according to any one of the preceding claims, wherein said variant Fc region is of the human IgG1m(f), IgG1m(a), IgG1m(x), IgG1m(z) allotype, or mixed allotypes thereof, except for the mutations listed.

42. 4. The antibody variant for use according to any one of the preceding claims, which is a bivalent antibody.

43. 4. The antibody variant for use according to any one of the preceding claims, which is a full length antibody.

44. 2. The antibody variant for use according to any one of the preceding claims, which, except for the mutations listed, is a human antibody.

45. 4. The antibody variant for use according to any one of the preceding claims, which is a bivalent antibody.

46. 4. The antibody variant for use according to any one of the preceding claims, which is a monoclonal antibody.

47. 2. The antibody variant for use according to any one of the preceding claims, which, except for the listed mutations, is an IgG1 antibody.

48. 4. The antibody variant for use according to any one of the preceding claims, which, except for the listed mutations, is a human monoclonal full length bivalent IgG1m(f),κ antibody.

49. (a) does not bind to a variant of human CD38 in which Asp at position 202 is replaced by Gly, (ii) binds to a variant of human CD38 in which Gln at position 272 is replaced by Arg, (iii) binds to a variant of human CD38 in which Ser at position 274 is replaced by Phe, and (iv) binds to a variant of human CD38 in which Thr at position 237 is replaced by Ala; (b) does not bind to a variant of human CD38 in which Ser at position 274 is substituted with Phe to the same extent as it binds to human CD38 and does not bind to a variant of human CD38 in which Gln at position 272 is substituted with Arg to the same extent as it binds to human CD38; or (c) binds to a variant of human CD38 in which Ser at position 274 is substituted with Phe to the same extent as it binds to human CD38, binds to a variant of human CD38 in which Gln at position 272 is substituted with Arg to the same extent as it binds to human CD38, and binds to a variant of human CD38 in which Thr at position 237 is substituted with Ala to the same extent as it binds to human CD38. An antibody variant for use according to any one of the preceding claims.

50. An antibody variant for use according to any one of the preceding claims, which specifically binds to the region SKRNIQFSCKNIYR (SEQ ID NO:86) and the region EKVQTLEAWVIHGG (SEQ ID NO:87) and optionally further has a binding characteristic according to (b) or (c) of claim 49.

51. (a) has an inhibitory effect on CD38 cyclase activity, and optionally has the binding characteristics of an antibody according to claim 49 (a) or (b); (b) has no inhibitory effect on CD38 cyclase activity, and optionally has the binding characteristics of an antibody according to claim 49(c); (c) induces complement-dependent cytotoxicity (CDC) of cells expressing human CD38; (d) induces antibody-dependent cellular cytotoxicity (ADCC) of cells expressing human CD38; (e) induces antibody-dependent cellular phagocytosis (ADCP); (f) does not induce apoptosis in the absence of an Fc cross-linking antibody; or (g) having any combination of characteristics of one of (a) and (b) and one or more of (c) through (f); An antibody variant for use according to any one of the preceding claims.

52. An antibody variant for use according to any one of the preceding claims, having an inhibitory effect on the cyclase activity of human CD38.

53. The cyclase activity is (a) seeding 200,000 Daudi or Wien133 cells in 100 μL of 20 mM Tris-HCL per well in a multi-well plate; or seeding 0.6 μg / mL His-tagged soluble CD38 (SEQ ID NO:84) in 100 μL of 20 mM Tris-HCL per well; (b) adding 1 μg / mL of CD38 antibody and 80 μM of NGD to each well; (c) measuring the fluorescence until a plateau is reached (e.g., 5, 10, or 30 minutes); and (d) determining the percent inhibition by comparison with a control, such as wells incubated with an isotype control antibody.

53. The antibody variant for use according to claim 51 or 52, determined by a method comprising:

54. The CDC: (a) plating 100,000 CD38-expressing cells per well in 40 μL of culture medium supplemented with 0.2% BSA in a multi-well plate; (b) pre-incubating the cells with 40 μL of serially diluted CD38 antibodies (0.0002-10 μg / mL) for 20 minutes; (c) incubating each well with 20% pooled normal human serum at 37° C. for 45 minutes; (d) adding a viability dye and measuring the percentage of cell lysis in a flow cytometer; (e) determining maximum lysis using nonlinear regression 54. The antibody variant for use according to any one of claims 51 to 53, as determined by an assay comprising:

55. The antigen-binding region comprises: (a) a VH CDR1 having the sequence set forth in SEQ ID NO:37, a VH CDR2 having the sequence set forth in SEQ ID NO:38, a VH CDR3 having the sequence set forth in SEQ ID NO:39, a VL CDR1 having the sequence set forth in SEQ ID NO:41, a VL CDR2 having the sequence AAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:42; (b) a VH CDR1 having the sequence set forth in SEQ ID NO:9, a VH CDR2 having the sequence set forth in SEQ ID NO:10, a VH CDR3 having the sequence set forth in SEQ ID NO:11, a VL CDR1 having the sequence set forth in SEQ ID NO:13, a VL CDR2 having the sequence DAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:14; (c) a VH CDR1 having the sequence set forth in SEQ ID NO:2, a VH CDR2 having the sequence set forth in SEQ ID NO:3, a VH CDR3 having the sequence set forth in SEQ ID NO:4, a VL CDR1 having the sequence set forth in SEQ ID NO:6, a VL CDR2 having the sequence AAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:7; (d) a VH CDR1 having the sequence set forth in SEQ ID NO:16, a VH CDR2 having the sequence set forth in SEQ ID NO:17, a VH CDR3 having the sequence set forth in SEQ ID NO:18, a VL CDR1 having the sequence set forth in SEQ ID NO:20, a VL CDR2 having the sequence set forth in SEQ ID NO:DAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:21; (e) a VH CDR1 having the sequence set forth in SEQ ID NO:23, a VH CDR2 having the sequence set forth in SEQ ID NO:24, a VH CDR3 having the sequence set forth in SEQ ID NO:25, a VL CDR1 having the sequence set forth in SEQ ID NO:27, a VL CDR2 having the sequence AAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:28; (f) a VH CDR1 having the sequence set forth in SEQ ID NO:30, a VH CDR2 having the sequence set forth in SEQ ID NO:31, a VH CDR3 having the sequence set forth in SEQ ID NO:32, a VL CDR1 having the sequence set forth in SEQ ID NO:34, a VL CDR2 having the sequence AAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:35; (g) a VH CDR1 having the sequence set forth in SEQ ID NO:44, a VH CDR2 having the sequence set forth in SEQ ID NO:45, a VH CDR3 having the sequence set forth in SEQ ID NO:46, a VL CDR1 having the sequence set forth in SEQ ID NO:48, a VL CDR2 having the sequence AAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:49; (h) a VH CDR1 having the sequence set forth in SEQ ID NO:51, a VH CDR2 having the sequence set forth in SEQ ID NO:52, a VH CDR3 having the sequence set forth in SEQ ID NO:53, a VL CDR1 having the sequence set forth in SEQ ID NO:55, a VL CDR2 having the sequence AAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:56; or (i) a VH CDR1 having the sequence set forth in SEQ ID NO:88, a VH CDR2 having the sequence set forth in SEQ ID NO:89, a VH CDR3 having the sequence set forth in SEQ ID NO:90, a VL CDR1 having the sequence set forth in SEQ ID NO:91, a VL CDR2 having the sequence AAS, and a VL CDR3 having the sequence set forth in SEQ ID NO:

92.

55. The antibody variant for use according to any one of claims 1 to 54, comprising a variable heavy (VH) region and a variable light (VL) region comprising complementarity determining regions (CDRs) selected from the group consisting of:

56. (i) a VH region comprising the VH CDRs and VL CDRs of (a) and an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:36, optionally differing from SEQ ID NO:36 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (ii) a VH region comprising the VH CDRs and VL CDRs of (b) and an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:8, optionally differing from SEQ ID NO:8 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (iii) a VH region comprising the VH CDRs and VL CDRs of (c) and an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:1, optionally differing from SEQ ID NO:1 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (iv) a VH region comprising the VH CDRs and VL CDRs of (d) and an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:15, optionally differing from SEQ ID NO:15 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (v) a VH region comprising the VH CDRs and VL CDRs of (e) and an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:22, optionally differing from SEQ ID NO:22 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (vi) a VH region comprising the VH CDRs and VL CDRs of (f) and an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:29, optionally differing from SEQ ID NO:29 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (vii) a VH region comprising the VH CDRs and VL CDRs of (g) and an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:43, optionally differing from SEQ ID NO:43 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; or (viii) a VH region comprising the VH CDRs and VL CDRs of (h) and an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:50, optionally differing from SEQ ID NO:50 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions.

56. The antibody variant for use according to claim 55, comprising:

57. (i) a VH region, and a VL region comprising an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:40, optionally differing from SEQ ID NO:40 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (ii) a VH region of, and a VL region comprising an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:12, optionally differing from SEQ ID NO:12 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (iii) a VH region and a VL region comprising an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:5, optionally differing from SEQ ID NO:5 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (iv) a VH region and a VL region comprising an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO:19, optionally differing from SEQ ID NO:19 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (v) a VH region and a VL region comprising an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:26, optionally differing from SEQ ID NO:26 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (vi) a VH region of, and a VL region comprising an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:33, optionally differing from SEQ ID NO:33 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; (vii) a VH region and a VL region comprising an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:47, optionally differing from SEQ ID NO:47 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally including or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions; or (viii) a VH region of, and a VL region comprising an amino acid sequence having at least 80% identity, e.g., 90%, 95%, 97%, 98%, or 99% identity to SEQ ID NO:54, optionally differing from SEQ ID NO:54 by one or more amino acid insertions, deletions and / or substitutions in the framework regions, and optionally comprising or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions.

57. The antibody variant for use according to claim 55 or 56, comprising:

58. (a) a VH region comprising SEQ ID NO:36 and a VL region comprising SEQ ID NO:40; (b) a VH region comprising SEQ ID NO:8 and a VL region comprising SEQ ID NO:12; (c) a VH region comprising SEQ ID NO:1 and a VL region comprising SEQ ID NO:5; (d) a VH region comprising SEQ ID NO:15 and a VL region comprising SEQ ID NO:19; (e) a VH region comprising SEQ ID NO:22 and a VL region comprising SEQ ID NO:26; (f) a VH region comprising SEQ ID NO:29 and a VL region comprising SEQ ID NO:33; (g) a VH region comprising SEQ ID NO: 43 and a VL region comprising SEQ ID NO: 47; or (h) a VH region comprising SEQ ID NO:50 and a VL region comprising SEQ ID NO:54 4. The antibody variant for use according to any one of the preceding claims, comprising:

59. 59. An antibody variant for use according to claim 58, comprising a VH region comprising SEQ ID NO:36 and a VL region comprising SEQ ID NO:

40.

60. 59. An antibody variant for use as described in claim 58, comprising a VH region comprising SEQ ID NO:8 and a VL region comprising SEQ ID NO:

12.

61. 1. A nucleic acid or combination of nucleic acids for use in treating cancer in a subject, comprising: The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing immune cells; Said nucleic acid or combination of nucleic acids.

62. A nucleic acid or a combination of nucleic acids for use according to claim 61, comprising the further features according to any one or more of claims 2 to 60.

63. 1. A delivery vehicle comprising a nucleic acid or a combination of nucleic acids for use in treating cancer in a subject, comprising: The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing immune cells; The delivery vehicle.

64. A delivery vehicle according to claim 63, comprising the further features according to any one or more of claims 2 to 60.

65. 65. The delivery vehicle of claim 63 or 64, which is a particle.

66. 66. The delivery vehicle of claim 65, wherein the particle is a lipid nanoparticle (LNP).

67. 67. The delivery vehicle of claim 66, wherein the LNP comprises a lipid, an ionizable amino lipid, a PEG lipid, cholesterol, or any combination thereof.

68. 1. An antibody variant for use in enhancing an immune response in a subject, comprising: an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells, The antibody variant.

69. 1. An antibody variant for use in treating cancer in a subject, comprising: an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing tumor cells, The antibody variant.

70. 70. An antibody variant for use according to claim 68 or 69, comprising the further features according to any one or more of claims 2 to 60.

71. 1. A method of treating cancer in a subject comprising administering to the subject an antibody variant, The antibody variant comprises: an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells, The method.

72. 1. A method of enhancing an immune response in a subject comprising administering to the subject an antibody variant, The antibody variant comprises: an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing immune cells, The method.

73. 1. A method of treating cancer in a subject comprising administering to the subject an antibody variant, The antibody variant comprises: an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and Induces trogocytosis-mediated depletion of CD38 on CD38-expressing tumor cells, The method.

74. 74. The method of any one of claims 71 to 73, wherein said antibody variant is administered in a therapeutically effective amount and / or for a time sufficient to treat said disease.

75. A method according to any one of claims 71 to 74, further comprising the features according to any one of claims 2 to 60.

76. 1. A nucleic acid or combination of nucleic acids for use in enhancing an immune response in a subject, comprising: The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing immune cells; Said nucleic acid or combination of nucleic acids.

77. 1. A nucleic acid or combination of nucleic acids for use in treating cancer in a subject, comprising: The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing tumor cells; Said nucleic acid or combination of nucleic acids.

78. A nucleic acid or a combination of nucleic acids for use according to claim 76 or 77, comprising the further features according to any one or more of claims 2 to 60.

79. 1. A delivery vehicle comprising a nucleic acid or a combination of nucleic acids for use in promoting an immune response in a subject, comprising: The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing immune cells; The delivery vehicle.

80. 1. A delivery vehicle comprising a nucleic acid or a combination of nucleic acids for use in treating cancer in a subject, comprising: The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing tumor cells; The delivery vehicle.

81. A delivery vehicle according to claim 79 or 80, comprising the further features according to any one or more of claims 2 to 60.

82. The delivery vehicle of any one of claims 79 to 81, which is a particle.

83. 83. The delivery vehicle of claim 82, wherein the particle is a lipid nanoparticle (LNP).

84. The delivery vehicle of claim 83, wherein the LNP comprises a lipid, an ionizable amino lipid, a PEG lipid, cholesterol, or any combination thereof.

85. 1. A method of treating cancer in a subject comprising administering to the subject a nucleic acid or a combination of nucleic acids, The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing immune cells; The method.

86. 1. A method of enhancing an immune response in a subject, comprising administering to the subject a nucleic acid or a combination of nucleic acids, The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing immune cells; The method.

87. 1. A method of treating cancer in a subject comprising administering to the subject a nucleic acid or a combination of nucleic acids, The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing tumor cells; The method.

88. Method according to any one of claims 85 to 87, further comprising the features according to any one or more of claims 2 to 60.

89. 1. A method of treating cancer in a subject comprising administering to the subject a delivery vehicle comprising a nucleic acid or a combination of nucleic acids, The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing immune cells; The method.

90. 1. A method of enhancing an immune response in a subject, comprising administering to the subject a delivery vehicle comprising a nucleic acid or a combination of nucleic acids, The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing immune cells; The method.

91. 1. A method of treating cancer in a subject comprising administering to the subject a delivery vehicle comprising a nucleic acid or a combination of nucleic acids, The nucleic acid or combination of nucleic acids is an antigen-binding region that binds to CD38; a variant Fc region comprising mutations of one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, said amino acid residues being numbered according to the EU index; and encoding an antibody variant comprising: the antibody variant induces a decrease in CD38 via trogocytosis on CD38-expressing tumor cells; The method.

92. 92. The method according to any one of claims 89 to 91, further comprising the features according to any one or more of claims 2 to 60.

93. 93. The method of any one of claims 89 to 92, wherein the delivery vehicle is a particle.

94. 94. The method of claim 93, wherein the particle is a lipid nanoparticle (LNP).

95. 95. The method of claim 94, wherein the LNP comprises a lipid, an ionizable amino lipid, a PEG lipid, cholesterol, or any combination thereof.

Citation Information

Patent Citations

  • Dimeric protein with triple mutation

    JP2015524387A

  • Human igg1fc region mutants and uses thereof

    JP2016509476A

  • Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38

    WO2016210223A1